Journal articles: '362.196 462 4'

1

Family, Leila, Su-Jau Yang, Zandra Klippel, Yanli Li, John H. Page, Roberto Rodriguez, and Chun Chao. "Risk of Febrile Neutropenia (FN) in Select Myelosuppressive Chemotherapy Regimens." Blood 126, no. 23 (December 3, 2015): 3257. http://dx.doi.org/10.1182/blood.v126.23.3257.3257.

Full text

Abstract:

Abstract Introduction Febrile neutropenia (FN) is a serious adverse effect of myelosuppressive chemotherapy, which often results in hospitalization and chemotherapy dose modification. FN risk depends on patient characteristics and chemotherapy regimen risk. Understanding the FN risk associated with individual chemotherapy regimens can help guide the use of prophylactic granulocyte colony-stimulating factor (G-CSF) and patient monitoring. To this end, the NCCN has classified regimens into high (≥20%), intermediate (10%-20%), or low (<10%) FN risk based primarily on clinical trial data. However, even for the same regimen, the FN risk is often higher in clinical practice than in clinical trials. In this study, we assessed the FN risk associated with several regimens for which FN risk has not been determined or has shown substantial variability outside of a clinical trial setting, using data from Kaiser Permanente Southern California (KPSC), a large, community-based practice. Methods Included were patients diagnosed with incident non-Hodgkin's lymphoma (NHL), breast cancer (BC), or multiple myeloma (MM) between 2008 and 2013 at KPSC who initiated the following chemotherapy regimens: bendamustine ± rituximab for NHL; docetaxel, carboplatin, and trastuzumab (TCH) or docetaxel and cyclophosphamide (TC) for BC; or Q4W lenalidomide 25 mg/dexamethasone for MM. Bendamustine ± rituximab, TCH, and lenalidomide are not classified by NCCN; TC is classified as intermediate FN risk but has shown considerable variability of FN incidence when used in clinical practice. Data on cancer diagnosis, chemotherapy use, G-CSF use, neutrophil count, and infections were obtained from KPSC's electronic medical records to estimate the incidence proportions of FN and grade 3 and 4 neutropenia. FN was defined as (1) hospitalization with absolute neutrophil count (ANC) <1000/µL or (2) hospitalization with primary or secondary diagnosis codes of neutropenia (ICD-9 288.0x) and fever (ICD-9 780.6), diagnosis code for bacterial/fungal infection, or antibiotic use. Grade 3 neutropenia was defined as ANC ≥500/µL to <1000/µL; grade 4 neutropenia as ANC <500/µL. Patients who received prophylactic G-CSF within 5 days of chemotherapy initiation were excluded from analysis. Results Overall, 40 (12%) NHL patients; 149 (24%) and 340 (28%) BC patients who received TCH and TC, respectively; and 0 (0%) MM patients were excluded due to prophylactic G-CSF. Over the first 6 cycles of bendamustine (median 338.4 mg/m2) ± rituximab for NHL patients (n = 307), 7.2% experienced FN, 4.2% grade 3 neutropenia, and 17.6% grade 4 neutropenia. Over the first 6 cycles of TCH for BC patients (n = 462), 24.2% experienced FN, 10.6% grade 3 neutropenia, and 44.6% grade 4 neutropenia. Over the first 6 cycles of TC for BC patients (n = 859), 20.5% experienced FN, 9.5% grade 3 neutropenia, and 37.5% grade 4 neutropenia. Over the first 4 cycles of lenalidomide/dexamethasone for MM patients (n = 186), 3.8% experienced FN, 5.9% grade 3 neutropenia, and 18.3% grade 4 neutropenia (Table 1). Conclusions Using NCCN criteria, bendamustine ± rituximab for NHL and lenalidomide/dexamethasone for MM would be classified as low-FN-risk regimens (<10%). By contrast, BC regimens TCH and TC would be classified as high-FN-risk regimens (>20%) based on our data. These results could help inform prophylactic G-CSF use for the selected regimens in clinical practice. Table 1. Number and Incidence Proportion of Neutropenic Outcomes Overall and by Cycle Cancer: Regimen Cycle Patients n FN Events n (%) Grade 3 Neutropenia Events n (%) Grade 4 Neutropenia Events n (%) NHL: Bendamustine ± rituximab Overall 307 22 (7.2) 13 (4.2) 54 (17.6) 1 307 12 (3.9) 5 (1.6) 28 (9.1) 2 225 3 (1.3) 4 (1.8) 21 (9.3) 3 173 2 (1.2) 4 (2.3) 15 (8.7) 4 130 2 (1.5) 4 (3.1) 10 (7.7) 5 92 4 (4.4) 4 (4.4) 8 (8.7) 6 69 2 (2.9) 2 (2.9) 0 (0) BC: TCH Overall 462 112 (24.2) 49 (10.6) 206 (44.6) 1 462 70 (15.2) 39 (8.4) 138 (29.9) 2 326 13 (4.0) 15 (4.6) 42 (12.9) 3 282 17 (6.0) 9 (3.2) 39 (13.8) 4 247 6 (2.4) 8 (3.2) 31 (12.6) 5 199 4 (2.0) 6 (3.0) 25 (12.6) 6 169 8 (4.7) 3 (1.8) 12 (7.1) BC: TC Overall 859 176 (20.5) 82 (9.5) 322 (37.5) 1 859 126 (14.7) 51 (5.9) 266 (30.9) 2 649 21 (3.2) 42 (6.5) 82 (12.6) 3 571 19 (3.3) 23 (4.0) 62 (10.9) 4 511 14 (2.7) 22 (4.3) 45 (8.8) 5 94 1 (1.1) 3 (3.2) 9 (9.6) 6 84 2 (2.4) 1 (1.2) 2 (2.4) MM: Lenalidomide / dexamethasone Overall 186 7 (3.8) 11 (5.9) 34 (18.3) 1 186 2 (1.1) 8 (4.3) 17 (9.1) 2 101 3 (3.0) 5 (5.0) 14 (13.9) 3 63 2 (3.2) 2 (3.2) 8 (12.7) 4 37 0 (0) 0 (0) 4 (10.8) Disclosures Family: Amgen Inc.: Research Funding. Klippel:Amgen Inc.: Employment, Equity Ownership. Li:Amgen Inc.: Employment, Equity Ownership. Page:Amgen Inc.: Employment, Equity Ownership.

APA, Harvard, Vancouver, ISO, and other styles

2

Autorzy, Różni. "Notki recenzyjne." Z Badań nad Książką i Księgozbiorami Historycznymi 9 (December 12, 2019): 355–77. http://dx.doi.org/10.33077/uw.25448730.zbkh.2015.153.

Full text

Abstract:

Historia nauki polskiej, t. 10: 1944–1989, Cz. 1: Warunki rozwoju nauki polskiej, państwo i społeczeństwo; Cz. 2: Instytucje; Cz. 3: Idee i praktyka, pod red. Leszka Zasztowta i Joanny Schiller- Walickiej, Warszawa: Polska Akademia Nauk, 2015, Cz. 1: ss. 447, Cz. 2: ss. 717, Cz. 3: ss. 445, ISBN 978-83-7545-607-3 (całość) – Agnieszka Chamera-Nowak [355-358] Modlitewnik Olbrachta Gasztołda kanclerza wielkiego litewskiego 1528 r. Facsimile, Wstęp Wiesław Wydra, Libri Precationum Illuminati Poloniae Veteris. Facsimilia, editores: Catharina Krzak-Weiss, Raphael Wójcik, Wiesław Wydra, t. 1, Poznań: Wydawnictwo Naukowe UAM, 2015, ss. 560, ISBN 978-83232- 2774-8 – Karolina Figaszewska [358-360] Katalog inkunabułów Biblioteki Naukowej PAU i PAN w Krakowie, oprac. Teresa Dąbrowa, Elżbieta Knapek, Jacek Wojtowicz, Kraków: Polska Akademia Umiejętności, 2015, ss. 285, ISBN 978-83-7676-223-4 – Agnieszka Chamera-Nowak [360-361] Przyjaźń w kulturze staropolskiej, pod redakcją naukową Agnieszki Czechowicz i Małgorzaty Trębskiej, Lublin: Wydawnictwo Katolickiego Uniwersytetu Lubelskiego, 2013, ss. 331, ISBN: 978-83-7702-798-1 – Magdalena Bejm [362-364] Olaf Kwapis, Do Rzymu, Warszawa: Stowarzyszenie Pro Cultura Litteraria, Instytut Badań Literackich PAN, 2014, ss. 366, ISBN 979-83-61757-54-1 – Magdalena Bejm [365-367] Urszula Paszkiewicz, Cathalogus cathalogorum. Inwentarze i katalogi bibliotek z ziem wschodnich Rzeczypospolitej od XVI wieku do 1939 roku. Spis scalony, poprawiony i uzupełniony, t. 1–2, Warszawa: Ministerstwo Kultury i Dziedzictwa Narodowego, 2015, t. 1: ss. 717, t. 2: ss. 772 ISBN 978-83-62622-41-2 (całość) – Agnieszka Chamera-Nowak [367-369] Zdabytki: dokumental’nyja pomniki na Belarusi, Nacyjanalnaja biblioteka Belarusi; Wypusk 16; Minsk 2013 – Michał Pędracki [369-372] Маteryjały IX Мiżnarodnych knigaznauczych czytannjau „Statut Wjalikaga Knjastwa Litouskaga u gistorii kultury Biełarusi”, Мinsk, 18–19 krasawika 2013 g. – Michał Pędracki [372-376] Kasaty klasztorów na obszarze dawnej Rzeczypospolitej Obojga Narodów i na Śląsku na tle procesów sekularyzacyjnych w Europie, t. 1–4, t. 1: Geneza. Kasaty na ziemiach zaborów austriackiego i rosyjskiego; t. 2: Kasaty na Śląsku Pruskim i na ziemiach zaboru pruskiego; t. 3: Źródła. Skutki kasat XVIII i XIX w. Kasata w latach 1954–1956; t. 4: Dokumentacja, redakcja Marek Derwich, Wrocław: Wrocławskie Towarzystwo Miłośników Historii, 2014, t. 1: ss. 464, t. 2: ss. 474, t. 3: ss. 520, t. 4: ss. 560, ISBN 978-83- 87843-21-2 (całość) – Agnieszka Chamera-Nowak [376-377]

APA, Harvard, Vancouver, ISO, and other styles

3

Gerhard, Thomas. "Die 68er-Bewegung im Spannungsfeld erinnerungspolitischer Deutungskämpfe und historischer Forschung." Das Historisch-Politische Buch 67, no. 2 (June 1, 2019): 147–61. http://dx.doi.org/10.3790/hpb.67.2.147.

Full text

Abstract:

Silja Behre: Bewegte Erinnerung. Deutungskämpfe um „1968“ in deutschfranzösischer Perspektive. 421 S., Mohr Siebeck, Tübingen 2016 Tilman P. Fichter / Siegward Lönnendonker: Geschichte des SDS. Der Sozialistische Deutsche Studentenbund 1946 – 1970. 342 S., Aisthesis Verlag, Bielefeld 2018 Bernd Gehrke / Gerd-Rainer Horn (Hg.): 1968 und die Arbeiter. Studien zum „proletarischen Mai“ in Europa. 342 S., VSA, Hamburg 2018 Claus-Jürgen Göpfert / Bernd Messinger: Das Jahr der Revolte. Frankfurt 1968. 303 S., Schöffling & Co., Frankfurt / M. 2017 Thomas Großbölting: 1968 in Westfalen. Akteure, Formen und Nachwirkungen einer Protestbewegung. 172 S., Ardey-Verlag, Münster 2018 Ulrike Heider: Keine Ruhe nach dem Sturm. 305 S., Bertz + Fischer, Berlin 2018 Ingo Juchler: 1968 in Berlin. Schauplätze der Revolte. Ein historischer Stadtführer. 96 S., be.bra Verlag, Berlin 2017 Wolfgang Kraushaar: Die 68er-Bewegung international. Eine illustrierte Chronik. 4 Bände, 2004 S., Klett-Cotta, Stuttgart 2018 Claus Leggewie: 50 Jahre ’68. Köln und seine Protestgeschichte. 111 S., Greven Verlag, Köln 2018 Bettina Röhl: „Die RAF hat Euch lieb“. Die Bundesrepublik im Rausch von 68. Eine Familie im Zentrum der Bewegung. 638 S., Heyne, München 2018 Uwe Soukup: Ein Schuss, der die Republik veränderte. Der 2. Juni 1967. 191 S., Transit, Berlin 2017 Martin Stallmann: Die Erfindung von „1968“. Der studentische Protest im bundesdeutschen Fernsehen 1977 – 1998. 412 S., Wallstein, Göttingen 2017 Dae Sung Jung: Der Kampf gegen das Presse-Imperium. Die Anti-Springer-Kampagne der 68er-Bewegung. 372 S., transcript, Bielefeld 2016 Thomas Wagner: Die Angstmacher. 1968 und die Neuen Rechten. 351 S., Aufbau, Berlin 2017

APA, Harvard, Vancouver, ISO, and other styles

4

Bernaudin, Francoise, Emmanuelle Lesprit, Lena Coïc, Cécile Arnaud, Emmanuelle Fleurence, Suzanne Verlhac, and Christophe Delacourt. "Long Term Prospective Follow-Up after Treatment Intensification in Pediatric Sickle Cell Patients: Comparative Effects of Transfusion Program (TP), Hydroxyurea (HU) or Stem Cell Transplant (SCT) on Annual Check-Ups." Blood 106, no. 11 (November 16, 2005): 3196. http://dx.doi.org/10.1182/blood.v106.11.3196.3196.

Full text

Abstract:

Abstract Treatment intensifications in SCD with HU, TP or SCT are applied in order to reduce SCD related complications but their comparative effects have still to be described. We report our experience concerning the annual check-up performed in SCD pediatric patients. Patients and Methods: Among our cohort of 397 SS/Sb0 pediatric SCD patients, 157 of them were intensified with HU (n= 86), TP (n=104) or SCT (n=36) and some of them received successively HU, TP and SCT. HU was proposed to patients > 3 years of age and having experienced more than 3 VOC/ACS/year or < 7g/dl severe anemia. TP defined as > 4 months program was applied in patients with cerebral vasculopathy defined by an history of stroke or abnormal TCD (> 200 cm/sec). TP was also proposed in patients with HU-failure and in patients with frequent VOC, less than 3 years old. SCT was proposed in patients with an indication of treatment intensification and an available HLA identical sibling donor. Annual check-up were performed in our day-care unit. We analysed 1261 check-ups performed and recorded since 1992 in 341 SS/Sb0 patients (sex: 164 F, 177 M). Median age was 8.8 ± 5.1 years. Mean number of annual check-ups per patient was 3.7 ± 2.8 (range 1 to 13): 816 were performed in non intensified patients, 196 in HU, 123 in TP and 126 in transplanted patients. Categories of age were distinguished: < 2 y of age (n=110), 2–5y (n=244), 5–10y (n=415), 10–15y (n=317) and 15–20y (n=175). Results: Respective follow-up were 4.4 y ± 3.3 in HU, 2.6 y ± 2.6 inTP and 5.8 y ± 4.7 in SCT patients. Comparison with non intensified patients showed that weight was significantly higher in SCT patients > 15 y of age (p=0.001), spleen size was significantly higher in (2–5y) young patients treated with HU (p=0.005) or TP (0.001) and in 5–10 y old patients on HU (p=0.046) but no difference was observed after the age of 10 y. O2 saturation was significantly improved after SCT (p<0.001) (98.8 ± 1.0 vs 97.1 ± 2.6) and was unchanged on HU and TP. Cardiac pulsations were significantly (p<0.001) decreased after all type of intensification. Biological data are shown (table1and 2). Conclusion : Treatment intensifications (TP, HU, SC) reduced the decrease of weight observed with aging in SCD patients and significantly reduced anemia using different mechanisms. SCT was the most effective to correct anemia, supress hemolysis and decrease leucocytosis. Intensif. n Follow-up HbF% Eryht Hb MCV Retic mean (SD) No 816 11.4 (9.2) 3.1 (0.9) 8.1 (1.2) 81.4 (8.9) 268.9 (105.2) HU 196 4.4 y. (3.3) 13.9 (7.0) 2.7 (0.6) 8.5 (1.2) 97.7 (13.7) 188 (83.8) TP 126 2.6 y.(2.7) 3.3 (3.1) 3.1 (0.6) 9.1 (1.4) 86.8 (4.8) 258.2 (126.0) SCT 123 5.8 y.(4.7) 4.6 (6.4) 4.3 (0.9) 11.4 (1.6) 81.5 (8.9) 89.4 (63.4) Intensif. n Tot Bili Conj Bili LDH Ferritin Leucocytes Platelets No 816 49.8 (34.4) 5.7 (3.4) 1016 (312) 192 (322) 13.2 (9.9) 385 (124) HU 196 47.5 (34.4) 5.0 (2.2) 943 (264) 399 (582) 9.7 (3.8) 352 (133) TP 126 58.8 (39.6) 5.6 (2.2) 973 (377) 2238 (6310) 13.1 (4.7) 365 (128) SCT 123 15.6 (13.9) 2.8 (4.2) 493 (200) 1099 (1386) 6.8 (3.3) 295 (109)

APA, Harvard, Vancouver, ISO, and other styles

5

Кузьминых, Сергей Владимирович, and Валерий Николаевич Саенко. "«ВЫ ВЕДЬ ЕДИНСТВЕННЫЙ, КОТОРЫЙ МОЖЕТ ОБНЯТЬ ЕЩЕ РУССКУЮ АРХЕОЛОГИЮ ВО ВСЕМ ЕЕ ОБЪЕМЕ»: ПЕРЕПИСКА А.И. ТЕРЕНОЖКИНА И В.А. ГОРОДЦОВА." Археология Евразийских степей, no. 5 (October 29, 2021): 183–211. http://dx.doi.org/10.24852/2587-6112.2021.5.183.211.

Full text

Abstract:

Письма А.И. Тереножкина 1939–1941 гг. относятся к периоду поиска ученым своего научного пути и началу его работы в Узбекистане. В них он делится с В.А. Городцовым первыми результатами исследований в зоне строительства Большого Ташкентского канала и на городище Ак-Тепе, знакомит учителя с Чимбайлыкским кладом и советуется по поводу его хронологии. Послания 1941–1942 гг. написаны с фронтовых дорог, но их главной темой по-прежнему является археология. В.А. Городцов в своих письмах отмечает важность новейших археологических открытий в Туркестане, делится новостями о ходе работы над 2 томом «Археологии», призывает бить врага. Публикуемая переписка приоткрывает для нас завесу в диалоге Учителя и ученика. Библиографические ссылки Аржанцева И.А. Хорезм. История открытий и исследований. Этнографический альбом. Ульяновск: Артишок, 2016. 288 с., 654 илл. Археологические экспедиции Государственной Академии истории материальной культуры и Института археологии Академии наук СССР (1919–1956 гг.): Указатель / Ред. Н.Н. Воронин, М.А. Тиханова. М.: АН СССР, 1962. 264 с. Балахонова Е.И. В.В. Троицкий и его коллекция в Музее антропологии // Вестник МГУ. Сер. XXIII: Антропология. 2009. № 3. С. 55–65. Балабина В.И. О прекрасной даме, ее рыцарях и бардах (Т.С. Пассек, Б.А. Латынин и А.А. Потапов) // Stratum plus. 2001–2002. № 2. С. 14–31. Белозëрова И.В., Гайдуков П.Г., Кузьминых С.В. К юбилею Института археологии РАН: Московская секция РАИМК–ГАИМК, Московское отделение ГАИМК–ИИМК // РА. 2019. № 4. С. 102–117. Белозёрова И.В., Кузьминых С.В. Жизненный и научный путь В.А. Городцова (по архивным документам и воспоминаниям) // Городцов В.А. Дневники. 1928–1944: в 2 кн. Кн. 1: 1928–1935 / Сост. И.В. Белозёрова, С.В. Кузьминых. М.: Триумф принт, 2015. С. 12–72. Бернштам А.Н. Археологические работы в Казахстане и Киргизии // ВДИ. 1939. № 4. С. 169–181. Бернштам А.Н., Бибиков С.Н. Н.И. Репников (1882–1940) [Некролог] // КСИИМК. 1941. Вып. IX. С. 121–123. Болелов С.Б. Толстов Сергей Павлович // БРЭ. 2016. Т. 32. С. 240. Борисковский П.И., Окладников А.П. Д.Н. Лев (1905–1969) [Некролог] // СА. 1970. № 3. С. 298–299. Бочкарев В.С. Этапы развития металлопроизводства эпохи поздней бронзы на юге Восточной Европы // Stratum plus. 2017. № 2. С. 159–204. Буряков Ю.Ф. Пскентские наусы // СА. 1968. № 3. С. 131–136. Буряков Ю.Ф. Генезис и этапы развития городской культуры Ташкентского оазиса. Ташкент: Фан, 1982. 212 с. Василий Афанасьевич Шишкин как ученый-археолог и общественный деятель (к 70-летию со дня рождения) // История материальной культуры Узбекистана. Вып. 6. / Отв. Ред.. Б.В. Лунин. Ташкент: Наука, 1965. С. 5–16. Васильев И.Б. К вопросу о двух ямно-полтавкинских поселениях в Куйбышевском Заволжье // Очерки истории и культуры Поволжья. Вып. 2. / Отв. ред. Е.И. Медведев. Куйбышев: Куйбышев. гос. ун-т, 1976. С. 97–112. Виноградов А.В. Неолитические памятники Хорезма. М.: Наука, 1968. 180 с. Гольмстен В.В. Археологические памятники Самарской губернии // В.А. Городцову – XL / ТСА РАНИОН. Т. IV. / Ред. В.М. Фриче и др. М.: РАНИОН, 1928. С. 125–137. Городцов В.А. Бытовая археология. Курс лекций, читанных в Московском Археологическом Институте. М.: Печ. А.И. Снегиревой, 1910. 474 с. Городцов В.А. Культуры бронзовой эпохи в Средней России // ОИРИМ за 1914 год. М.: Синод. тип., 1915. С. 121–226. Городцов В.А. Археология. Т. 1. Каменный период. М.–Пг.: Гос. изд-во, 1923. 397 с. Городцов В.А. Бронзовый век на территории СССР // БСЭ. 1927. Т. VII. Стлб. 610–626. Городцов В.А. К вопросу о киммерийской культуре // ТСА РАНИОН. М.: РАНИОН, 1928. Т. II. С. 46–60. Городцов Василий Алексеевич. Дневники (1928–1944): в 2-х кн. Кн. 1: 1928–1935 / Сост. И.В. Белозёрова, С.В. Кузьминых. М.: ИД Триумф принт, 2015а. 687 с. Городцов Василий Алексеевич. Дневники (1928–1944): в 2-х кн. Кн. 2: 1936–1944 / Сост. И.В. Белозёрова, С.В. Кузьминых. М.: ИД Триумф принт, 2015б. 695 с. Граков Б.Н. Работы в районе проектируемых южно-уральских гидроэлектростанций // Археологические работы Академии на новостройках 1932–1933 гг. Вып. 2. / Известия ГАИМК Вып. 110. / Отв. ред. И. Мещанинов. М.-Л.; Соцэкгиз, 1935.С. 91–119. Граков Б.Н. Археологические раскопки близ Никополя // ВДИ. 1939. № 1. С. 271–276. Гремяцкий В.А. Памяти В.В. Троицкого // Вопросы антропологии. 1963. Вып. 14. С. 112–114. Григорьев Г.В. Поселения древнего Согда: (По данным исследования городищ Самаркандского района) // КСИИМК. 1940. Вып. 6. С. 24–34. Григорьев Г.В. Находка мустьерского остроконечника в Самарканде // КСИИМК. 1940а. Вып. 8. С. 89–90. Джуракулов М.Д. Самаркандская стоянка и проблемы верхнего палеолита в Средней Азии. Ташкент: Фан, 1987. 171 с. Итина М.А. К 90-летию С.П. Толстова и 60-летию Хорезмской археолого-этнографической экспедиции // РА. 1997. № 4. С. 189–199. Канторович А.Р. Заметки о преподавательской деятельности В.А. Городцова в Московском университете // Хорошие дни. Памяти Александра Степановича Хорошева / Сост. А.Е. Мусин. М.: ЛеопАрт, 2009. С. 309–313. Каргин Ю.Ю. Полевые археологические исследования И.В. Синицына: (К 110-летию со дня рождения) // Археология Восточно-Европейской степи. Вып. 8. / Отв. ред. В.А. Лопатин. Саратов: ИЦ «Наука», 2010. С. 7–29. Китова Л.Ю. История сибирской археологии (1920–1930-е годы): изучение памятников эпохи металла. Новосибирск: ИАЭТ СО РАН, 2007. 272 с. Клюшкина И.В. (сост.). Отдел археологических памятников Государственного исторического музея: краткая историческая хроника. Часть первая: 1873–1935 гг. // Государственный исторический музей и отечественная археология. К 100-летию отдела археологических памятников / Тр. ГИМ. Вып. 201. / Отв. ред. Д.В. Журавлев, Н.И. Шишлина. М.: ГИМ, 2014. С. 232–288. Козенкова В.И. Евгений Игнатьевич Крупнов (к 90-летию со дня рождения) // РА. 1994. № 1. С. 191–196. Конопацкий А.К. Прошлого великий следопыт. Академик А.П. Окладников: страницы биографии. Кн. 1. Новосибирск: Сиб. хронограф, 2001. 492 с. Конопацкий А.К. Прошлого великий следопыт. Академик А.П. Окладников: страницы биографии. Кн. 2. М.: АИРО-XXI, Нов. хронограф, 2009. 549 с. Крайнов Д.А. Памяти В.А. Городцова // Проблемы изучения древних культур Евразии / Отв. ред. Д.А. Крайнов. М.: Наука, 1991. С. 12–27. Крупнов Е. К 50-летнему юбилею научной деятельности проф. В.А. Городцова // ВДИ. 1938. № 3. С. 236–238. Кузьминых С.В. Граков Борис Николаевич // БРЭ. 2007. Т. 7. С. 611. Кузьминых С.В., Сафонов И.Е., Сташенков Д.А. Вера Владимировна Гольмстен: материалы к биографии. Самара: Офорт, 2007. 168 с. Кызласова И.Л. Об археологе В.П. Левашевой и ее отце, протоиерее П.Н. Левашеве // Человек и древности: памяти Александра Александровича Формозова (1928–2009) / Отв. ред. И.С. Каменецкий, А.Н. Сорокин. М.: Гриф и К, 2010. С. 751–769. Лев Д.Н. Самаркандская палеолитическая стоянка (предварительное сообщение) // История материальной культуры Узбекистана. Вып. 6. / Отв. ред. Б.В. Лунин. Ташкент: Наука, 1965. С. 22–29. Лунин Б.В. В.А. Шишкин [Некролог] // СА. 1967. № 2. С. 301. Максимов Е.К., Малов Н.М. Профессор Иван Васильевич Синицын – советский археолог XX века // Взаимодействие и развитие древних культур южного пограничья Европы и Азии / Ред. Е.К. Максимов и др. Саратов: СГУ, 2000. С. 9–19. Мелюкова А.И., Свиридов А.В. Борис Николаевич Граков (1899–1970) // Портреты историков. Время и судьбы. Т. 3: Древний мир и Средние века / Отв. ред. Г.Н. Севостьянов, Л.Т. Мильская. М.: Наука, 2004. С. 45–63. Мизинова В.П., Сальников К.В. Памяти В.В. Гольмстен // СА. 1962. № 4. С. 121–123. Молодин В.И. Академик Окладников – страницы творчества (в честь 105-юбилея). Новосибирск: НГУ, 2013. 96 с. Молодин В.И. Окладников Алексей Павлович // БРЭ. 2014. Т. 24. С. 26–27. Мунчаев Р.М. Евгений Игнатьевич Крупнов: к столетию со дня рождения // РА. 2004. № 1. С. 5–14. Найденко А.В. Старейший археолог Северного Кавказа: (Памяти Т. М. Минаевой, 1896–1973) // МИСК. 1976. Вып. 14. С. 327–332. Неразлик Е.Е. Сергей Павлович Толстов // Портреты историков. Время и судьбы. Т. 4: Новая и новейшая история / Отв. ред. Г.Н. Севостьянов. М.: Наука, 2004. С. 462–484. Окладников А.П. Неандертальский человек и следы его культуры в Средней Азии. (Предварительные данные и выводы о раскопках в гроте Тешик-Таш) // СА. 1940. T. VI. С. 5–19. Отрощенко В. Проблема формування наукових шкіл на прикладі відділу археології енеоліту та бронзового віку ІА АН УРСР // Наукові студії: Збірник наукових праць. Львів-Винники: Апріорі, 2013. Вип. 6. С. 3–12. Отрощенко В.В. О.І. Тереножкін як дослідник бронзової доби в Степовій Україні // Ранній залізний вік Євразії: до 100-річчя від дня народження О.І. Тереножкіна / Відп. ред. С.А. Скорий. Київ–Чигирин: Формат, 2007. С. 13–14. И жизнь, и слезы, и любовь / сост. Плешивенко А.Г. Запорожье: ООО «ЛИПС» ЛТД, 2011. 368 с. Потапов А.А. Обзор тепе среднего течения Чирчика / Архив ГУОПМК УзССР. Ташкент, 1929. Д. 96. Потапов А.А. Пскентский курганный могильник / Архив ГУОПМК УзССР, 1930. Д. 31. Равдоникас В.И. Неолитический могильник на Онежском озере: (Предварительное сообщение) // СА. 1940. Т. VI. С. 46–62. Рапопорт Ю.А., Левина Л.М., Неразик Е.Е., Гертман А.Н., Болелов С.Б. Приложение 1. Хроника работ Хорезмской археолого-этнографической экспедиции // Аржанцева И.А. Хорезм. История открытий и исследований. Этнографический альбом. Ульяновск: Артишок, 2016. С. 198–234. Саєнко В. Порівняльні життєписи: Борис Миколайович Граков та Олексій Іванович Тереножкін // МДАПВ. 2015. Вип. 19: Історія археології: міжособистісні та інституціональні комунікації. С. 123–135. Сафонов И.Е. Подготовка В.А. Городцовым второго тома серии «Археология» // Археология в российских университетах / Отв. ред. А.Д. Пряхин. Воронеж: ВГУ, 2002. С. 62–70. Синицын И.В. Кремневые орудия с дюнных стоянок Калмыцкой области // ИНВИК. 1931. Т. IV. С. 81–91. Скаков А.Ю. Крупнов Евгений Игнатьевич // БРЭ. 2010. Т. 16. С. 128–129. Смирнов А.П. М. В. Городцов [Некролог] // СА. 1969. № 4. С. 320. Сташенков Д.А., Кочкина А.Ф. Страницы истории самарской археологии: к юбилею В.В. Гольмстен. Самара: СОИКМ, 2020. 48 с. Столяр А.Д. Деятельность Владислава Иосифовича Равдоникаса // Тихвинский сборник. Вып. 1: Археология Тихвинского края / Науч. ред. Г.С. Лебедев. Тихвин, 1988. С. 8–30. Тереножкин А.И. Памятники материальной культуры на Ташкентском канале // ИУзФАНСССР. 1940а. № 9. С. 30–36. Тереножкин А.И. Археологические разведки в Хорезме // СА. 1940б. Т. VI. C. 168–189. Тереножкин А.И. О древнем гончарстве в Хорезме // ИУзФ АН СССР. 1940в. № 6. С. 54–64. Тереножкин А.И. Жилые постройки XI–XII вв. н. э. в Кара-Калпакской АССР // ИУзФ АН СССР. 1940г. № 7. С. 58–73. Тереножкин А.И. Раскопки холма Ак-Тепе близ Ташкента в 1940 г. // ИУзФ АН СССР. 1941. № 3. С. 30–36. Тереножкин А.И. Холм Ак-Тепе Ташкента (раскопки 1940 г.) // ТИИА АН УзССР. 1948. Т. І. С. 71–133. Тереножкин А.И. Согд и Чач (Автореф. канд. дисс.) // КСИИМК. 1950. Вып. 33. С. 152–169. Тереножкин А.И. Основы хронологии предскифского периода // СА. 1965. № 1. С. 63–85. Тереножкин А. И. Киммерийцы. Киев: Наукова думка, 1976. 223 с. Тереножкин А.И. Из жизни Алексея Тереножкина (написано его рукой, собрано его сыном). Киев: Корвин пресс, 2006. 112 с. Тихонов И.Л. Равдоникас Владислав Иосифович // БРЭ. 2015. Т. 28. С. 113. Толстов С.П. Древний Хорезм. Опыт историко-археологического исследования. М.: МГУ, 1948. 433 с. Тункина И.В. Репников Николай Иванович / Биобиблиографический словарь членов РАО (1846–1924) // С.А. Жебелёв. Русское археологическое общество за третью четверть века своего существования. 1897–1921: Исторический очерк. Изд. 2. М.: Индрик, 2017. С. 512–513. Формозов А.А. К столетнему юбилею В.И. Равдоникаса // РА. 1996. № 3. С. 197–202. Черных Е.Н. Древняя металлообработка на Юго-Западе СССР. М.: Наука, 1976. 302 с. Шишкин В.А. Исследование городища Варахша и его окрестностей // КСИИМК. 1941. Вып. 10. С. 3–15. Шишкин В.А. Варахша. Опыт исторического исследования. М.: АН СССР, 1963. 250 с. Щапов А.П. Историко-географическое распределение русского народонаселения // Русское Слово. 1865. №№ 6, 7, 8, 9.

APA, Harvard, Vancouver, ISO, and other styles

6

Demetrio, D., A. Magalhaes, M. Oliveira, R. Santos, and R. Chebel. "11 Invivo-derived embryo pregnancy rates at Maddox Dairy from 2008 to 2018." Reproduction, Fertility and Development 32, no. 2 (2020): 130. http://dx.doi.org/10.1071/rdv32n2ab11.

Full text

Abstract:

Maddox Dairy, located in Riverdale, CA, USA, is a Holstein herd that milks 3500 cows with a 305-day mature-equivalent milk production of 12 800 kg, and they have been producing high genetic animals by embryo transfer (ET) since the early 1980s. Invivo-derived embryos from Holstein donors were transferred fresh (grade 1 or 2) or frozen (grade 1), at morula (4), early blastocyst (5), or blastocyst (6) stage, to virgin heifers (VH, natural oestrus, 13-15 months old) or lactating cows (LC, Presynch-Ovsynch, 86 days in milk, first or second lactation) 6 to 9 days after oestrus. Pregnancy diagnosis was done by transrectal ultrasonography at 32-46 days in VH and by the IDEXX PAG test at 30 days in LC. June, July, August, September, and October were called critical months (first service AI conception rate drops below 44%) and compared with the other months. The data from 32 503 ETs between January 2008 and December 2018 are summarised on Table 1. Pregnancy rates (PR) are lower for LC recipients than for VH. Embryo transfers performed 7 or 8 days after oestrus had higher PR in both types of recipients and embryos, but Day 6 and 9 oestrus are also used with fair results. The season does not seem to affect PR. There is not enough difference in the combination of stage and days from oestrus for invivo-derived embryos. These numbers do not belong to a planned experiment. Several management changes during the years were made, which make it very difficult to apply statistical methods to analyse the data correctly. They are used as a tool to make decisions in an attempt to improve future results. Table 1.Pregnancy rate (PR) of virgin heifers (top) and lactating cows (bottom)-fresh (SH) and frozen (OZ) invivo-derived embryo transfer1 Heat-months SH-ST4 SH-ST5 SH-ST6 SH-All OZ-ST4 OZ-ST5 OZ-ST6 OZ-All PR% n PR% n PR% n PR% n PR% n PR% n PR% n PR% n Heifers 6 d-CM 62 934 66 243 68 69 63 1246 56 473 58 219 62 42 57 734 6 d-OM 62 1623 67 489 69 211 64 2323 56 600 55 296 48 137 55 1033 6 d-T 62 2557 67 732 69 280 63 3569 56 1073 57 515 51 179 56 1767 7 d-CM 64 1506 68 495 67 221 65 2222 60 822 62 340 63 156 61 1318 7 d-OM 66 2723 68 1021 69 510 67 4254 57 1120 59 581 57 231 58 1932 7 d-T 66 4229 68 1516 69 731 67 6476 58 1942 60 921 60 387 59 3250 8 d-CM 65 1348 64 518 67 322 65 2188 59 595 64 258 63 108 61 961 8 d-OM 66 2166 68 886 70 510 67 3562 61 770 60 364 51 130 60 1264 8 d-T 66 3514 67 1404 69 832 66 5750 60 1365 62 622 56 238 60 2225 9 d-CM 60 109 56 43 70 20 60 172 60 5 33 6 50 4 47 15 9 d-OM 58 129 63 57 60 40 60 226 63 16 50 18 75 4 58 38 9 d-T 59 238 60 100 63 60 60 398 62 21 46 24 63 8 55 53 All-CM 64 3897 66 1299 67 632 65 5828 58 1895 61 823 63 310 60 3028 All-OM 65 6641 67 2453 69 1271 66 10 365 58 2506 58 1259 53 502 58 4267 All-T 65 10 538 67 3752 69 1903 66 16 193 58 4401 60 2082 57 812 59 7295 Lactating cows 6 d-CM 54 265 48 86 50 12 53 363 38 141 31 77 50 10 36 228 6 d-OM 49 463 52 203 45 56 50 723 46 101 48 54 59 27 48 182 6 d-T 51 728 51 289 46 68 51 1086 41 242 38 131 57 37 42 410 7 d-CM 54 755 59 274 56 103 55 1137 43 928 48 450 43 192 45 1570 7 d-OM 55 914 66 367 54 109 58 1393 46 1052 45 564 47 353 46 1969 7 d-T 55 1669 63 641 55 212 57 2530 45 1980 46 1014 46 545 45 3539 8 d-CM 63 252 68 82 76 33 65 368 48 219 56 80 42 33 50 332 8 d-OM 61 257 64 161 53 47 61 466 50 191 53 77 56 16 51 284 8 d-T 62 509 65 243 63 80 63 834 49 410 55 157 47 49 50 616 All-CM 56 1272 58 442 60 148 57 1868 44 1288 47 607 43 235 45 2130 All-OM 55 1634 62 731 51 212 56 2582 47 1344 46 695 48 396 47 2435 All-T 55 2906 60 1173 55 360 57 4450 45 2632 47 1302 46 631 46 4565 1ST=stage; CM=critical months (June, July, August, September, and October); OM=other months.

APA, Harvard, Vancouver, ISO, and other styles

7

Bezerra, Ilana Nogueira, Nila Mara Smith Galvão Bahamonde, Dirce Maria Lobo Marchioni, Dóra Chor, Letícia de Oliveira Cardoso, Estela ML Aquino, Maria da Conceição Chagas de Almeida, Maria del Carmen Bisi Molina, Maria de Jesus Mendes da Fonseca, and Sheila Maria Alvim de Matos. "Generational differences in dietary pattern among Brazilian adults born between 1934 and 1975: a latent class analysis." Public Health Nutrition 21, no. 16 (August 8, 2018): 2929–40. http://dx.doi.org/10.1017/s136898001800191x.

Full text

Abstract:

AbstractObjectiveTo identify generational differences in the dietary patterns of Brazilian adults born between 1934 and 1975.DesignA cross-sectional study from the baseline of the multicentre Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) cohort. Year of birth was categorized into three birth generations: Traditionalists (born between 1934 and 1945); Baby Boomers (born between 1946 and 1964); and Generation X (born between 1965 and 1975). Food consumption was investigated using an FFQ. Latent class analysis (LCA) was used to identify data-driven dietary patterns.SettingBrazil.SubjectsIndividuals (n 15 069) aged 35–74 years.ResultsA three-class model was generated from the LCA for each birth generation. Generation X presented higher energy intakes (kJ/kcal) from soft drinks (377·4/90·2) and sweets (1262·3/301·7) and lower energy intakes from fruit (1502·5/359·1) and vegetables (311·3/74·4) than Baby Boomers (283·7/67·8, 1047·7/250·4, 1756·0/419·7 and 365·3/87·3, respectively) and Traditionalists (186·2/44·5, 518·8/124·0, 1947·7/465·5 and 404·6/96·7, respectively). For Baby Boomers and Generation X, we found food patterns with similar structures: mixed pattern (22·7 and 29·7 %, respectively), prudent pattern (43·5 and 34·9 %, respectively) and processed pattern (33·8 and 35·4 %, respectively). Among Traditionalists, we could also identify mixed (30·9 %) and prudent (21·8 %) patterns, and a third pattern, named restricted dietary pattern (47·3 %).ConclusionsThe younger generation presented higher frequencies of consuming a pattern characterized by a low nutritional diet, compared with other generations, indicating that they may age with a greater burden of chronic diseases. It is important to develop public health interventions promoting healthy foods, focusing on the youngest generations.

APA, Harvard, Vancouver, ISO, and other styles

8

Dominietto, Alida, Anna Maria Raiola, Barbara Bruno, Maria Teresa van Lint, Francesco Frassoni, Carmen Di Grazia, Francesca Gualandi, et al. "Rapid Immune Reconstitution Following Unmanipulated Haploidentical BMT with Post-Transplant High Dose Cyclophosphamide." Blood 118, no. 21 (November 18, 2011): 3050. http://dx.doi.org/10.1182/blood.v118.21.3050.3050.

Full text

Abstract:

Abstract Abstract 3050 Background. Allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice for the majority of hematological malignancies. Early and successful immunologic reconstitution after HSCT reduces morbidity and mortality due to infection complications and improves survival. Aim of the study. We analyzed immune recovery after HSCT in 444 patients according to donor source. Patients and Methods. From January 2005 to June 2011 176 patients were grafted from HLA identical siblings (MSD), 125 from alternative donors (1 antigen mismatched family or unrelated donors) (ALT), 103 from unrelated cord blood grafted intra bone (CBIB) and 40 from haplo-identical mismatched family donors (HAPLO). All patients received unmanipulated bone marrow: 283 after a myeloablative (MA) conditioning regimen (CY-TBI or BU-CY) and 161 after a fludarabine based reduced intensity regimen (RIC). Graft versus host disease (GvHD) prophylaxis was cyclosporin methotrexate (CyA+MTX) for all patients except for CBIB (CyA and mycophenolate, MMF) and for HAPLO transplants which consisted of CyA+MMF and post-transplant high dose cyclophosphamide (HDCY) according to the Baltimore protocol (Lutznik et al BBMT 2008). Anti-thymocyte globulin (ATG) was used only for ALT transplants. Results. We compared immune reconstitution in MA and RIC transplants according to donor type at different time points post BMT. CD3+ absolute median counts/μl in MA conditioning on day+30, +90, +180 were respectively in MSD 477, 565, 700; in ALT donors were 146, 404, 470; in CBIB were 30, 57, 196; for HAPLO transplants they were 195, 182, 499. CD3+ absolute median counts/μl in RIC conditioning on day+30, +90, +180 were respectively in MSD 301, 660, 700; in ALT donors were 506, 186, 721; in CBIB 234, 399, 522; in HAPLO were 178, 276, 1300. CD4+ absolute median counts/μl in MA conditioning on day+30, +90, +180 were respectively in MSD 166, 170, 198; in ALT donors were 36, 86, 111; in CBIB 7, 36, 106; for HAPLO transplants they were 45, 127, 211. CD4+ absolute median counts/μl in RIC conditioning on day+30, +90, +180 were respectively in MSD 89, 189, 274; in ALT donors were 131, 210, 220; in CBIB 52, 110, 130; for HAPLO transplants they were 41, 205, 385. CD8+ absolute median counts/μl in MA conditioning on day+30, +90, +180 were respectively in MSD 280, 389, 500; in ALT donors were 102, 278, 413; in CBIB 42, 16, 51; in HAPLO transplants were 73, 424, 408. CD8+ absolute median counts/μl in RIC conditioning on day+30, +90, +180 were respectively in MSD 196, 432, 300; in ALT donors were 366, 65, 494; in CBIB 71, 167, 199; for HAPLO transplants they were 137, 129, 900. CD3, CD8, and CD4 counts in HAPLO transplants were not statistically different from MSD with the only exception of day +30, both for MA and RIC conditioning. Platelet median counts/μl on day+30, +90, +180 in MA conditioning were in MSD 142, 129, 180, in ALT 75, 101, 147, in CBIB were 19, 77, 128 and for HAPLO transplants were 67, 126, 128; in RIC conditioning platelets counts were in MSD 137, 156, 168, in ALT 33, 134, 142, in HAPLO were 77, 95, 188. Acute GvHD II-IV developed in 29% (MSD) 38% (ALT) 16% (CBIB) and 12% (HAPLO) (p=0.004) in MA conditioning and 40% (MSD) 18% (ALT) 25% (CBIB) and 10% (HAPLO) (p=0.07). Overall Cumulative Incidence of Non-Relapse Mortality (CI-NRM) was respectively 18% (MSD), 35% (ALT), 34% (CBIB), 22% (HAPLO) (p=0.02) in MA conditioning (p=0.02) and was 30% (MSD), 33% (ALT), 45% (CBIB), 0% (HAPLO) (p=0.02) in RIC conditioning (p=0.02). Day+100 CI-NRM was respectively 10% (MSD), 21% (ALT), 19% (CBIB), 12% (HAPLO) in MA conditioning (p=0.01) and 11% (MSD), 19% (ALT), 26% (CBIB), 0% (HAPLO) in RIC conditioning (p=0.02). Death due to infections were respectively 6% (MSD), 26% (ALT), 30% (IBCB), 17% (HAPLO) in MA conditioning and for RIC were 15 (MSD), 36% (ALT), 32% (IBCB), 0% (HAPLO). Conclusions. HAPLO transplant with HDCY post transplant as proposed by the Baltimore group, is associated with (1) rapid immunologic (CD3, CD4, CD8) recovery (2) low infectious death rate, (3) low overall and Day+100 CI-NRM, (4) rapid hematologic recovery. These results are comparable with those achieved with MSD and warrant further studies with HDCY post transplant as a GvHD prophylaxis. Figure: absolute CD4+ counts/μl on day+30, +90, +180, according to donor type in MA conditioning regimen. Disclosures: No relevant conflicts of interest to declare.

APA, Harvard, Vancouver, ISO, and other styles

9

Ahmad, Mushtaq, Farial Naima Rahman, Md Zubaidur Rahman, Md Zulfikar Ali, and Mohammad Ali. "Knowledge, Attitude and Practices Among Medical Students And Their Family Members Towards The COVID-19 Pandemic: An Online Based Cross-Sectional Study." KYAMC Journal 11, no. 4 (February 11, 2021): 166–70. http://dx.doi.org/10.3329/kyamcj.v11i4.51990.

Full text

Abstract:

Background: COVID-19 is an emerging infectious disease which has created a global health emergency status. It is now super spreading in the community of Bangladeshi population causing morbidity and mortality amongst masses. Objectives: The aim of this study is to find out the knowledge, attitude and practices of medical college students and their family members towards the Covid-19. Materials & Methods: This online cross sectional study was conducted from the 15 April to 30 April 2020 during the lockdown period in Bangladesh. Collected data was analyzed by using SPSS IBM version 22.0. Results: A total of 517 responses were obtained. The majority of the population 326 (63.06%) were female and 352 (68.09%) belonged to an age group of 21-30 years. This study has revealed that 412(79.69%) believe COVID-19 affect all age group, 311(60.15%) thinks that it affect the elder people seriously, 215(41.59%) thinks specific treatment is not available for COBID-19, Greater part of respondents 256(49.52%) says COVID-19 infection is preventable, 452(87.43%) gives positive opinion about government lockdown to avoid further spread of infection and 402(77.76%) believes physical distancing is helpful to prevent spread of this disease. Regarding 14 days quarantine period 375(72.53%) give positive answer, 425(82.20%) says COVID-19 affects world economy badly, 298(57.64%) thinks the situation may be controlled soon. Conclusion: Since prevention is better that cure, hence an increasing need of awareness amongst the local population regarding COVID-19 is required. Further extensive survey studies are required in future that can provide supportive data in developing and implementing public health policies regarding COVID-19 pandemic in our country. KYAMC Journal Vol. 11, No.-4, January 2021, Page 166-170

APA, Harvard, Vancouver, ISO, and other styles

10

Muhani, Nova, and Besral Besral. "Pre-eklampsia Berat dan Kematian Ibu." Kesmas: National Public Health Journal 10, no. 2 (November 8, 2015): 80. http://dx.doi.org/10.21109/kesmas.v10i2.884.

Full text

Abstract:

AbstrakPre-eklampsia berat, salah satu penyebab utama kematian ibu di Indonesia dan di RSUD Dr. H. Abdul Moeloek Lampung, merupakan penyebab kematian ibu nomor satu (47,25%). Penelitian ini bertujuan untuk mengetahui hubungan prediktor pre-eklampsi berat (PEB) yang dinilai dari tekanan darah sistolik, tekanan darah diastolik, proteiunuria, eklampsia, sindrom hemolysis, elevated liver enzymes, low platelets count (HELLP) dengan kematian ibu di RSUD Dr. H. Abdul Moeloek. Penelitian ini menggunakan desain kasus kontrol dengan jumlah sampel 60 kasus dan 120 kontrol. Data diolah dari rekam medis rumah sakit selama periode lima tahun (2010 – 2014). Hasil penelitian ini memperlihatkan bahwa sindrom HELLP memiliki risiko kematian ibu 12 kali lebih tinggi (95%CI 2,9 – 53,7) dan eklampsia memiliki risiko 12,1 kali lebih tinggi (95%CI 3,8 – 38,6). Tekanan darah diastolik 110 – 119 mmHg memiliki risiko 7,4 kali lebih tinggi (95%CI 1,8 – 29,2), tekanan darah diastolik ≥ 120 mmHg memiliki risiko 5,5 kali lebih tinggi (95%CI 1,1 – 23,1), tekanan darah sistolik > 190 mmHg memiliki risiko 2,1 kali lebih tinggi (95%CI 0,5 – 7,4), tekanan darah sistolik 170 – 190 mmHg memiliki risiko 1,6 kali lebih tinggi (95%CI 0,5 – 4,5), proteinuria +3 memiliki risiko 4,2 kali lebih tinggi (95%CI 0,3 – 27,4), proteinuria +4 memiliki risiko 3,2 kali lebih tinggi (95%CI 0,5 – 31,7) setelah dikontrol oleh usia ibu, gravida, usia kehamilan, metode persalinan, pemberian diasepam, pendidikan, tempat tinggal, dan pekerjaan. Oleh karena itu, perlu meningkatkan deteksi dini komplikasi kehamilan dan penanganan yang baik kasus preeklampsia untuk mencegah kematian ibu akibat eklampsia dan sindrom HELLP.AbstractSevere preeclampsia, one of main causes of maternal death in Indonesiaand at Dr. H. Abdul Moeloek Lampung Public Hospital, is the leading cause of maternal death (47.25%). This study aimed to determine relation of severe preeclampsia predictor as assessed from systolic blood pressure, diastolic blood pressure, proteiunuria, eclampsia and HELLP syndrome withmaternal death at Dr. H. Abdul Moeloek Public Hospital. This study usedcase control design with 60 cases and 120 control total of sample. Data was managed from hospital medical records during five years period (2010 – 2014). Results of study showed HELLP syndrome had risk of maternaldeath 12 times higher (95%CI 2.9 – 53.7) and eclampsia had the risk 12.1 times higher (95%CI 3.8 – 38.6). Then diastolic blood pressure 110 – 119 mmHg had the risk 7.4 times higher (95%CI 1.8 – 29.2), diastolic blood pressure ≥ 120 mmHg had the risk 5.5 times higher (95%CI 1.1 – 23.1), sistolic blood pressure > 190 mmHg had the risk 2.1 times higher (95%CI 0.5 – 7.4), sistolic blood pressure 170 – 190 mmHg had the risk 1.6 times higher (95%CI 0.5 – 4.5), proteinuria +3 had the risk 4.2 times higher (95%CI 0.3 – 27.4), proteinuria +4 had the risk 3.2 times higher (95%CI 0.5 – 31.7) after controlled by maternal age, gravida, pregnancy age, delivery method, diazepam provision, education, domicile and employment. Therefore, it needs to improve early detection of pregnancy complication and good management of preeclampsia case to prevent maternal death due to eclampsia and HELLP syndrome.

APA, Harvard, Vancouver, ISO, and other styles

11

Kuzmitskaya, P. V., K. S. Karaleva, and O. Yu Urbanovich. "Apple gene MD13G1109800 is a member of Trihelix family transcription factors and expressed in response to abiotic stress." Proceedings of the National Academy of Sciences of Belarus, Biological Series 66, no. 4 (November 10, 2021): 426–32. http://dx.doi.org/10.29235/1029-8940-2021-66-4-426-432.

Full text

Abstract:

The Trihelix family of transcription factors plays an important role in the plant’s response to various abiotic stress types. In this work in apple Golden Delicious genome we identified apple gene MD13G1109800 as a member of Triheilx family in silico. Analysis of chromosomal localization showed that it is located on chromosome 13 and has four introns. The hypothetical protein encoded by it has a length of 365 amino acid residues, a molecular weight of 42097.23 Da, an isoelectric point pI = 6.21 and located in the nucleus. Analysis of the promoter region of the MD13G1109800 gene indicates that its product is a member of many signaling pathways triggered by both external and internal factors. The expression level of the MD13G1109800 gene increases under drought, low and high temperatures, as well as salinity in the MM-106 apple rootstock.

APA, Harvard, Vancouver, ISO, and other styles

12

Нуретдинова, Алсу Ренатовна. "СФЕРОКОНИЧЕСКИЕ СОСУДЫ ЦАРЕВСКОГО ГОРОДИЩА." Археология Евразийских степей, no. 4 (September 29, 2021): 130–40. http://dx.doi.org/10.24852/2587-6112.2021.4.130.140.

Full text

Abstract:

Сфероконические сосуды – особая категория посуды полифункционального назначения, часто встречающаяся на средневековых поволжских памятниках археологии. В статье рассматриваются основные типы сфероконусов Царевского городища, хранящиеся в Археологическом музее Казанского федерального университета, Волгоградском областном краеведческом музее, Государственном Эрмитаже, а также форма из камня для изготовления конусообразных сосудов. Обзор этих изделий в контексте изучения сфероконических сосудов с других золотоордынских памятников позволяет установить особенности их бытования на нижневолжских памятниках. ЛИТЕРАТУРААбызова Е.Н. К вопросу о сфероконусах из Старого Орхея и Костешт // Археологические исследования в Молдавии в 1977-1978 гг. / Отв. ред. П.П. Бырня. Кишинев: Штиинца, 1982. С. 171–174.Алпаткина Т.Г. Место стеклянных сфероконусов из Золотой Орды в общей классификации этого вида ремесленных изделий // Золотоордынская цивилизация. Вып. 4 / Отв. ред. И.М. Миргалеев. Казань: Фолиант; Институт истории им. Ш. Марджани АН РТ, 2011. С. 238–244.Валиулина С.И. Стекло Волжской Булгарии (по материалам Билярского городища). Казань: КГУ им. В.И. Ульянова-Ленина, 2005. 280 с.Виноградов З.З. Сфероконические сосуды с узким горловым отверстием // Казанский музейный вестник. 1922. №2. С. 75–119.Волков И.В. Химическая посуда в золотоордынских городах // 125 лет обществу археологии, истории и этнографии при Казанском университете. Проблемы историко-культурного развития Волго-Уральского региона. Археологические исследования: сб. научных докладов и сообщений. Ч. 1 / Под ред. С.И. Валиулиной. Казань: КГУ, 2004. С. 145–149.Джанполадян Р.М. Сфероконические сосуды из Двина и Ани // СА. 1958. №1. С. 201–213.Джанполадян Р.М. Сфероконические сосуды из Двина и Ани. Ереван: АН АрмССР, 1982. 50 с.Зиливинская Э.Д., Васильев Д.В., Гречкина Т.Ю. Раскопки на городище Самосделка в астраханской области в 2000-2004 гг. // РА. 2006. №4. С. 24–35.Йосифов Д. За технологичните особености на каменните калъпи от София // Изследвания по българска средновековна археология / Отг. ред. П. Георгиев. Велико Търново: Фабер, 2007. С. 396–404.Кравченко A.A. Средневековый Белгород на Днестре (конец XIII–XIV в.). Киев: Наукова думка, 1986. 186 с.Кротков А.А. Сфероконические сосуды из Археологического Отдела Саратовского Государственного Областного музея // Труды Нижне-Волжского областного научного общества. Саратов, 1926. Вып. 35, ч. 1. С. 51–66.Ленц Э. О глиняных сосудах с коническим дном, находимых в пределах мусульманского востока // ЗВОРАО. Т. 15, Вып. 4. СПб.: Типография Императорской Академии Наук, 1904.. С. 101–115.Масловский А.Н. Керамический комплекс Азака.Краткая характеристика // Историко-археологические исследования в г. Азове и на Нижнем Дону в 2004 году. Вып. 21. / Отв. ред. В.Я. Кияшко.Азов: Азовский музей-заповедник, 2006. С. 417–420.Недашковский Л.Ф. Золотоордынский город Укек и его округа. М.: Восточная литература, 2000. 224 с.Нуретдинова А.Р. Сфероконические сосуды из старых собраний (XIX – начало XX вв.) музеев России. Казань: Изд-во Казан. ун-та, 2018. 108 с. URL: https://shelly.kpfu.ru/e-ksu/docs/F_1521378007/Sferokonusy_elektr..izdanie.pdf (дата обращения: 31.05.2021). Нуретдинова А.Р. Типология сферо-конических сосудов Волжской Булгарии // Урало-Поволжье в древности и средневековье. Материалы международной научной конференции V Халиковские чтения / Археология Евразийских степей. Вып. 11 / Отв. ред. Ф.Ш. Хузин. Казань: Институт истории АН РТ, 2011. С. 150-160.Пигарев Е.М. Сфероконические сосуды из фондов Астраханского краеведческого музея-заповедника // Древности Волго-донских степей Вып. 4. / Ред. В.И. Мамонтов. Волгоград: Перемена, 1994. С. 210–215.Полевой Л.Л. Городское гончарство Пруто-Днестровья в XIV в.: по материалам раскопок гончарного квартала на поселении Костешны. Кишинев: АН МолдССР, 1969. 211 С. 135–136.Ртвеладзе Э.В. Сфероконические сосуды из Маджар // СА. 1974. №4. С. 280–284.Самашев З., Кузнецова О., Плахов В. Керамика Сарайчика ( на казахском, русском и английском языках). Алматы: ZUR advertizing, 2008. 264 сСкэнлон Дж.Т. Заметка о фатимидско-сельджукской торговле // Мусульманский мир / Отв. ред. В.В. Наумкин, М.Б. Пиотровский. М.: Наука, 1981. С. 282–291.Станчева М. Каменни калъпи за сфероконуси от София // Археология. 1961. № 1. С. 22–27.Древние памятники, отрываемые в Царевском уезде Саратовской губернии // ЖМВД. Спб., 1843. Ч. II. С. 426–430.Трубникова Н.В. Обломок сфероконического сосуда из Булгар // Сборник статей по археологии СССР. Труды ГИМ. Вып. XI / Под ред. Д.Н. Эдинга. М.: Изд-во ГИМ, 1940. С. 137–139.Федоров-Давыдов Г.А. Научный отчет о раскопках 1962 г. на городище Сарай-Берке – столицы Золотой Орды / Архив ВОКМ. Д. 12.Федоров-Давыдов Г.А. Научный отчет о раскопках на Царевском городище /Сарай-Берке/ в 1964 г. / Архив ВОКМ. Д. 17.Федоров-Давыдов Г. А. Золотоордынские города Поволжья. М.: Изд. МГУ, 1994. 232 с.Федоров-Давыдов Г.А. Раскопки Нового Сарая в 1959 – 1962 гг. // СА. 1964. № 1. С. 248–271.Федоров-Давыдов Г.А., Вайнер И.С. Мухамадиев А.Г. Археологические исследования Царевского городища (Новый Сарай) // Поволжье в средние века / Отв. ред. А.П. Смирнов. М.: Наука, 1970. С. 68–171.Feherwari G. Ceramics of the Islamic World inthe Tareg Rajab Museum. I.B. Tauris. London, New York, 2000. 399 p.Ettinghausen R. The uses of sphero-conical vessels in the Muslim East // Journal of Near Eastern Studies, 1965. V. XXIV, № 3. P. 218–229.Mănucu-Adameşteanu Gh. Din nou despre vasele sferoconice in lumina descoperirilor din nordul Dobrogei // Peuce: rapoarte, cataloage, studiişi note de istorieşi arheologie. 1984. Peuce IX (seria istorie). P. 363–374, 716–723.Monchamp J. Sphero-conical Vessels from the Ayyubid Wall in Cairo: A Typology (11th–15th c.) // Journal of Islamic Archaeology. 2016. Vol. 3, № 2. P. 195–207.Nicolle D. Medieval Islamic Fire Grenades: Further Evidence from a Military Context // Journal of Islamic Archaeology. 2016. Vol. 3, № 2. P. 163–177.Sharvit J. The sphero-conical vessels // IAA Report. Paneas. Vol. II. Small finds and other studies. 2007. № 38. P. 101–112. Stănică A.-D., Szmoniewski B.S. The sphero-conical vessels from Lower Danube in the ligth of new discoveries from Isaccea, county Tulcea, Romania // Sprawozdania Archeologiczne. 2016. № 68. P. 327–344.Valiulina S. Medieval workshop of an alchemist, Jeweller and Glassmaker in Bilyar (Middle Volga Region, Russian Federation) // Pamatky Archeologicke. 2016. Vol. 107. P. 237–278.Vezzoli V. Sphero-conical Vessels from Baalbek: A Diverse and Challenging Collection // Journal of Islamic Archaeology. 2016. Vol. 3, № 2. P. 209–231.Whitcomb D. A Note on “Grenades” as Fire-starter Flasks // Journal of Islamic Archaeology. 2016. Vol. 3, № 2. P. 179–186.Wulzinger K., Wittek P., Sarre F. Tongranaten oder Handbrandgeschosse // Das islamische Milet. Berlin; Leipzig, 1935. S. 76–78.

APA, Harvard, Vancouver, ISO, and other styles

13

Guérin, Claude, Martin Cour, Neven Stevic, Florian Degivry, Erwan L’Her, Bruno Louis, and Laurent Argaud. "Simultaneous ventilation in the Covid-19 pandemic. A bench study." PLOS ONE 16, no. 1 (January 19, 2021): e0245578. http://dx.doi.org/10.1371/journal.pone.0245578.

Full text

Abstract:

COVID-19 pandemic sets the healthcare system to a shortage of ventilators. We aimed at assessing tidal volume (VT) delivery and air recirculation during expiration when one ventilator is divided into 2 test-lungs. The study was performed in a research laboratory in a medical ICU of a University hospital. An ICU (V500) and a lower-level ventilator (Elisée 350) were attached to two test-lungs (QuickLung) through a dedicated flow-splitter. A 50 mL/cmH2O Compliance (C) and 5 cmH2O/L/s Resistance (R) were set in both A and B test-lungs (A C50R5 / B C50R5, step1), A C50-R20 / B C20-R20 (step 2), A C20-R20 / B C10-R20 (step 3), and A C50-R20 / B C20-R5 (step 4). Each ventilator was set in volume and pressure control mode to deliver 800mL VT. We assessed VT from a pneumotachograph placed immediately before each lung, pendelluft air, and expiratory resistance (circuit and valve). Values are median (1st-3rd quartiles) and compared between ventilators by non-parametric tests. Between Elisée 350 and V500 in volume control VT in A/B test- lungs were 381/387 vs. 412/433 mL in step 1, 501/270 vs. 492/370 mL in step 2, 509/237 vs. 496/332 mL in step 3, and 496/281 vs. 480/329 mL in step 4. In pressure control the corresponding values were 373/336 vs. 430/414 mL, 416/185 vs. 322/234 mL, 193/108 vs. 176/ 92 mL and 422/201 vs. 481/329mL, respectively (P<0.001 between ventilators at each step for each volume). Pendelluft air volume ranged between 0.7 to 37.8 ml and negatively correlated with expiratory resistance in steps 2 and 3. The lower-level ventilator performed closely to the ICU ventilator. In the clinical setting, these findings suggest that, due to dependence of VT to C, pressure control should be preferred to maintain adequate VT at least in one patient when C and/or R changes abruptly and monitoring of VT should be done carefully. Increasing expiratory resistance should reduce pendelluft volume.

APA, Harvard, Vancouver, ISO, and other styles

14

Кравченко, Эдуард Евгеньевич. "ПРЕДМЕТЫ ВООРУЖЕНИЯ И КОНСКОГО СНАРЯЖЕНИЯ ХАЗАРСКОГО ВРЕМЕНИ (СРЕДНЕЕ ТЕЧЕНИЕ СЕВЕРСКОГО ДОНЦА)." Археология Евразийских степей, no. 6 (December 20, 2020): 198–223. http://dx.doi.org/10.24852/2587-6112.2020.6.198.223.

Full text

Abstract:

Статья посвящена находкам предметов вооружения и конского снаряжения, выявленным на памятниках салтово-маяцкой культуры, расположенных в среднем течении р. Северский Донец. В верхнем ее течении (в пределах лесостепной зоны) эти предметы являются частой находкой и встречаются в основном в захоронениях катакомбных и кремационных некрополей. В степи они попадаются реже, что вызвало появление версий о слабом знакомстве проживавшего здесь населенияс военным делом. Анализ материалов, выявленных в среднем течении Северского Донца, показывает несостоятельность указанных точек зрения. На расположенных здесь памятниках предметы вооружения и конского снаряжения встречаются достаточно часто. Так, на крупном поселении у с. Маяки Славянского р-на количество предметов этой категории составляет около 20% от общего количества находок металлических изделий. Данный вывод вполне согласуется с наличием в рассматриваемом регионе группы укрепленных поселений (Донецких городищ), оборонять которые без значительного воинского контингента не представляется возможным. Вполне логично, что большая часть находок предметов вооружения сконцентрирована именно на этих памятниках. Библиографические ссылки Аксенов В.С. Комплексы конского снаряжения салтовского времени с начельниками (по материалам Верхнесалтовского катакомбного могильника) // Степи Европы в эпоху средневековья. Т 4. Хазарское время / Гл.ред. А.В. Евглевский. Донецк: ДонНУ, 2005. С. 245−260. Аксенов В.С. Новые поминальные комплексы воинов-всадников салтовского времени с территории Верхнего Подонечья // Степи Европы в эпоху средневековья. Т 4. Хазарское время / Гл.ред. А.В. Евглевский. Донецк: ДонНУ, 2005а. Т.4. С. 357−368. Аксенов В.С., Колода В.В. Богатый вещевой комплекс близ Старой Покровки на Харьковщине // Хазарский альманах. Т.15. / Гл. ред. О.Б. Бубенок. М.: Институт славяноведения РАН, 2017. С. 37−57. Армарчук Е.А. Конская упряжь из могильников Северо-Восточного Причерноморья X–XIII вв. М.: ИА РАН, 2006. 226 с. Артамонов М.И. Саркел – Белая Вежа // МИА. № 62 / Отв. ред. М.И. Артамонов. М.-Л.: АН СССР, 1958. С. 7–84. Бабенко В.А. Древние памятники Хозарской культуры в сел. Верхнем Салтове // Труды XV Археологического съезда в Новгороде. Т. I. М., 1914. С. 446−464. Бартольд В.В. Введение к изданию Худуд ал-‛āлам // Сочинения. Т.VIII. М.: Наука, 1973. С. 504−545. Бобров Л.А., Худяков Ю.С. Вооружение и тактика кочевников Центральной Азии и Южной Сибири в эпоху позднего средневековья и раннего Нового времени (XV – первая половина XVIII в.). СПб.: Филологический факультет СПбГУ, 2008. 776 с. Габуев Т.А. Аланский всадник. Сокровища князей I–XII веков. Каталог выставки. М.: Государственный музей Востока (ГМИНВ), 2005. 74 с. Голубев А.М. Хронология салтовских памятников Верхнего Подонцовья в контексте венгерской проблематики // // III Междунарoдный мадьярский симпозиум (Будапешт, 6–10 июня 2016 г.) / Ред. А. Тюрк, А.С. Зеленков. Будапешт: 2018. С. 367–402. Голубєв А.М. Салтово-маяцький кремаційний могильник «Государів Яр» у Середньому Подонців’ї. // Археологія. 2017. №2. С. 57–64. Гриб В.К. Щит, как элемент защитного вооружения у населения Салтово-Маяцкой культуры // Вестник Донецкого национального университета. Серия Б. Гуманитарные науки. 2019. №3. С. 23−28. Гриб В.К., Швецов М.Л. Серебряный пояс из погребения 40 могильника Зливки // Археология как жизнь. Памяти Евгения Павловича Мыськова / Под ред. Е.В. Круглова, А.С. Лапшина, И.Ю. Лапшиной. Волгоград: Сфера, 2019. С. 158−173. Грінченко В.А. Памятка VIII ст. коло с. Вознесенки на Запоріжжі // Археологія. Т.III. К.: Вид. АН УССР, 1950. С. 37−63. Давыденко В.В., Гаврилова А.Н. Новый комплекс раннего средневековья «Государев Яр» в Святогорье // Святогірський альманах 2011. / Ред.-упоряд. В.М. Дєдов. Донецк: Вид. «Донбас», ТОВ «РА Ваш імідж», 2011. С. 20−31. Давыденко В.В., Гриб В.К. «Государев Яр» - новый памятник X-XI вв. в среднем течении Северского Донца (предварительная публикация) // Археологический альманах. № 25 / Гл. ред. А.В. Колесник. Донецк: Бытсервис, 2011. С. 25–269. Дедов В.Н., Швецов М.Л. Находка древнерусского меча в Донбассе // СА. 1987. №1. С. 262−263. Дмитриев А.В. Могильник Дюрсо – эталонный памятник древностей IV-IX вв. // Крым, Северо-Восточное Причерноморье и Закавказье в эпоху средневековья IV-XIII вв. / Отв. ред. Т.И. Макарова, С.А. Плетнева. М.: Наука, 2003. С. 200−206. Дьячков С.В. X научная конференция-презентация «Проблемы исследования и охраны историко-культурного наследия Украины» Итоги полевых исследований в 2015 году // Древности. 2016. Вып. 14. С. 222–225. Кирпичников А.Н. Древнерусское оружие. Копья, сулицы, боевые топоры, булавы, кистени. IX–XIII вв. Вып. II / САИ. Вып. Е1-36. М.-Л.: Наука, 1966. 181 с. Кирпичников А.Н. Снаряжение всадника и верхового коня на Руси IX-XIII вв. / САИ. Вып. Е-1-36. Л.: Наука,1973. 140 c. Колода В.В. Два салтовских комплекса из Государева Яра // Салтово-маяцька археологічна культура: проблеми та дослідження. Вип. 3 / Отв. ред. О.О. Савчук. Харків: ОКЗ «ХНМЦОКС», 2013. С. 73–81. Колода В.В. О хозяйственных со стандартизированными наборами предметов на салтовских поселениях // Проблемы истории и археологии Украины. Материалы IX международной научной конференции / Отв. ред. С.В. Дьячков Харьков, 2014. С. 54–55. Колода В.В., Колода Т.А. Кузнечная мастерская нового ремесленного центра лесостепной Хазарии // Хазарский альманах. Т. 8 / Гл. ред. Н.Н. Олейник. Киев-Харьков: Изд-во Международного Соломонового университета, 2009. С. 203–215. Комар А.В., Сухобоков О.В. Вооружение и военное дело Хазарского каганата // Восточноевропейский археологический журнал. 2000. № 2(3), март-апрель. Доступно по URL: http://archaeology.kiev.ua/journal/020300/komar_sukhobokov.htm (дата обращения: 04.12.2020) Кравченко Э.Е. Городища среднего течения Северского Донца // Хазарский альманах. № 3 / Гл. ред. В.К. Михеев. Киев-Харьков: Изд-во Международного Соломонового университета, 2004. С. 242–276. Кравченко Э.Е. Исследование хозяйственного объекта на археологическом комплексе у с. Сидорово в среднем течении Северского Донца // Проблеми збереження і використання культурної спадщини в Україні. Слов’янськ: Печатный двор, 2005. С. 208–222. Кравченко Э.Е. Памятники золотоордынского времени в степях между Днепром и Доном // Генуэзская Газария и Золотая Орда / Отв. ред. С.Г. Бочаров, А.Г. Ситдиков. Кишинёв: Stratum plus, 2015. С. 407−474. Кравченко Э.Е. Оборонительные сооружения археологического комплекса у с. Сидорово // Поволжская археология. 2018. № 2(24). С. 10−32. Кравченко Э.Е. Сидоровский археологический комплекс на р. Северский Донец / Археология Евразийских степей. 2020. №4. 344 с. Кравченко Э.Е., Давыденко В.В. Сидоровское городище // Степи Европы в эпоху средневековья. Т. 2 / Гл. ред. А.В. Евглевский. Донецк: Изд-во ДонНУ, 2001. С. 233–302. Кравченко Э.Е. Петренко А.Н., Шамрай А.В. Отчет об исследованиях на археологическом комплексе Маяки в 2008 году // НА ИА НАНУ №2008/82. Кравченко Э.Е., Шамрай А.В. О группе комплексов с Царина городища (среднее течение Северского Донца) // Проблеми збереження і використання культурної спадщини в Україні. Матеріали II Всеукраїнської науково-практичної конференції, присвяченої 10-й річниці надання Святогірському Успенському монастиреві статусу Лаври (2004), 170-річчю відновлення Святогірського Успенського монастиря (1844), 80-річчю створення краєзнавчого музею М.В.Сібільовим у Святогірську (1934).25-26 вересня 2014 року м. Святогірськ. Донецьк: ТОВ «Східний видавничий дім», Ваш імідж, 2014. С. 183–192. Красильников К.И. Этнокультурные признаки населения степей Хазарской периферии (к вопросу об идентификации) // Научные труды по иудаике. Материалы XVII Международной ежегодной конференции по иудаике. Т. II / Отв. ред. В.В. Мочалова. М.: Пробел-2000, 2010. С. 16–32. Крыганов А.В. Вооружение и конское снаряжение кочевников юга Восточной Европы VII-X вв. Дисс. ... канд. истор. наук. Харьков: Харьковский Государственный университет. 1987 //НА ИА НАНУ Ф. 12; № 656. Локтюшев С.А. Научно-ценные ранне-исторические памятники, выявленные археологическими раскопками в Ворошиловградской области // Краєзнавчі записки. 2009. Вип. V. С. 299–300. Мажитов Н.А. Бахмутинская культура. Этническая история населения Северной Башкирии середины I тысячелетия нашей эры. М.: Наука, 1968. 161 с. Майко В.В., Гаврилов А.В., Гукин В.Д. Комплекс оружия, конского снаряжения и бытовых предметов с праболгарского поселения IX – 1-й пол. X вв. в Юго-Восточном Крыму // Хазарский альманах. Т. 8 / Гл. ред. Н.Н. Олейник. Киев-Харьков: Изд-во Международного Соломонового университета, 2009. С. 237–263. Матвеева Г.И. Могильники ранних болгар на Самарской Луке. Самара: Самарский университет, 1997. 226 с. Матеріальна та духовна культура населення Подінців’я в період середньовіччя VIII-XIV ст. на прикладі городища «Царине» (Маяцьке). Каталог виставки / Автори укладачі Дєдов В.Н., Шамрай А.В., Соловкін О.О. Київ: Вид. САМ. 2017. 95 с. Медведев А.Ф. Ручное метательное оружие. Лук и стрелы. Самострел / САИ. Вып. Е1-36. М.: Наука. 1966. 154 с. Михеев В.К. К итогам исследований поселения салтово-маяцкой культуры у с.Маяки. Рукопись. 1968 а. 11 с. Михеев В.К. Отчет о работе средневековой археологической экспедиции ХГУ им. А.М. Горького в 1971 г. // НА ИА НАНУ № 1971/76. Михеев В.К. Отчет о раскопках поселения и могильника салтовской культуры у с. Маяки летом 1965 г. //НА ИА НАНУ №1965/18. Михеев В.К. Отчет об археологических исследованиях поселения салтово-маяцкой культуры у с. Маяки в 1968 г. // Архив ИА НАНУ 1968/48. Михеев В.К. Отчет об археологических раскопках поселения у с. Маяки в 1964 г. // НА ИА НАНУ №1964/28 Михеев В.К. Отчет об археологических раскопках у с. Маяки Славянского р-на Донецкой обл. // НА ИА НАНУ 1966/80. Михеев В.К. Подонье в составе Хазарского каганата. Харьков, 1985. 148 с. Михеев В.К. Результаты археологических работ на Маяцком городище в 1963 г. // Архив музея истории и этнографии Слободской Украины Харьковского национального университета. Ф. 1; Оп. 2; Ед. хр. 4. Орлов Р.С., Моця А.П., Покас П.М. Исследования летописного Юрьева на Росси и его окрестностей // Земли Южной Руси IХ-ХIV вв. / Под ред. П.П. Толочко. К.: Наукова думка, 1985. С. 41−60. Плетнева С.А. От кочевий к городам / МИА. № 142. М.: Наука, 1967. 198 с. Плетнева С.А. На славяно-хазарском пограничье. Дмитриевский археологический комплекс. М.: Наука, 1989. 288 с. Плетнева С.А. Очерки хазарской археологии. М.; Иерусалим: Гешарим / Мосты культуры, 1999. 280 с. Сібільов М.В. Археологічні пам’ятки на Дінці у зв’язку з походами Володимира Мономаха та Ігоря Новгород Сіверського // Археологія, Вип. IV. К.: Вид. АН УССР, 1950. С. 99−114. Сорокин С.С. Железные изделия Саркела-Белой Вежи // МИА. № 75 / Отв. ред. М.И. Артамонов. М.-Л.: Изд-во АН СССР, 1959. С. 148–150. Татаринов С.И., Копыл А.Г. Дроновские древнеболгарские могильники на р. Северский Донец // СА. 1981. №1. С. 300−307. Татаринов С.И., Копыл А.Г., Шамрай А.В. Два праболгарских могильника на Северском Донце // СА. 1986. №1. С. 209−221. Тахтай А.К. Погребальный комплекс хазарского времени из округи г. Чистяково Сталинской области // Vita antiqua. 1999. №2. С. 160−169. Федоров-Давыдов Г.А. Кочевники Восточной Европы под властью золотоордынских ханов. Археологические памятники. М.: Изд-во МГУ, 1966. 276 с. Ходжайов Т.К., Швецов М.Л., Ходжайова Г.К., Фризен С.Ю. Население Подонцовья эпохи Золотой Орды (по материалам могильников у с. Маяки) // Степи Европы в эпоху средневековья. Т. 11. Золотоордынское время. / Гл. ред. А.В. Евглевский.. Донецк: ДНУ, 2012.С. 125−192. Худяков Ю.С. Вооружение енисейских кыргызов. Новосибирск: Наука, 1980. 176 с. Худяков Ю.С. Вооружение средневековых кочевников Южной Сибири и Центральной Азии. Новосибирск: Наука, 1986. 269 с. Худяков Ю.С. Вооружение центральноазиатских кочевников в эпоху раннего и развитого средневековья. Новосибирск: Наука, 1991. 190 c. Швецов М.Л. Могильник Зливки // Проблеми на прабългарската история и култура. Т.2. София: Аргес, 1991. С. 109−123. Швецов М.Л. Погребение 40 могильника Зливки // Проблемы истории и археологии Украины. Материалы международной научной конференции / Отв. ред. С.Б. Сорочан. Харьков: ХНУ, 2001. С. 110–111. Швецов М.Л., Кравченко Э. Е. Отчет об археологических исследованиях экспедиции в 1988 г. // НА ИА НАНУ 1988/165. Швецов М.Л., Кравченко Э.Е. Отчет о спасательных археологических исследованиях на памятнике у с. Маяки и пос. Донецкого Славянского р-на Донецкой обл. в 1989 г. //НА ИА НАНУ №1989/249. 22 с.

APA, Harvard, Vancouver, ISO, and other styles

15

Chebotarev, A. N., I. S. Efimova, E. V. Raboshvil, and E. M. Rakhlitskaya. "Redox-Reaction Products Of 4-Sulfo-2-(4'-Sulfonaphthalene-1'-Azo) Naphthol-1 With Ce(IV) - New Analytical Forms For Its Quantitative Determination." Methods and Objects of Chemical Analysis, no. 4 (2018): 167–76. http://dx.doi.org/10.17721/moca.2018.167-176.

Full text

Abstract:

The results of redox interaction of Ce (IV) with 4-sulfo-2-(4’-sulfonaphthalene-1’-azo) naphthol-1 (carmosine- KAN) in aqueous solutions (pH 1.75) have been presented. The destructive oxidation of CAS into two fragments (2-nitroso-4-sulfonaphthol-1 (L1) and 1-nitroso-4-sulfonaphthalene (L2)) is accampanied by reduction of Ce(IV) to Ce(III). It was found that an increase in the Ce(III) -L1 -L2 system acidity to pH ~ 11 leads to formation of the [Ce(III)(ОН)2·L1·2Н2О] complex. After acetonitrile is introduced to [Ce(III)(ОН)2·L1 ·2Н2О] – L2 system (up to 40 % by volume) self-organization of products involving CH3CN is observed. The resulting water-acetonitrile system becomes turbid, and after ~10 min phase separation is observed. Phase I contains a solvate {L2·(CH3CN)п } of «straw» color (360 nm) and phase II (lower layer) contains solvated complex {[Ce (III) (ОН) 2 ·L 1 ·(CH 3 CN) 2 ]·(CH 3 CN)n} of «blue» color (640 nm). The use of these solvates allows determination of Ce(IV) in the range 2.2 ч 50.1 μg/cm3 (y = 0.5526с + 0.0575, R2 = 0.9917, ε360 = 6.2·103) and 4.2 ч 84.0 μg/cm3 (y = 0.1862c + 0.0265, R2 = 0.9952, ε640 = 2.05·103), respectively. The revealed dependence was used for indirect (volumetric) determination of Ce(IV) (y = -0.7857c + 20.4440, R2=0.9988). The methods was tested on standard samples of mineral origin and herbal pharmaceutical preparations.

APA, Harvard, Vancouver, ISO, and other styles

16

Zimmermann, Camilla, Nadia Swami, Gary Rodin, Ian Tannock, Monika K. Krzyzanowska, Natasha B. Leighl, Amit M. Oza, Malcolm J. Moore, Anne Rydall, and Allan Donner. "Cluster-randomized trial of early palliative care for patients with metastatic cancer." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 9003. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.9003.

Full text

Abstract:

9003 Background: Patients with metastatic cancer have compromised quality of life (QOL), which tends to worsen towards the end of life. We conducted a cluster-randomized trial of early versus routine palliative care in patients with metastatic cancer, to assess impact on QOL, symptom control and satisfaction with care. Methods: Twenty-four medical oncology clinics were randomized, stratified by tumour site (4 lung clinics, 8 gastrointestinal, 4 genito-urinary, 6 breast, 2 gynecological), to intervention and follow-up (at least monthly) by a palliative care team, or to routine cancer care. Eligible patients had ECOG performance status 0-2 and a clinical prognosis of 6 months to 2 years. Patients completed measures of QOL (FACIT-Sp, including physical, social, emotional, functional and spiritual well-being; range 0-156, with higher scores indicating better QOL), symptom severity (Edmonton Symptom Assessment System; range 0-90, with higher scores indicating worse symptom severity), and satisfaction with care (FAMCARE-P16; score range 16-80) at baseline and monthly for 4 months. The primary outcome was the change in FACIT-Sp at 3 months. The planned sample size was 225 patients per arm, assuming 80% power and a 2-sided significance level of 0.05. Results: From December 2006 to September 2010, 461 patients completed baseline measures (228 intervention, 233 control); 442 patients completed at least one follow-up assessment (mean patients/cluster 18.8±11.6 control, 18.1±12.6 intervention). At 3 months, patients in the intervention group had marginally improved QOL (mean change in intervention vs. control, 1.6±14.5 vs. -2.0±13.6, p=0.07) but not symptom severity (0.1±16.9 vs. 2.1±13.9, p=0.34). At 4 months the change in QOL was more marked (2.5±15.5 vs. -4.0±14.2, p=0.008) and symptom severity was marginally better (-1.3±16.0 vs. 3.2±13.9, p=0.05). Improvement in satisfaction with care was evident at one month (p=0.001) and remained significant at both 3 months (2.3±9.1 vs.-1.8±8.2, p=0.001) and 4 months (3.7±8.6 vs. -2.4±8.3, p<0.001). Conclusions: In patients with metastatic cancer, early palliative care intervention immediately improved satisfaction with care, while QOL and symptom control improved later.

APA, Harvard, Vancouver, ISO, and other styles

17

Skyrud, Katrine Damgaard, Kjersti Helene Hernæs, Kjetil Elias Telle, and Karin Magnusson. "Impacts of mild COVID-19 on elevated use of primary and specialist health care services: A nationwide register study from Norway." PLOS ONE 16, no. 10 (October 8, 2021): e0257926. http://dx.doi.org/10.1371/journal.pone.0257926.

Full text

Abstract:

Aim To explore the temporal impact of mild COVID-19 on need for primary and specialist health care services. Methods In all adults (≥20 years) tested for SARS-CoV-2 in Norway March 1st 2020 to February 1st 2021 (N = 1 401 922), we contrasted the monthly all-cause health care use before and up to 6 months after the test (% relative difference), for patients with a positive test for SARS-CoV-2 (non-hospitalization, i.e. mild COVID-19) and patients with a negative test (no COVID-19). Results We found a substantial short-term elevation in primary care use in all age groups, with men generally having a higher relative increase (men 20–44 years: 522%, 95%CI = 509–535, 45–69 years: 439%, 95%CI = 426–452, ≥70 years: 199%, 95%CI = 180–218) than women (20–44 years: 342, 95%CI = 334–350, 45–69 years = 375, 95%CI = 365–385, ≥70 years: 156%, 95%CI = 141–171) at 1 month following positive test. At 2 months, this sex difference was less pronounced, with a (20–44 years: 21%, 95%CI = 13–29, 45–69 years = 38%, 95%CI = 30–46, ≥70 years: 15%, 95%CI = 3–28) increase in primary care use for men, and a (20–44 years: 30%, 95%CI = 24–36, 45–69 years = 57%, 95%CI = 50–64, ≥70 years: 14%, 95%CI = 4–24) increase for women. At 3 months after test, only women aged 45–70 years still had an increased primary care use (14%, 95%CI = 7–20). The increase was due to respiratory- and general/unspecified conditions. We observed no long-term (4–6 months) elevation in primary care use, and no elevation in specialist care use. Conclusion Mild COVID-19 gives an elevated need for primary care that vanishes 2–3 months after positive test. Middle-aged women had the most prolonged increased primary care use.

APA, Harvard, Vancouver, ISO, and other styles

18

Walz, Lars, Gian M. Salzmann, Thomas Fabbro, Stefan Eichhorn, and Andreas B. Imhoff. "The Anatomic Reconstruction of Acromioclavicular Joint Dislocations Using 2 TightRope Devices." American Journal of Sports Medicine 36, no. 12 (September 2, 2008): 2398–406. http://dx.doi.org/10.1177/0363546508322524.

Full text

Abstract:

Background For the reconstruction of acromioclavicular (AC) joint separation, several operative procedures have been described; however, the anatomic reconstruction of both coracoclavicular ligaments has rarely been reported. Purpose The aim of this biomechanical study is to describe a new procedure for anatomic reconstruction of the AC joint. Study Design Controlled laboratory study. Materials and Methods Forty fresh-frozen cadaveric shoulders were tested. Cyclic loading and a load-to-failure protocol was performed in vertical (native, n = 10; reconstructed, n = 10) and anterior directions (native, n = 10; reconstructed, n = 10) on 20 AC joints and repeated after anatomic reconstruction. Reconstruction of conoid and trapezoid ligaments was achieved by 2 TightRope devices (Arthrex, Naples, Florida). Dynamic, cyclic, and static loading until failure in vertical (n = 5) and horizontal (n = 5) directions were tested in native as well as reconstructed joints in a standardized setting. Results The native coracoclavicular ligaments in static load for vertical force measured 598 N (range, 409–687), elongation 10 mm (range, 6–14), and stiffness 99 N/mm (range, 67–130); static load for anterior force was 338 N (range, 186–561), elongation 4 mm (range, 3–7), and stiffness 140 N/mm (range, 70–210). The mean maximum static load until failure in reconstruction for vertical force was 982 N (range, 584–1330) ( P = .001), elongation 4 mm (range, 3–6) ( P < .001), and stiffness 80 N/mm (range, 66.6–105) ( P = .091); and for anterior static force 627 N (range, 364–973) ( P < .001), elongation 6.5 mm (range, 4–10) ( P = .023), and stiffness 78 N/mm (range, 46–120) ( P = .009). During dynamic testing of the native coracoclavicular ligaments, the mean amount of repetitions (100 repetitions per stage, stage 0–100 N, 100–200 N, 200–300 N, etc, and a frequency of 1.5 Hz) in native vertical direction was 593 repetitions (range, 426–683) and an average of 552 N (range, 452–683) load until failure. In vertical reconstructed testing, there were 742 repetitions (range, 488–893) ( P = .222; with a load until failure of 768 N (range, 486–900) ( P = .095). In the anterior direction load, the native ligament failed after an average of 365 repetitions (range, 330–475) and an average load of 360 N (range, 307–411), while reconstructed joints ended in 549 repetitions (range, 498–566) (P = .008J with a load until failure of 547 N (range, 490–585) ( P = .008). In all testing procedures, a preload of 5 N was performed. Conclusion The anatomic reconstruction of the AC joint using TightRope is a stable and functional anatomic reconstruction procedure. The reconstruction technique led to favorable in vitro results with equal or even higher forces than native ligaments. Clinical Relevance Through anatomic repair, stable function of the AC joint can be achieved in an anatomic manner.

APA, Harvard, Vancouver, ISO, and other styles

19

Ciriello, John, James K. Simon, and Paul F. Mercer. "Effect of renal denervation on plasma renin activity after aortic baroreceptor deafferentation." Canadian Journal of Physiology and Pharmacology 69, no. 8 (August 1, 1991): 1237–42. http://dx.doi.org/10.1139/y91-181.

Full text

Abstract:

Renal nerves are thought to play an important role in cardiovascular regulation under both normotensive and hypertensive conditions. In the present study the effect of renal denervation on the changes in plasma renin activity (PRA) after aortic baroreceptor deafferentation (tADN) were investigated in the rat. Bilateral renal denervation did not alter arterial pressure (AP, 100 ± 4 mmHg; 1 mmHg = 133.32 Pa), heart rate (HR, 363 ± 12 bpm), or PRA (2.9 ± 0.6 ng∙mL−1∙h−1) compared with the respective sham renal denervation values of 106 ± 3 mmHg (AP), 385 ± 13 bpm (HR), and 3.3 ± 0.7 ng∙mL−1∙h−1 (PRA). On the other hand, bilateral tADN resulted in significant increases in AP, HR, and PRA. One and 3 days after tADN, AP was 130 ± 4 and 127 ± 6 mmHg, HR was 461 ± 15 and 463 ± 20 bpm, and PRA was 9.1 ± 3.0 and 11.9 ± 4.5 ng∙mL−1∙h−1, respectively. Renal denervation before tADN prevented the increases in AP and PRA, but it did not affect the increase in HR. These data indicate that renal denervation does not alter basal PRA in normotensive animals but prevents the increased renin release observed in neurogenic hypertension. These data suggest that the increased PRA may be one of several factors that contributes to the elevated AP after tADN.Key words: aortic depressor nerve, afferent renal nerves, cardiovascular regulation, hypertension.

APA, Harvard, Vancouver, ISO, and other styles

20

Ullah, Sadiq, Shaheen Ahmad, Burhan A. Khan, and James A. Flint. "A multi-band switchable antenna for Wi-Fi, 3G Advanced, WiMAX, and WLAN wireless applications." International Journal of Microwave and Wireless Technologies 10, no. 8 (May 11, 2018): 991–97. http://dx.doi.org/10.1017/s1759078718000776.

Full text

Abstract:

AbstractThis paper presents a hexa-band frequency reconfigurable planar antenna, printed on a 1.6 mm thicker FR 4 substrate and backed by a truncated ground plane. The given antenna operates in four different frequency modes, depending on the state of the two lumped element switches. The proposed antenna works at six frequencies, 2.10, 2.40, 3.35, 3.50, 5.28, and 5.97 GHz. These frequency bands are dedicated to useful wireless applications, including 3G Advanced (2.10 GHz), Wireless Fidelity (Wi-Fi) (2.40 GHz), WiMAX (3.35 GHz), WiMAX (3.5 GHz), WLAN (5.28 GHz) and fixed-satellite and mobile satellite services (5.97 GHz). Satisfactory gain of 1.96, 2.20, 2.671, 2.81, 3.80, and 3.88 dBi, efficiency of 92.5, 94.5, 94.56, 95.0, 93.8, and 97.0% and bandwidth of 332, 485, 1020, 1080, 512, and 465 MHz has been obtained at 2.10, 2.40, 3.35, 3.50, 5.28, and 5.97 GHz, respectively. The modeling and simulations are conducted in CST MWS (2014). The simulated reflection coefficient and radiation pattern are validated in antenna measurement facility. In addition, the specific absorption rate of the antenna on a flat section of human body is also studied. The antenna is compact, low profile, and vastly suitable for multi-band wireless devices.

APA, Harvard, Vancouver, ISO, and other styles

21

DiPersio, John F., Ivana NM Micallef, Patrick J. Stiff, Brian J. Bolwell, Richard Thomas Maziarz, Gary Bridger, and Gary Calandra. "Months Report from the Phase 3 Study of Plerixafor+G-CSF VS. Placebo+G-CSF for Mobilization of Hematopoietic Stem Cell for Autologous Transplant in Patients with NHL." Blood 112, no. 11 (November 16, 2008): 1136. http://dx.doi.org/10.1182/blood.v112.11.1136.1136.

Full text

Abstract:

Abstract Introduction: We previously reported that plerixafor + G-CSF was as safe as and more effective than placebo + G-CSF in mobilizing hematopoietic stem cell for autologous transplant in patients with non-Hodgkins lymphoma (NHL) through 100 days follow-up (DiPersio ASH 2007). We report herein the 12 months data. Methods: This was a phase 3, multicenter, randomized, double-blind, placebo-controlled study. NHL patients requiring an autologous hematopoietic stem cell transplant were eligible. Patients received G-CSF (10 μg/kg) subcutaneously daily for up to 8 days. Beginning on evening of Day 4 and continuing daily for up to 4 days, patients received either plerixafor (240 μg/kg) or placebo subcutaneously. Starting on morning of Day 5, patients began daily apheresis for up to 4 days or until ≥ 5 x 106 CD34+cells/kg were collected. We report herein the 12 months graft durability and hematology data. Results: As reported previously, 89/150 (59%) patients in the plerixafor group and 29/148 (20%) patients in the placebo group met the primary endpoint of collecting ≥ 5 x 106 CD34+ cells/kg in ≤ 4 days of apheresis, p < 0.001. 135 patients (90%) in plerixafor group and 82 patients (55%) in placebo group underwent transplantation. Median time to neutrophil and platelet engraftment was similar in both groups. There were no differences in graft durability through 12 months follow-up between the two groups. Two plerixa for treated patients had graft failure (one had pre-existing MDS and one developed AML). One plerixafor-treated patient had delayed platelet engraftment. The hematology profiles were similar between the two groups through 12 months follow-up, except that patients in the plerixafor group had significantly higher platelet count at 12 months than patients in the placebo group (p=0.026) (Table 1). During the 12 months follow-up, 14/135 (10.4%) patients in plerixafor group and 10/82 (12.2%) patients in the placebo group died. 7/14 in the plerixafor group and 5/10 in the placebo group died of disease progression. Plerixafor + G-CSF Placebo + G-CSF Hematology data presented as mean ± SD and n= number of patients with available data aAll patients who underwent transplantation bAll patients who underwent transplantation and had laboratory data at the study visit cP values were NS for all variables at all time points between groups except for platelet count at 12 months (p=0.026) Graft durability (n, %) 100 daysa 128/135 (94.8%) 78/82 (95.1%) 6 monthsb 120/123 (97.6%) 77/78 (98.7%) 12 monthsb 110/112 (98.2%) 65/65 (100.0%) Platelet (x 109/L) 100 days 183 ± 83 (n= 113) 169 ± 81 (n=63) 6 months 190 ± 78 (n=100) 180 ± 77 (n=64) 12 monthsc 209 ± 81 (n=50) 170 ± 78 (n=37) Neutrophils (x 109/L) 100 days 3.1 ± 1.7 (n=107) 3.2 ± 2.1 (n=61) 6 months 3.3 ± 1.4 (n=98) 3.8 ± 2.6 (n=64) 12 months 3.5 ± 1.4 (n=50) 4.2 ± 2.7 (n=38) Hemogloblin (mg/dL) 100 days 12.3 ± 1.5 (n=112) 12.3 ± 1.5 (n=63) 6 months 12.5 ± 1.5 (n=100) 12.4 ± 1.5 (n=64) 12 months 13.0 ± 1.4 (n=50) 12.7 ± 1.6 (n=37) Conclusions: The addition of plerixafor to G-CSF resulted in higher CD34+ cell collection in fewer days of apheresis and higher proportion of patients proceeding to transplant than G-CSF alone. Importantly, this 12 months report showed that transplants with cells collected with plerixafor resulted in graft durability rates that were similar to cells collected with G-CSF alone.

APA, Harvard, Vancouver, ISO, and other styles

22

Aeberhard, Carla, Mirjam Abt, Olga Endrich, Emilie Aubry, Michèle Leuenberger, Philipp Schütz, Anna-Barbara Sterchi, and Zeno Stanga. "Auswirkung der Kodierung der Mangelernährung im SwissDRG-System." Aktuelle Ernährungsmedizin 43, no. 02 (April 2018): 92–100. http://dx.doi.org/10.1055/a-0595-2481.

Full text

Abstract:

Zusammenfassung Hintergrund Die krankheitsassoziierte Mangelernährung (KAM) ist in Krankenhäusern ein häufiges Problem mit medizinischen und ökonomischen Folgen. Die vorliegende Vier-Jahres-Analyse soll zeigen, ob die Aufwände für die Ernährungstherapien der mangelernährten Patienten durch den Mehrertrag, der durch die Kodierung der KAM im SwissDRG-System erreicht wird, gedeckt werden. Material und Methodik In dieser Datenerhebung (2013 – 2016) wurden alle stationären Patienten mit einer E4-Diagnose im Universitätsspital Bern analysiert. Betrachtet wurden die E-Diagnose, Hauptdiagnose, Spitalaufenthaltsdauer, Alter, Art der Ernährungstherapie, Mehrertrag und Kosten, welche durch die ernährungstherapeutischen Behandlungen generiert wurden. Der Aufwand für die Ernährungsberatung, daas Pflegefachpersonal und die Ernährungstherapien wurde hochgerechnet. Zudem wurden die Patienten aufgrund ihrer Hauptdiagnose in 12 Gruppen eingeteilt (beruhend auf der WHO ICD-10-Klassifikation). Ergebnisse Von den stationären Patienten (n = 169 515) wurden insgesamt 5442 Fälle (3,2 %) in den betrachteten 4 Jahren mit einer KAM kodiert. Davon waren 462 Fälle (8,5 %) erlösrelevant. Von den 5442 Patienten erhielten 3211 (59 %) orale Trinknahrungen, 1578 (29 %) eine enterale Ernährung per Sonde und 653 (12 %) eine parenterale Ernährung. Die Kodierung der KAM ergab einen Mehrertrag von insgesamt CHF 3 494 081 und einen Aufwand von hochgerechnet CHF 2 803 432. Am häufigsten wurden onkologische Patienten mit einer KAM kodiert (n = 1708; 31,4 %), gefolgt von Patienten mit Krankheiten des Verdauungssystems (n = 671; 12,3 %) und des Kreislaufsystems (n = 609; 11,2 %). Schlussfolgerung Diese Analyse zeigt, dass der Mehrertrag durch die Kodierung der KAM im SwissDRG-System den finanziellen Aufwand für die Ernährungstherapien deckt. Die konsequente und frühzeitige Erfassung, Behandlung und Kodierung der KAM führt zu einer hohen Behandlungsqualität und -sicherheit für die Patienten und ist kostendeckend für das Krankenhaus.

APA, Harvard, Vancouver, ISO, and other styles

23

Burk, Kathleen. "The Marshall Plan: Filling in Some of the Blanks." Contemporary European History 10, no. 2 (July 2001): 267–94. http://dx.doi.org/10.1017/s0960777301002053.

Full text

Abstract:

Dominique Barjot, Rémi Baudouï and Danièle Voldman, eds., Les Reconstructions en Europe (1945–1949) (Paris: Editions Complexe, 1997), 342 pp., FF175, ISBN 2-870-27693-1. Matthias Kipping and Ove Bjarnar, eds., The Americanisation of European Business: The Marshall Plan and the Transfer of US Management Models (London: Routledge, 1998), 235 pp., £50.00, ISBN 0-415-17191-1. Jeffry M. Diefendorf, Axel Frohn and Hermann-Josef Rupieper, eds., American Policy and the Reconstruction of Western Germany, 1945–1955 (Cambridge: Cambridge University Press and the German Historical Institute, Washington, DC, 1993), 537 pp., £45.00, ISBN 0-521-43120-4. Hans-Herbert Holzamer and Marc Hoch, eds., Der Marshall-Plan: Geschichte und Zukunft (Landsberg/Lech: Olzog, 1997), 214 pp., ISBN 3-789-29349-0. Haus der Geschichte der Bundesrepublik Deutschland, 50 Jahre Marshall-Plan (Berlin: Argon Verlag, Berlin, 1997), 140 pp., ISBN 3-870-24387-2. Günter Bischof, Anton Pelinka and Dieter Stiefel, eds., The Marshall Plan in Austria (New Brunswick: Transaction Publishers, 2000), 588 pp., ISBN 0-765-80679-7. Michael Kennedy and Joseph Morrison Skelly, eds., Irish Foreign Policy 1919–1966: From Independence to Internationalism (Dublin: Four Courts Press, 2000), 352 pp., £39.50, ISBN 1-851-82404-9. Bernadette Whelan, Ireland and the Marshall Plan 1947–1957 (Dublin: Four Courts Press, 2000), 426 pp., £39.50, ISBN 1-851-82517-7. Charles Silva, Keep Them Strong, Keep them Friendly: Swedish–American Relations and the Pax Americana, 1948–1952 (Stockholm: Akademitryck AB, 1999), 376 pp., Kl.10.00, ISBN 9-171-53974-3. Chiarello Esposito, America's Feeble Weapon: Funding the Marshall Plan in France and Italy, 1948–1950 (Westport: Greenwood Press, 1994), 226 pp., £49.50, ISBN 0-313-29340-6. Fernando Guirao, Spain and the Reconstruction of Western Europe 1945–57 (London: Macmillan, 1998), 240 pp., ISBN 0-312-21291-7. Martin A. Schain, Marshall Plan Fifty Years After (Houndmills: Palgrave, 2001), £30.00, ISBN 0-333-92983-7 was published after this article went to press.

APA, Harvard, Vancouver, ISO, and other styles

24

Duong, Hien K., Anna Koo, Lisa Rybicki, Ed Copelan, Matt Kalaycio, Ronald Sobecks, Robert M. Dean, et al. "Obese Patients Have Improved Survival Following Autologous Hematopoietic Stem Cell Transplantation." Blood 120, no. 21 (November 16, 2012): 1989. http://dx.doi.org/10.1182/blood.v120.21.1989.1989.

Full text

Abstract:

Abstract Abstract 1989 High-dose chemotherapy followed by autologous stem cell transplant can improve long-term outcome of patients with hematologic malignancies. Outcomes following transplant are variable. Obesity has implications for stem cell mobilization, chemotherapy administration, and medication dosing. We analyze the impact of obesity on transplant outcomes including neutrophil recovery, platelet recovery, length of hospital stay, and survival. From 1/2004 to 12/2009, 573 patients underwent autologous stem cell transplant. From these patients, 17 were excluded due to incomplete data. Of the remaining 556 patients, the median age was 53 years, and 346 (62%) were male. The diagnoses were 286 (51%) non-Hodgkin lymphoma, 161 (29%) multiple myeloma, 91 (16%) Hodgkin lymphoma, and 18 (3.2%) other. A majority of these patients (93%) had received 3 or less prior chemotherapy regimens. Most patients (76%) had not received prior radiation therapy. Most patients had chemosensitive disease (92% were in complete or partial remission) at time of transplant. For stem cell mobilization regimen, 376 (68%) received chemotherapy and G-CSF, 176 (32%) received G-CSF alone, and 4 (<1%) received G-CSF and Plerixafor. For a preparative regimen, 360 (65%) received busuflan/etoposide/cyclophosphamide, 125 (23%) received melphalan, and 71 (13%) received busulfan/cyclophosphamide. Patients were categorized into four groups based on the body mass index (BMI): underweight (BMI<18.5), normal (18.5–24.9), overweight (25.0–29.9), or obese (≥30.0). Using these definitions, there were 5 (1%) underweight, 133 (24%) normal, 188 (34%) overweight, and 230 (41%) obese patients. Underweight and normal were combined into a single group due to the small number of underweight patients. Baseline and transplant characteristics of these patients are listed in Table 1. Variables were compared among BMI groups using the Chi-square test (categorical variables), Kruskal-Wallis test (continuous variables), or log-rank test (survival). Cox proportional hazards analysis was used to identify prognostic factors for survival. On univariable and multivariable analyses, obese patients demonstrate better survival than those who are not obese (hazard ratio 0.73, P=0.026; Figure 1). In conclusion, obesity has no impact on neutrophil or platelet recovery, length of transplant hospitalization, or 100-day mortality. Obese patients appear to have improved overall survival. The reasons for this are unclear, but may have to do with higher total dose of chemotherapy for the preparative regimen. Although obesity is associated with many co morbidities and possibly more aggressive disease, these patients do not have cancer cachexia and may have other protective benefits. Table 1. Patient and transplant characteristics according to BMI Underweight/ Normal N = 138 Overweight N = 188 Obese N = 230 Variable N (%) N (%) N (%) P-value Gender Male 63 (46) 136 (72) 147 (64) <0.001 Female 75 (54) 52 (28) 83 (36) Age, years Median (range) 50 (20–74) 55 (20–73) 54 (19–75) 0.013 Number of prior chemotherapy regimens ≤ 3 130 (94) 177 (94) 212 (92) 0.65 >3 8 (6) 11 (6) 18 (8) Prior radiation therapy Yes 38 (28) 45 (24) 53 (23) 0.61 No 100 (72) 143 (76) 177 (77) Diagnosis NHL 74 (54) 98 (52) 114 (50) 0.025 MM 28 (20) 53 (28) 80 (35) HL 33 (24) 30 (16) 28 (12) Other 3 (2) 7 (4) 8 (4) Disease status at transplant CR/PR 120 (87) 172 (91) 217 (94) 0.048 Active disease 18 (13) 16 (9) 13 (6) Mobilizing regimen G-CSF+chemotherapy 106 (77) 126 (67) 144 (63) 0.05 G-CSF alone 32 (23) 61 (32) 83 (36) G-CSF + Plerixafor 0 (0) 1 (0.5) 3 (1) Preparative regimen Bu/VP/Cy 94 (68) 128 (68) 138 (60) 0.22 Melphalan 30 (21) 34 (18) 61 (27) Bu/Cy 14 (10) 26 (14) 31 (13) CD34+ dose, × 106/kg Median (range) 6.19 (2.11–47.97) 5.67 (2.06–65.18) 7.01 (1.62–51.90) 0.21 Days to ANC > 500 Median (range) 11 (9–13) 11 (9–17) 10 (9–15) 0.36 Days to platelet > 20,000 Median (range) 14 (6–129) 14 (5–432) 14 (3–46) 0.48 Length of hospital stay Median (range) 21 (13–30) 20 (13–74) 20 (12–37) 0.08 100-day mortality Yes 9 (7) 9 (5) 4 (2) 0.06 No 129 (93) 179 (95) 226 (98) Figure 1: Survival outcomes according to BMI Figure 1:. Survival outcomes according to BMI Disclosures: No relevant conflicts of interest to declare.

APA, Harvard, Vancouver, ISO, and other styles

25

Barber, J. D., W. W. Harrington, N. G. Moss, and C. W. Gottschalk. "Prostaglandin blockade impairs denervation diuresis and natriuresis in the rat." American Journal of Physiology-Renal Physiology 250, no. 5 (May 1, 1986): F895—F900. http://dx.doi.org/10.1152/ajprenal.1986.250.5.f895.

Full text

Abstract:

Acute unilateral renal denervation of control rats produced an ipsilateral diuresis (5.5 +/- 0.8 to 10.0 +/- 1.0 microliter/min, P less than 0.01) and natriuresis (579 +/- 202 to 2,668 +/- 225 neq/min, P less than 0.01) without a significant change in glomerular filtration rate or effective renal plasma flow. Inhibition of prostaglandin synthesis with indomethacin or meclofenamate (4 mg/kg iv) after acute unilateral denervation eliminated the diuresis (13.3 +/- 1.6 to 5.0 +/- 0.9 microliter/min, P less than 0.01) and attenuated the natriuresis (3,098 +/- 462 to 1,097 +/- 163 neq/min, P less than 0.01). Denervation diuresis and natriuresis were significantly impaired to the same extent when denervation was performed after inhibition of prostaglandin synthesis (3.2 +/- 0.3 to 4.9 +/- 0.4 microliter/min, NS; and 490 +/- 154 to 1,036 +/- 274 neq/min, P less than 0.05 vs. control, respectively). These results indicate that the natriuresis and diuresis seen after acute unilateral denervation in anesthetized rats are highly dependent upon prostaglandins and cannot be initiated or maintained when prostaglandin synthesis is impaired by indomethacin or meclofenamate.

APA, Harvard, Vancouver, ISO, and other styles

26

Caporali, R., D. Aletaha, R. Sanmartí, T. Takeuchi, D. Mo, E. Haladyj, L. Zaremba-Pechmann, and P. C. Taylor. "POS0701 LONG-TERM EFFICACY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO HAVE HAD INADEQUATE RESPONSE TO csDMARDs: RESULTS FROM RA-BEYOND UP TO 7 YEARS OF TREATMENT." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 630–31. http://dx.doi.org/10.1136/annrheumdis-2022-eular.4546.

Full text

Abstract:

BackgroundBaricitinib (BARI), an oral selective Janus kinase 1/2 inhibitor, has demonstrated efficacy in patients (pts) with rheumatoid arthritis (RA) for up to 3 years (yrs) in a long-term extension (LTE) study RA-BEYOND.1ObjectivesDisclose efficacy of BARI in csDMARD-IR pts in the completed LTE study (up to 7 yrs).MethodsIn RA-BUILD, csDMARD-IR pts were randomized 1:1:1 to BARI 4 mg, 2 mg, or placebo (PBO). Completers to week (wk) 24 could enter the LTE and received BARI 4 or 2 mg. In RA-BEAM, MTX-IR pts were randomized 1:1:1 to BARI 4 mg, adalimumab (ADA) 40 mg, or PBO. Completers to wk 52 received BARI 4 mg in the LTE. Pts with no response could be rescued after wk 16 in both studies. Data were analysed by treatment assigned at baseline in originating studies as observed up to time of stepdown (if applicable), study discontinuation or completion, whichever occurred earlier. Efficacy response rates (RR) were assessed as proportions of pts with observed data up to yr 7 (wk 364) for low-disease activity (LDA) (SDAI ≤ 11, DAS28-hsCRP ≤ 3.2, CDAI ≤ 10), remission (REM) (SDAI ≤ 3.3, DAS28-hsCRP < 2.6, CDAI ≤ 2.8, Boolean), and physical function (HAQ-DI ≤ 0.5). No formal statistical comparisons were conducted.ResultsApproximately 56%/25% of pts in BARI 4 mg, 80%/31% in BARI 2 mg, and 60%/25% in PBO from RA-BUILD remained active at yr 3/7; 59%/17% of pts in ADA, 54%/16% in BARI 4 mg, and 67%/14% in PBO from RA-BEAM remained active at year 3/7. SDAI and CDAI had comparable RR for LDA and REM (Table 1). DAS-28CRP LDA RR were similar to SDAI and CDAI, while REM RR were about twice those of SDAI and CDAI (Table 1). HAQ-DI ≤ 0.5 RR was achieved by 25-30% of BARI-treated pts from both trials and maintained to the end of LTE.Table 1.Efficacy outcomes in RA-BEYONDTimeaN/n (%)LDAREMHAQ-DI ≤0.5SDAICDAIDAS-28 CRPSDAICDAIDAS-28 CRPBooleanRA-BEYOND entryBARI 2 mg (BUILD)197/109197/103200/108197/38 (19.3)197/35 (17.8)200/72 (36.0)200/29 (14.5)200/50 (25.0)(55.3)(52.3)(54.0)BARI 4 mg (BUILD)188/113191/116189/112188/33191/35 (18.3)189/75 (39.7)189/26 (13.8)193/44 (22.8)(60.1)(60.7)(59.3)(17.6)BARI 4 mg (BEAM)412/288414/290412/280412/112414/108412/199412/78 (18.9)414/133 (27.3)(69.9)(70.0)(68.0)(27.2)(26.1)(48.3)Yr 3BARI 2 mg (BUILD)156/120158/116156/112156/41 (26.3)158/44 (27.8)156/81 (51.9)156/34 (21.8)159/38 (23.9)(76.9)(73.4)(71.8)BARI 4 mg (BUILD)107/76107/76107/74107/24107/26 (24.3)107/56 (52.3)107/17 (15.9)108/26 (24.1)(71.0)(71.0)(69.2)(22.4)BARI 4 mg (BEAM)222/166224/166222/164222/72224/71 (31.7)222/119222/48224/54 (24.1)(74.8)(74.1)(73.9)(32.4)(53.6)(21.6)Yr 7BARI 2 mg (BUILD)61/5061/4961/5161/17 (27.9)61/18 (29.5)61/40 (65.6)61/12 (19.7)62/16 (25.8)(82.0)(80.3)(83.6)BARI 4 mg (BUILD)45/3748/3745/3445/13 (28.9)48/16 (33.3)45/25 (55.6)45/8 (17.8)48/14 (29.2)(82.2)(77.1)(75.6)BARI 4 mg (BEAM)60/5364/5760/53 (88.3)60/18 (30.0)64/22 (34.4)60/38 (63.3)60/13 (21.7)64/14 (21.9)(88.3)(89.1)N: Number of pts with observed data; n: Number of pts with response. aTime from randomization in originating studies. Entry to RA-BEYOND=wk 24 and wk 52; Yr 3=wk 156 and wk 160; and Yr 7=wk 360 and wk 364 of RA-BUILD and RA-BEAM, respectively.ConclusionIn observed data, BARI demonstrated maintained efficacy in treatment and maintenance of physical function of a csDMARDs-IR RA pt population up to 7 yrs.References[1]Smolen JS, et al. Rheumatology (Oxford). 2021; 60(5):2256-66.Disclosure of InterestsRoberto Caporali Speakers bureau: Abbvie, Amgen, BMS, Celltrion, Eli Lilly and Company, Galapagos, Pfizer, Fresenius-Kabi, MSD, UCB, Roche,Janssen, Novartis, Sandoz, Consultant of: Abbvie, Amgen, BMS, Celltrion, Eli Lilly and Company, Galapagos, Pfizer, MSD, UCB, Janssen, Novartis, Sandoz, Daniel Aletaha Speakers bureau: Abbvie, Amgen, Eli Lilly and Company, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, Grant/research support from: Abbvie, Amgen, Eli Lilly and Company, Novartis, Roche, SoBi, Sanofi, Raimón Sanmartí Speakers bureau: Eli Lilly and Company, Grant/research support from: Eli Lilly and Company, Tsutomu Takeuchi Speakers bureau: AbbVie Japan GK, Ayumi Pharmaceutical Co., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co, Ltd. Daiichi Sankyo Co., Ltd. Eisai Co., Ltd. Eli Lilly Japan K.K.; Gilead Sciences, Inc. Janssen Pharmaceutical K.K.; Mitsubishi-Tanabe Pharma Co.; Novartis Pharma Co.; Pfizer Japan Inc.; Sanofi K.K.; UCB Japan Co., Ltd., Consultant of: AbbVie Japan GK, Astellas Pharma, Inc.; Chugai Pharmaceutical Co, Ltd.; Eli Lilly Japan K.K.; Eisai Co., Ltd.; Gilead Sciences, Inc.; Janssen Pharmaceutical K.K.; Mitsubishi-Tanabe Pharma Corp., Pfizer Japan Inc., Grant/research support from: AbbVie Japan GK, Asahikasei Pharma Corp., Chugai Pharmaceutical Co, Ltd., DNA Chip Research Inc.; Eisai Co., Ltd., Eli Lilly Japan K.K.; Mitsubishi-Tanabe Pharma Corp., UCB Japan Co., Ltd., Daojun Mo Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Ewa Haladyj Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Liliana Zaremba-Pechmann: None declared, Peter C. Taylor Consultant of: AbbVie, Biogen, Eli Lilly and Company, Fresenius, Galapagos, Gilead Sciences, GlaxoSmithKline, Janssen, Nordic Pharma, Pfizer Inc, Roche, and Sanofi, Grant/research support from: Celgene, and Galapagos

APA, Harvard, Vancouver, ISO, and other styles

27

Zhou, Ying, Arick Wang, Lorraine Yeung, Yan Ping Qi, and Krista Crider. "Folate and Vitamin B12 Usual Intake and Biomarker Status in U.S. Adults: National Health and Nutrition Examination Survey (NHANES) 2007–2018." Current Developments in Nutrition 6, Supplement_1 (June 2022): 1199. http://dx.doi.org/10.1093/cdn/nzac074.028.

Full text

Abstract:

Abstract Objectives There are 3 major folic acid intake sources in the US—enriched cereal grain products (ECGP), ready-to-eat cereals (RTE), and folic acid containing supplements (SUP), generating 4 mutually exclusive consumption groups. This study aims to describe the contribution of these sources to folic acid intakes above the tolerable upper intake level (UL, 1000 mg/d), and their impact on red blood cell (RBC) folate and serum vitamin B12 concentrations. Methods We used data for nonpregnant US adults (≥19 y) from the National Health and Nutrition Examination Survey (NHANES) 2007–2018 (n = 31,128); serum vitamin B12 data were only available for 2011–2014 (n = 9,298). Median usual intake was estimated from two 24-h dietary recalls using the National Cancer Institute (NCI) method. Statistical analyses accounted for complex survey design using appropriate weights. Results The proportions of those who consumed folic acid from ECGP only, ECGP +RTE, ECGP +SUP, and ECGP +RTE +SUP were 50%, 18%, 22%, and 10%, and the median modelled usual folic acid intakes (mg/d) were 126 (interquartile range (IQR): 92,168), 308 (IQR: 267, 360), 490 (IQR: 347, 586), and 687 (IQR: 577, 767), respectively. Overall, 1.97% (95% CI: 1.96%, 1.98%) of adults consumed >UL. Adults who did not consume SUP did not have intakes >UL. The median usual vitamin B12 intake was 6.4 (IQR: 4.1, 11.7) mg/d. Consumption of RTE and/or SUP was associated with higher RBC folate concentrations (nmol/L) (ECGP only: 976 [95% CI: 963, 989], ECGP +RTE: 1130 [95% CI: 1110, 1150], ECGP +SUP: 1307 [95% CI: 1283, 1332], ECGP +RTE +SUP: 1467 [95% CI: 1439, 1495]). Serum vitamin B12 concentrations (pmol/L) were 350 (95% CI: 343, 356; ECGP only), 380 (95% CI: 366, 393; ECGP +RTE), 456 (95% CI: 440, 473; ECGP +SUP), and 485 (95% CI: 462, 509; ECGP +RTE +SUP). RBC folate deficiency (<305 nmol/L) was < 2% and vitamin B12 deficiency (<148 pmol/L) was < 6% across all folic acid consumption groups. Conclusions Folate and vitamin B12 deficiencies are low in the US population. At current fortification levels, US adults who do not consume supplements do not have usual folic acid intake exceeding the UL. Vitamin B12 intake among most US adults meets the recommended daily allowance (2.4 mg/d). Funding Sources This project was conducted with no specific support..

APA, Harvard, Vancouver, ISO, and other styles

28

Акилбаев, Александр Владимирович. "ЖЕРТВЕННЫЕ КОМПЛЕКСЫ МОГИЛЬНИКА КУЗИНСКИЕ ХУТОРА." Археология Евразийских степей, no. 3 (July 27, 2021): 192–200. http://dx.doi.org/10.24852/2587-6112.2021.3.192.200.

Full text

Abstract:

В статье публикуются данные о жертвенных комплексах, обнаруженных в ходе раскопок могильника Кузинские хутора в 2017–2018 годах. Дается характеристика инвентарю, приводятся аналогии, хронологические рамки, в том числе результаты определения монеты. Всего рассмотрено три комплекса. Первый представлен двумя углублениями: в одном находился керамический горшок, в другом короб с одеждой и украшениями. Во втором комплексе в короб также сложены одежда и украшения. В третьем обнаружены поломанные вещи и дирхем. Первые два объекта характерны для марийской культуры X–XI веков. Они, в сочетании с другими признаками, подтверждают присутствие на могильнике марийского компонента. Третий же комплекс либо оставлен предками коми-зырян, которые являются вторым культурным компонентом могильника, либо культура коми-зырян оказала сильное влияние на его обряд. Библиографические ссылки Акилбаев А.В. Раскопки могильника Кузинские хутора // Археологические открытия. 2018 год. / Отв. ред. Н.В. Лопатин. М.: ИА РАН, 2020. С. 146–148. Архипов Г.А. Марийцы IX–XI вв. К вопросу о происхождении народа. Йошкар-Ола: Марийское книжное издательство, 1973. 199 с. Археология севернорусской деревни X–XIII веков. Т. 2. Средневековые поселения и могильники на Кубенском озере / Отв. ред. Н.А. Макаров, С.Д. Захаров. М.: Наука, 2008. 365 с. Белавин А.М., Крыласова Н.Б., Козлов А.И. Приуральские материалы в средневековых древностях Ветлужско-Вятского междуречья (комментарий этнокультурных процессов I–II тыс. н.э.) // Материалы и исследования по археологии Поволжья. Вып. 5 / Ред. Ю.А. Зеленеев, Б.С. Соловьев. Йошкар-Ола: МарГУ, МарНИИЯЛИ, 2010. С. 106–121. Иванов А.Г. Этнокультурные и экономические связи населения бассейна р. Чепцы в эпоху средневековья. Ижевск: Удмурт. ин-т истории, языка и литературы УрО РАН, 1998. 308 с. Казаков Е.П. Культура ранней Волжской Болгарии. М.: Наука, 1992. 335 с. Корзухина Г.Ф. Русские клады IX–XIII вв. М.-Л.: АН СССР, 1954. 156 с. Мальм В.А. Подковообразные и кольцевидные застежки-фибулы // Очерки по истории русской деревни X–XIII вв. / Труды ГИМ. Вып. 43 / Отв. ред. Б.А. Рыбаков. М.: Советская Россия, 1967. С. 149–206. Мальм В.А., Фехнер М.В. Привески-бубенчики // Очерки по истории русской деревни X–XIII вв. / Труды ГИМ. Вып. 43 / Отв. ред. Б.А. Рыбаков. М.: Советская Россия, 1967. С. 133–148. Материалы по истории мордвы VIII–XI вв. (Дневник археологических раскопок П.П. Иванова) / Отв. ред. А.П. Смирнов. Моршанск: Изд-во Моршан. краевед. музея, 1952. 231 с. Никитина Т.Б. Жертвенно-поминальные комплексы как этноопределяющий признак погребального обряда марийцев в эпоху средневековья // Древности Поволжья и Прикамья / Археология и этнография Марийского края. Вып. 25. / Ред. Никитин В.В., Соловьев Б. С. Йошкар-Ола: МарНИИ, 2001. С. 42−51. Никитина Т.Б. Марийцы в эпоху средневековья. Йошкар-Ола: МарНИИЯЛИ, 2002. 432 с. Никитина Т.Б. Погребальные памятники IX–XI вв. Ветлужско-Вятского междуречья // Археология Евразийских степей. Вып. 14. Казань: Отечество, 2012. 408 с. Никитина Т.Б. Поясные кошельки/сумочки в средневековых могильниках Ветлужско-Вятского междуречья // Поволжская археология. 2013. № 2(4). С. 151–161. Никитина Т.Б. Жертвенные комплексы Выжумского могильника X–начала XII вв. (к вопросу о связи живых и мертвых) // Интеграция археологических и этнографических исследований: сборник научных трудов / гл. ред. Н. А. Томилов; отв. ред.: М. А. Корусенко, А. А. Тишкин, К. Н. Тихомиров, М. Н. Тихомирова, Н. Н. Серегин. Барнаул; Омск: Наука, 2015. С. 234–237. Никитина Т.Б. Население Верхнего Поветлужья в начале II тыс. н.э.: новые материалы // КСИА. 2015а. Вып. 240. С. 124–140. Никитина Т.Б. Жертвенные комплексы с одеждой из могильников Ветлужско-Вятского междуречья IX-XI вв. // Вестник археологии, антропологии и этнографии. 2017. № 1 (36). С. 21–32. Никитина Т.Б., Акилбаев А.В. Погребальный обряд могильника «Кузинские хутора» IX–XI вв. // Финно-угроведение. 2020. № 61. С. 110–122. Никитина Т.Б., Акилбаев А.В., Аристов А.А. Погребальный инвентарь могильника «Кузинские хутора» // Поволжская археология. 2019. № 4 (30). С. 82–98. Никитина Т.Б., Алибеков С.Я. Древнемарийская вышивка по материалам Русенихинского могильника X–XI вв. (междисциплинарный подход к изучению) // VIII исторические чтения памяти Михаила Петровича Грязнова / Отв. ред. И.В. Толпеко. Омск: Амфора, 2012. С. 140–147. Рябцева С.С. Змеи и драконы. О продолжении одной античной традиции в ювелирном деле эпохи средневековья // Stratum Plus. 1999. №3. С. 228–240. Фехнер М.В. Внешнеэкономические связи по материалам ярославских могильников // Ярославское Поволжье X–XI вв. по материалам Тимеревского, Михайловского и Петровского могильников / Отв. ред. А.П. Смирнов. М., 1963. С 75–85. Халиков А.Х., Безухова Е.А. Материалы к древней истории Поветлужья (археологические исследования в Ветлужском районе Горьковской области в 1957 году). Горький, 1960. 60 с. Моця О., Скороход В. Протоміста Подесення в процесі одержавлення регіону. Випуск І. Шестовицький археологічний комплекс. Київ: ІА НАН України, 2020. 228 с. Arbman H. Birka I. Die Graber: Tafeln. Uppsala: Almqvist & Wiksells, 1940. 283 s. Lena Thunmark-Nylen. Die Wikingzerzeit Gotland I. Abbildungen der Graberfunde. Stocholm: Kungl. Vitterhets Historie och Antikvitets Akademien, 1995. 377 s.

APA, Harvard, Vancouver, ISO, and other styles

29

Nybo, Lars, Thorbjørn Jensen, Bodil Nielsen, and José González-Alonso. "Effects of marked hyperthermia with and without dehydration onV˙o 2 kinetics during intense exercise." Journal of Applied Physiology 90, no. 3 (March 1, 2001): 1057–64. http://dx.doi.org/10.1152/jappl.2001.90.3.1057.

Full text

Abstract:

This study determined whether marked hyperthermia alone or in combination with dehydration reduces the initial rate of rise in O2 consumption (V˙o 2on-kinetics) and the maximal rate of O2 uptake (V˙o 2 max) during intense cycling exercise. Six endurance-trained male cyclists completed four maximal cycle ergometer exercise tests (402 ± 4 W) when euhydrated or dehydrated (4% body wt) with normal (starting esophageal temperature, 37.5 ± 0.2°C; mean skin temperature, ∼31°C) or elevated (+1 and +6°C, respectively) thermal strain. In the euhydrated and normal condition, subjects reachedV˙o 2 max (4.7 ± 0.2 l/min) in 228 ± 34 s, with a mean response time of 42 ± 2 s, and fatigued after 353 ± 39 s. Hyperthermia alone or in combination with dehydration reduced mean response time (17–23%),V˙o 2 max (16%), and performance time (51–53%) (all P < 0.01) but did not alter the absolute response time (i.e., the time to reach 63% response in the control trial, 3.2 ± 0.1 l/min, 42 s). Reduction inV˙o 2 max was accompanied by proportional decline in O2 pulse and significantly elevated maximal heart rate (195 vs. 190 beats/min for hyperthermia vs. normal). Preventing hyperthermia in dehydrated subjects restoredV˙o 2 max and performance time by 65 and 50%, respectively. These results demonstrate that impaired high-intensity exercise performance with marked skin and internal body hyperthermia alone or in combination with dehydration is not associated with a diminished rate of rise in V˙o 2 but decreased V˙o 2 max.

APA, Harvard, Vancouver, ISO, and other styles

30

Schwendener, Corina L., Laura M. Kiener, Kristen Jafflin, Sarah Rouached, Anna Juillerat, Vincent Meier, Susanna Schärli Maurer, et al. "HPV vaccine awareness, knowledge and information sources among youth in Switzerland: a mixed methods study." BMJ Open 12, no. 1 (January 2022): e054419. http://dx.doi.org/10.1136/bmjopen-2021-054419.

Full text

Abstract:

ObjectivesWe aimed to provide a detailed characterisation of human papillomavirus (HPV) vaccine awareness, knowledge and information sources in the HPV vaccine decision-making process of youth, both male and female, in Switzerland.DesignWith a mixed-method study design, we conducted quantitative questionnaires and qualitative interviews, which lasted 20–45 min.Setting and participantsWe recruited participants, 15–26 years of age, in physicians’ offices, in a local sexual health clinic, and during military enlistment. We administered quantitative questionnaires to 997 youth participants (585 male, 412 female) and conducted qualitative interviews with 31 youth (17 male, 14 female).Primary and secondary outcome measuresWe assessed HPV vaccine awareness, knowledge, information sources and vaccination status.ResultsIn the study’s quantitative component, 108 (20%) male and 262 (65%) female participants had received ≥1 dose of HPV vaccine. 697 (70%) participants were knowledgeable about the HPV vaccine. Females were more likely to be knowledgeable than males (342/412 (83%) vs 355/585 (61%); p<0.01). Younger participants in the sample compared with older participants were more likely to be aware of HPV vaccine (135/148 (91%) vs 695/849 (82%); p<0.01). The three most mentioned information sources were school health programmes (442 (53%)), healthcare providers (190 (23%)) and participants’ social networks (163 (20%)). Overall, 554/710 (78%) participants had a female-gendered perception of HPV vaccine, a finding which was further supported and explained by qualitative data.ConclusionsDespite a male HPV vaccine recommendation being made >4 years prior to the data collection, HPV vaccine knowledge was higher among females than males, and a female-gendered perception of HPV vaccine remains prevalent. Internet and social media were minor HPV vaccine information sources. Study findings demonstrate that HPV knowledge matters for HPV vaccine uptake and suggest that we should improve HPV information quality and access for youth, particularly by tailoring knowledge campaigns to young men.

APA, Harvard, Vancouver, ISO, and other styles

31

Lazo-Langner, Alejandro, Jeff Hawell, Michael J. Kovacs, Philip S. Wells, Dimitrios Scarvelis, Melissa Anne Forgie, and Marc Rodger. "A Systematic Review and Meta-Analysis of Proportions of Thrombosis and Bleeding in Patients Receiving Venous Thromboembolism (VTE) Prophylaxis After Orthopedic Surgery (OS). An Update." Blood 114, no. 22 (November 20, 2009): 3125. http://dx.doi.org/10.1182/blood.v114.22.3125.3125.

Full text

Abstract:

Abstract Abstract 3125 Poster Board III-62 VTE is the most frequent complication of OS and it can be prevented through anticoagulant prophylaxis. Numerous studies have evaluated different agents for this purpose and there are new agents currently under development or recently approved for this indication. We conducted a systematic review of randomized controlled trials (RCT) evaluating administration of anticoagulants for VTE prophylaxis in OS and performed a MA of proportions to estimate the overall incidence of major VTE (proximal VTE, pulmonary embolism (PE), or death from PE), total VTE (proximal and distal VTE, PE or death from PE), symptomatic VTE and major bleeding episodes (as defined by the International Society on Thrombosis and Hemostasis). We included RCT comparing currently approved anticoagulants (head-to-head or placebo-controlled) for VTE prophylaxis in OS (hip and knee arthroplasty and hip fracture surgery) using systematic evaluation of VTE (ultrasound or venography, pulmonary angiography, CT pulmonary angiography, or ventilation perfusion scan). Heterogeneity of proportions was evaluated using a chi2 test and pooled estimates of proportions were obtained using either a fixed or a random effects model in which the weights were estimated as proposed by Laird and Mosteller. We retrieved 74 studies including180 research arms and enrolling 71,012 patients. The total number of events and evaluable patients, percentage of events and 95% CI, and number of study arms included are shown in the table. We found differences in the percentage of VTE and bleeding events associated with the use of different anticoagulants for VTE prophylaxis after OS. Due to the nature of the analysis no effect measure can be estimated. These estimates might help to design future studies. Major VTE Total VTE Symptomatic VTE Major Bleeding Cases / Evaluable Pts. (N) Percentage (95% CI) Study arms (N) Cases / Evaluable Pts. (N) Percentage (95% CI) Study arms (N) Cases / Evaluable Pts. (N) Percentage (95% CI) Study arms (N) Cases / Evaluable Pts. (N) Percentage (95% CI) Study arms (N) All patients LMWH 993/23692 5.96 (5.81, 6.11) 72 4068/22610 20.29 (20.04, 20.55) 80 193/19431 1.32 (1.27, 1.37) 35 476/28725 1.98 (1.93, 2.02) 70 UFH 234/2407 13.39 (12.86, 13.93) 14 596/2537 22.54 (22, 23.08) 17 11/339 3.24 (3.06, 3.43) 4 70/2849 2.75 (2.61, 2.89) 16 Warfarin 269/5677 6.28 (6.09, 6.46) 12 1317/4203 31.05 (30.44, 31.66) 12 71/4146 1.95 (1.83, 2.08) 6 96/6751 1.78 (1.69, 1.87) 12 Fonda 96/3673 3.81 (3.53, 4.09) 7 223/3477 6.82 (6.57, 7.07) 6 69/6398 1.06 (1.01, 1.1) 8 121/6576 1.63 (1.55, 1.71) 9 Riva 50/5025 2.02 (1.86, 2.19) 8 242/4595 13.05 (12.16, 13.94) 8 29/6252 0.46 (0.45, 0.48) 6 31/6643 0.63 (0.59, 0.68) 8 Dabi 149/4091 3.64 (3.59, 3.69) 6 834/4051 22.96 (21.91, 24.01) 6 26/3664 0.71 (0.67, 0.75) 4 67/5419 1.21 (1.17, 1.26) 6 Placebo 193/710 24.26 (23.17, 25.34) 10 379/816 49.35 (48.08, 50.62) 11 19/198 12.02 (10.32, 13.72) 3 12/753 1.59 (1.5, 1.68) 7 Total 1984/45275 129 7659/42289 140 418/40428 66 873/57716 128 Total Hip Arthroplasty LMWH 653/15978 6 (5.85, 6.16) 50 1817/14480 15.58 (15.35, 15.82) 55 81/11552 0.7 (0.69, 0.72) 19 306/18010 1.97 (1.92, 2.02) 45 UFH 187/1739 14.3 (13.64, 14.96) 11 354/1836 20.13 (19.46, 20.8) 13 11/246 4.47 (4.21, 4.73) 3 52/1451 3.2 (3.01, 3.39) 11 Warfarin 77/2758 4.28 (4.08, 4.48) 6 265/1273 20.82 (20.59, 21.04) 6 32/1833 1.75 (1.69, 1.81) 2 47/2856 2.23 (2.09, 2.37) 5 Fonda 28/1799 2.96 (2.58, 3.33) 3 85/1695 5.01 (4.91, 5.12) 2 15/2255 0.67 (0.63, 0.7) 2 69/2349 2.94 (2.87, 3.01) 3 Riva 25/2938 2.21 (1.95, 2.46) 5 73/2749 9.72 (8.92, 10.53) 5 10/3468 0.29 (0.27, 0.31) 3 14/3795 0.49 (0.44, 0.54) 5 Dabi 72/1803 3.99 (3.88, 4.11) 2 124/1766 7.02 (6.77, 7.27) 2 21/2293 0.92 (0.91, 0.93) 2 38/2309 1.65 (1.58, 1.72) 2 Placebo 105/414 26.01 (24.76, 27.27) 7 174/418 45.43 (43.74, 47.13) 7 4/147 2.72 (2.46, 2.98) 2 3/388 0.77 (0.69, 0.86) 5 Total 1147/27429 84 2892/24217 90 174/21794 33 529/31158 76 Total Knee Arthroplasty LMWH 277/6916 4.45 (4.34, 4.55) 25 2062/7326 30.72 (30.37, 31.07) 32 83/4902 1.69 (1.66, 1.73) 11 89/7808 1.14 (1.12, 1.16) 26 UFH 42/638 6.58 (6.39, 6.78) 3 226/638 35.42 (35.05, 35.79) 3 0/93 NE 1 3/318 0.94 (0.84, 1.05) 2 Warfarin 192/2919 8.1 (7.88, 8.32) 9 1052/2930 39.36 (38.69, 40.02) 9 39/2056 1.9 (1.84, 1.96) 3 28/3407 0.82 (0.79, 0.85) 8 Fonda 23/452 9.3 (7.93, 10.67) 2 45/361 12.47 (12.12, 12.81) 1 3/517 0.58 (0.51, 0.65) 1 12/601 2 (1.88, 2.11) 2 Riva 25/2087 1.2 (1.15, 1.24) 3 169/1846 18.55 (16.47, 20.63) 3 19/2784 0.68 (0.65, 0.71) 3 17/2848 0.6 (0.57, 0.63) 3 Dabi 77/2288 3.37 (3.32, 3.41) 4 710/2285 30.98 (30.42, 31.55) 4 5/1371 0.36 (0.32, 0.41) 2 29/3110 0.93 (0.89, 0.98) 4 Placebo 88/296 27.12 (24.54, 29.7) 4 205/398 55.19 (53.53, 56.84) 5 15/51 29.41 (28.16, 30.66) 1 9/365 2.47 (2.31, 2.62) 4 Total 724/15596 50 4469/15784 57 164/11774 22 187/18457 49 LMWH Low molecular weight heparin, UFH unfractionated heparin, Riva Rivaroxaban, Dabi Dabigatran etexilate Disclosures Lazo-Langner: Boehringer Ingelheim: Honoraria. Rodger:Bayer: Research Funding; Leo Pharma: Research Funding; Pfizer: Research Funding; Boehringer Ingelheim: Membership on an entity's Board of Directors or advisory committees; Biomerieux: Research Funding; GTC Therapeutics: Research Funding.

APA, Harvard, Vancouver, ISO, and other styles

32

Patel, Priti, Mayra Telesca, and De-Hui Ku. "The Comparison of Fibrin Monomer (FM) Performance to Other Activation Markers (TAT, PF1.2 and DD)." Blood 118, no. 21 (November 18, 2011): 5259. http://dx.doi.org/10.1182/blood.v118.21.5259.5259.

Full text

Abstract:

Abstract Abstract 5259 In this study, we attempted to determine the performance of the soluble fibrin monomer complex (SFMC) test in comparison to known activation markers, such as prothrombin fragment 1.2 (PF1.2), thrombin antithrombin complex (TAT) and d-dimer (DD). We have used the STA(R)-Liatest FM and STA(R)-Liatest D-Di kits to measure the SFMC and d-dimer levels. A total of 25 patients were included in this study. The data and demographic information are shown in the table below. ID GENDER AGE FM TAT PF1.2 D-dimer 1 M 66 0.42 2.3 1988 0.05 2 F 31 27.93 >60.0 >12000 2.39 3 F 24 3.41 14.1 1367 0.48 4 F 61 2.22 7.7 335 0.63 5 F 18 4.61 6.9 940 0.22 6 F 38 156.52 43.5 >12000 10.37 7 F 20 0.42 2.2 149 0.66 8 F 21 0.42 2.4 143 0.24 9 M 44 >150 15.4 11043 5.5 10 F 42 3.4 <2.0 134 0.24 11 M 46 0 4.8 271 0.3 12 M 76 90.73 29.4 1712 >20.0 13 F 61 3.41 3.8 484 0.52 14 M 1 0.1 3.8 116 0.33 15 F 33 4.2 37 6346 2.03 16 F 35 3.2 2.6 325 0.09 17 F 23 1.1 4.7 232 0.2 18 M 64 2.3 2.6 189 0.15 19 M 1 1.7 2.9 253 0.49 20 M 64 2.2 33.2 451 2.43 21 M 60 1.6 2.9 126 0.42 22 F 55 2.2 2.6 189 0.97 23 F 65 1.3 2.3 79 0.25 24 F 39 3.6 8.1 222 0.18 25 M 2 4.8 <2.0 109 0.53 Reference range >6.0 ug/mL <4 mcg/L 41–372 pmol/L <0.45 ug/mL The data indicate that in 16 out 25 patients, the SFMC levels are correlated with TAT and PF1.2. Only 3 out of 25 patients have elevated TAT and PF1.2 with normal SFMC levels. Therefore, our data would tend to indicate that SFMC level could be used as an activation marker to assess an ongoing prothrombotic process. In order to more fully determine the efficacy of the SFMC assay, we will obtain a detailed clinical history for the cases shown above. Disclosures: No relevant conflicts of interest to declare.

APA, Harvard, Vancouver, ISO, and other styles

33

Lohmeyer, Jörn, Mai Alawadi, Philipp Bergmann, Daniel Schmauss, and Klaus Wittig. "Gezielte Antibiotika-Prophylaxe und Therapie periprothetischer Infektionen der Brust – Erfahrungen aus 468 konsekutiven Implantatentfernungen." Handchirurgie · Mikrochirurgie · Plastische Chirurgie 49, no. 02 (April 2017): 91–102. http://dx.doi.org/10.1055/s-0042-120842.

Full text

Abstract:

Zusammenfassung Hintergrund Periprothetische Infektionen sind gefürchtete Komplikationen sowohl der ästhetischen, als auch der rekonstruktiven Brustchirurgie. Ziel dieser Arbeit ist die Aufarbeitung der in einem Referenzzentrum für primäre und sekundäre Brustchirurgie behandelten Implantatlagerinfektionen, um eine Empfehlung zur prophylaktischen, aber auch therapeutischen antibiotischen Therapie aussprechen zu können. Patienten und Methoden Für den Zeitraum vom 01.01.2012 bis 31.12.2015 wurden retrospektiv alle Patientinnen erfasst, bei denen ein Wechsel oder die Entfernung von Brustimplantaten erfolgt war. Anhand der Patientenakten wurden die OP-Indikationen herausgearbeitet und speziell auf Infektzeichen und Angaben zu Kapselfibrosen analysiert. Zudem wurden alle mikrobiologischen Untersuchungen dieser Eingriffe erfasst und ausgewertet. Ergebnisse In unserer Klinik wurden im betrachteten Zeitraum 468 Implantatwechsel bzw. -explantationen bei 360 Patientinnen durchgeführt. Bei insgesamt 169 Patientinnen wurden mikrobiologische Abstrichuntersuchungen aus 245 Implantatlagern durchgeführt. Aus 23 Implantatlagern (21 Patientinnen) erfolgte ein Erregernachweis. Bei 6 weiteren Implantaten (4 Patientinnen) lagen Zeichen eines periprothetischen Infektes vor, ohne dass jedoch ein Keimnachweis gelang. In den meisten Fällen ergab die fortgeschrittene Kapselfibrose die Indikation zum Implantatwechsel. In 17 Abstrichen erfolgte ein Keimnachweis trotz fehlendem klinischen Infektverdacht. Als Erreger wurden in 17 Fällen koagulasenegative Staphylokokken, in 4 Staphylococcus aureus, und jeweils in einem Fall E. coli, Morganella morganii und Proprionibacterium acnes nachgewiesen (eine Doppelinfektion). Alle Erreger waren gegenüber Piperacillin/Tazobactam und Vancomycin sensibel, gegenüber Cefuroxim und Amoxycillin/Clavulansäure lagen jeweils eine, gegenüber Gentamycin, Ciprofloxacin und Clindamycin je 2 Resistenzen vor. Schlussfolgerung In der Mehrzahl der Fälle ergab sich ein Keimnachweis als Zufallsbefund, während die Kapselfibrose klinisch führend war. Erreger und Resistenzlage unterschieden sich von der Mehrzahl internationaler Publikationen. Cefuroxim und Amoxycillin/Clavulansäure haben sich mit jeweils einer Resistenz als Antibiotika zur empirischen Infektprophylaxe und -therapie bewährt. Als Reserveantibiotikum, insbesondere bei fulminanten Infekten, bietet sich unter anderem Piperacillin/Tazobactam an.

APA, Harvard, Vancouver, ISO, and other styles

34

Matos da Silva, Maria de Fátima. "Decoração e simbolismo das pedras formosas dos balneários-sauna castrejos da Idade do Ferro: leituras possíveis." Vínculos de Historia. Revista del Departamento de Historia de la Universidad de Castilla-La Mancha, no. 8 (June 20, 2019): 191. http://dx.doi.org/10.18239/vdh_2019.08.10.

Full text

Abstract:

RESUMENLos balnearios-sauna castreños del noroeste peninsular son monumentos con horno con una arquitectura muy original, posiblemente asociada a los diversos modelos termales. Se conocen cerca de tres decenas, distribuidos por el noroeste peninsular. La arquitectura compleja de estos monumentos se organiza estructuralmente hacia posibilitar baños de sauna y baños de agua fría. Las dos áreas son divididas por una estela, monolítica, normalmente ornamentada – la pedra formosa. El papel simbólico que tendrían en el seno de la sociedad castreña de la Edad del Hierro del noroeste peninsular permanece por aclarar y envuelto en gran misticismo, fruto de una posible sacralidad. Este entorno, referido por diversos autores a lo largo de los tiempos, está posiblemente asociado al culto de los dioses de las aguas y a la sacralidad del baño purificador, medicinal, que se refleja en las decoraciones frontales de las pedras formosas, cuya maestría de los escultores que las insculpieran, tipología decorativa, interpretación simbólica y semiótica estudiamos, como objetivos primordiales, a lo largo de este trabajo de investigación.PALABRAS CLAVE: Protohistoria, monumentos con horno, decoración pétrea, interpretación simbólica / semiótica.ABSTRACTThe Iron Age sauna-baths of the northwest peninsular are monuments with an oven with very original architecture, possibly associated with the diverse thermal models. There are about three dozen known sauna-baths spread over the northwest peninsular. The complex architecture of thesemonuments is structurally organized to allow for cold water baths and sauna baths. The two areas are divided by a tectiforme stele, monolithic, usually ornamented, known as pedra formosa (beautiful stone). The symbolic role that they would have had in the heart of the Iron Age “castreña” society in the northwest peninsular remains unclear and shrouded in mysticism, the fruit of a possible sacredness. This environment, referred to by various authors throughout the ages, is possibly associated with the worship of the water gods and the sacredness of the medicinal and purifying bath, which is reflected in the frontal decorations of the pedras formosas, whose masterful sculpting, decorative typology, symbolic interpretation and semiotics we studied as primary objectives of this research work.KEYWORDS: Protohistory, monuments with oven, stone decoration, symbolic / semiotic interpretation. BIBLIOGRAFIAAlmagro-Gorbea, M. e Álvarez Sanchís, J. R. (1993), “La ‘sauna’ de Ulaca: saunas y baños iniciáticos en el mundo céltico”, Cuadernos de Arqueología de la Universidad de Navarra, 1, pp. 177-232.Almagro-Gorbea, M. e Moltó, L. (1992), “Saunas en la Hispania prerromana”, Espacio, Tempo y Forma, 3 (5), pp. 67-102.Almeida, C.A.F. (1974), “O monumento com forno de Sanfins e as escavações de 1973”, III Congresso Nacional de Arqueologia, pp. 149-172.— (1983), “O Castrejo sob o domínio romano. A sua transformação”, Estudos de Cultura Castrexa e de Historia Antiga da Galícia, pp. 187-198.— (1986), “Arte Castreja. A sua lição para os fenómenos de assimilação e resistência a Romanidade”, Arqueologia, 13, pp. 161-172.Araújo, J. R. (1920), Perosinho: Apontamentos para a sua monografia, Porto.Azevedo, A. (1946), “O “Monumento Funerário” da Citânia (Nova interpretação)”, Revista de Guimarães, 56 (1-2), pp. 150-164.Berrocal Rangel, L., Martínez Seco, P. e Ruíz Triviño, C. (2002), El Castiellu de Llagú, Madrid.Bosch Gimpera, P. (1921), “Los Celtas y la civilización celtica en la Península Ibérica”, Boletin de la Sociedad Española de Excursiones, 29, pp. 248-300.Cabré, J. (1922), “Una nueva hipótesis acerca de “Pedra Formosa” de la Citania de Sabroso (sic)”, Sociedad Espanhola de Antropologia, Etnografía y Prehistoria, 1, pp. 56-71.Calo Lourido, F. (1983), “Arte, Decoracion, Simbolismo e outros elementos da Cultura material Castrexa, ensaio de síntese”, Estudos de Cultura Castrexa e de História Antiga de Galicia, pp. 159-185.— (1993), A cultura castrexa, Vigo.Carballo Arceo, L. X. e Soto Arias, P. (1998), “A escultura xeométrica castrexa”, Historia da Arte Galega I. A Nosa Terra. Vigo, pp. 161-176.Cardozo, M. (1928), “A Pedra Formosa”, Revista de Guimarães, 38, 1-2, 139-152; 39,1-2, pp. 87-102.— (1931-1932), “A última descoberta arqueológica na Citânia de Briteiros e a interpretação da ‘Pedra Formosa’”, Revista de Guimarães, 41 (1-2), 55-60; 41 (3), 201-209; 41 (4), 250-260; 42 (1-2); 1932, 7 -25; 42 (3-4), pp. 127-139.— (1934), “A Pedra Formosa da Citânia de Briteiros e a sua interpretação arqueológica”, Brotéria, 18, 3, 30-43.— (1946), “O ‘monumento funerário’ da Citânia”, Revista de Guimarães, 56 (3-4), pp. 289-308.Cardozo, M. (1949), “Nova estela funerária do tipo da ‘Pedra Formosa’”, Revista de Guimarães, 59 (34), pp. 487-516.Cartailhac, E. (1886), Ages préhistoriques de 1’ Espagne et du Portugal, Paris.Chamoso Lamas, M. (1955), “Santa Mariña de Aguas Santas (Orense)”, Cuadernos de Estudios Gallegos, 10 (30), pp. 41-88.Conde Valvis, F. (1955), “Las termas romanas de la ‘Cibdá’ de Armea en Santa Marina de Aguas Santas”, III Congreso Arqueologico Nacional, pp. 432-446.Craesbeck, F. (1726), Memorias ressuscitadas da Província de Entre-Douro-e-Minho, Manuscrito da Biblioteca Nacional de Lisboa, 217 do Núcleo Geral.Dias, L. A. T. (1997), Tongóbriga, Lisboa.Dinis, A. P. (2002), “O balneário do Alto de Quintãs (Póvoa de Lanhoso, Norte de Portugal). Um novo caso a juntar ao livro negro da arqueologia de Entre-Douro-e-Minho”, Mínia, 3ª Série, 10, pp. 159-179.Dechelette, J. (1909), “Essai sur la chronologie de la Péninsule Ibérique“, Revue Archéologique, 13, pp. 26-36.Eco, H. (1972), “Semiologia de los mensajes visuales”, Análises de las imagenes, pp. 23-80.— (1988), O Signo, Labor.— (1979), A Theory of Semiotics, Indiana University Press, Bloomington.Estrabón (1965), Livro III Da Geografia, Amphitheatrvm, IX, Porto.Fernández Fuster, L. (1953), “Sobre la interpretación de los monumentos con ‘pedras formosas’”, Archivo Español de Arqueología, 26 (88), pp. 379-384.Ferreira, E. Veiga (1966), “Uma estela do tipo Pedra Formosa encontrada no Castro de Fontalva (Elvas)”, Revista de Guimarães, 76, pp- 359-363.Fernández Vega, P. A., Mantecón Callejo, L., Callejo Gómez, J. y Bolado del Castillo, R. (2014), “La sauna de la Segunda edad del Hierro del oppidum de Monte Ornedo (Cantabria, España)”, Munibe, 65, pp. 177-195.García Quintela, M. V. e Santos-Estévez M. (2015), “Iron Age saunas of northern Portugal: state of the art and research perspectives”, Oxford Journal of Archaeology, 34(1), pp. 67–95.García Quintela, M. V. (2016), “Sobre las saunas de la Edad del Hierro en la Península ibérica: novedades, tipologías e interpretaciones”, Complutum, 27 (1), pp. 109-130.García y Bellido, A. (1931), “Las relaciones entre el Arte etrusca y el ibérico”, Archivo Español de Arte y Arqueología, 7, pp. 119-148.— (1940), “El castro de Coaña (Asturias) y algunas notas sobre el posible origen de esta cultura”. Revista de Guimarães, 50(3–4), pp. 284-311.— (1968), “Las cámaras funerarias de la cultura castreña”, Archivo Español de Arqueología, 41, pp. 16-44.Gómez Tabanera, J. M., La caza en la Prehistoria, Madrid, Istmo, 1980.González Ruibal, A. (2006), “Galaicos. Poder y comunidad en el Noroeste de la península Ibérica (1200 a.C.-50 d.C.)”. Brigantium, 18, A Coruña.Höck, M. (1984), “Acerca dos elementos arquitectónicos decorados de castros do noroeste peninsular”, Revista Guimarães, 94, pp. 389-405.Hübner, E. (1879), “Citania”, Dispersos, pp. 445-462.Jordá Cerdá, F. (1969), Guía del Castrillón de Coaña. Salamanca, 8-12.— (1983), “Introducción a los problemas del arte esquemático de la Península Ibérica”, Zephyrvs, 36, pp. 7-12.Júnior, J. R. S. (1966), “Dois fornos do povo em Trás-os-Montes”, Trabalhos de Antropologia e Etnologia, 1-2, 20, pp. 119-146.Lemos, F. S., Leite, J. M. F., Bettencourt, A. M. S. e Azevedo, M. (2003), “O balneário pré-romano de Braga”, Al-madan, II série, 12, pp. 43-46.López Cuevillas, F. (1953), La civilización celtica en Galicia, Compostela.Lorenzo Fernández, J. (1948), “El monumento proto-histórico de Águas Santas y los ritos funerarios de los castros”, Cuadernos de Estudios Gallegos, 2 (10), pp. 157-211.Martin, H. (1881), “La Citania de Briteiros“, Revue Archéologique, 42, pp. 160-164.Monteagudo, L. (1952), “Monumentos propiedad de la Sociedad Martins Sarmento”, Archivo Español de Arqueología, 25 (85), pp. 112-116.Moreira, A. B. (2013), “O Balneário Castrejo do Monte Padrão, Santo Tirso”, Santo Tirso Arqueológico, 5, pp. 7-36.Parente, J. (2003), O Castro de S. Bento (concelho de Vila Real) e o seu ambiente arqueológico. Vila Real.Queiroga, F. e Dinis, A. (2008-2009), “O Balneário Castrejo do Castro das Eiras”, Portugália, 39-40, pp. 139-152.Ramil, G. E. (1995-96), “O monumento com forno do Castro dos Prados-Espasante (Ortigueira, A Coruña) Memoria de investigação”, Brigantium, 9, pp. 13-60.Ribeiro, F. (1930-34), “Novas descobertas arqueológicas na Citânia de Briteiros”, Revista de Guimarães, 40 (3-4), 171-175; 44 (3-4), pp. 205-208.Ríos González, S. (2000), “Consideraciones funcionales y tipológicas en torno a los baños castreños del NO. de la Península Ibérica”, Gallaecia, 19, pp. 93-124.Romero Masiá, A. (1976), El habitat castreño, Santiago de Compostela.Santa-Olalla, J. (1932), “Las estelas funerarias en forma de casa en España”, Revista Investigación y Progreso, 10, pp. 182-193.Santos-Estévez, M. (2017), “Pitágoras na Gallaecia”, http://www.gciencia.com/author/manuel-santos-estevez/ [Consulta: 12-09-2017].Santos, J. N. (1963), “Serpentes geminadas em suástica e figurações serpentiformes do Castro de Guifões”, Lucerna, pp. 120-140.Sarmento, F. M. (1888), “Antigualhas”, Revista de Guimarães, 5, p. 150.— (1881), “Expedição Cientifica a Serra da Estrela”, Dispersos, 1933, pp. 127-152.— (1899), “A arte micénica no Noroeste de Espanha”, Portugália, 1, pp. 431-442.— (1904), “Materiaes para a Archeologia do Concelho de Guimarães”, Revista de Guimarães, 31.Silva, J. N. (1876), “Esculptura Romana conhecida pelo nome de Pedra Formosa achada em Portugal, e o que ella representa”, Boletim Real Associação dos Architectos Civis e Archeologos Portugueses, 9, 2.Silva, A. C. F. (1981-82), “Novos dados sobre a organização social castreja”, Portugália, Nova Série, 2-3, pp. 83-96.— (1983), Citânia de Sanfins (Paços de Ferreira). Paços de Ferreira.— (1983-84), “A cultura castreja no Noroeste de Portugal: habitat e cronologias”, Portugalia, Nova Série, 3-4, pp. 121-129.— (1986), A cultura castreja no Noroeste de Portugal, Paços de Ferreira.— (2007), “Pedra formosa: arqueologia experimental”, MNA/CMVNF, Vila Nova de Famalicão).Silva, A. C. F. e Maciel, T. (2004), “Balneários castrejos do noroeste peninsular. Notícia de um novo monumento do Castro de Roques”, Portugália, Nova Série, 25, pp. 115-131.Silva, A. C. F., Oliveira, J. e Lobato, R. (2010-11), “Balneários Castrejos: Do Primeiro Registo à Arqueologia Experimental”, Boletim Cultural Câmara Municipal de Vila Nova de Famalicão, III série, 6/7, pp. 79-87.Silva, A. C. F., Ferreira, J. S. (2016), “O Balneário Castrejo do Castro de Eiras/Aboim das Choças (Arcos de Valdevez): notícia do achado e ensaio interpretativo”, Al-Madan, II Série, 20, pp. 27-34.Silva, M. F. M. (1986a), “Subsídios para o estudo da Arte Castreja-Arte Decorativa Arquitectónica”, Revista de Ciências Históricas, 1, pp. 31-68.— (1987), “Subsídios para o estudo da Arte Castreja-Arte Decorativa Arquitectónica-II”, Revista de Ciências Históricas, 2, pp. 124-147.— (1988), Subsídios para o Estudo da Arte Castreja. A cultura dos Berrões: ensaio de Síntese”, Revista de Ciências Históricas, 3, pp. 57-93.— (2017), “Os primórdios do Termalismo: os balneários castrejos e o seu potencial turístico”, Tourism and Hospitality International Journal, 9(2), pp. 4-28.Trabant, J. (1980), Elementos de Semiótica, Editorial Presença, Lisboa.Tranoy, A. (1981), La Galice romaine. Recherches sur le Nord-Ouest de la Péninsule Ibérique dans l’Antiquité, Paris.Uría Ríu, J. (1941), “Excavaciones en el Castellón de Coaña”, Revista de la Universidad de Oviedo, 2, pp. 85-114.Vasconcelos, J. L. (1913), Religiões da Lusitânia, 3, Lisboa.Villa Valdés, A. (1999), “Castro del Chao Samartín (Grandas de Salime)”, Excavaciones arqueológicas en Asturias, 1995-1998, 4, pp. 11-123.— (2000), “Saunas castreñas en Asturias”, Termas romanas en el Occident del Imperio, pp. 97-114.— (2012), “Santuarios urbanos en la Protohistoria cantábrica: algunas consideraciones sobre el significado y función de las saunas castreñas”, Boletín del Real Instituto de Estudios Asturianos, 177, pp. 65-102.— (2016), “Laberintos en cruz, lacería, sogueado y otros patrones geométricos en la plástica de la Edad del Hierro de Asturias y su pervivencia en época romana”, Arqueología y Prehistoria del Interior Peninsular, 05, pp. 96-109.Villa Valdés, Á., Menéndez Granda, A., Fanjul Mosteirin, J. A. (2007), “Excavaciones arqueológicas en el poblado fortificado de Os Castros, en Taramundi”, Excavaciones Arqueológicas en Asturias 1999–2002, pp. 267-275.

APA, Harvard, Vancouver, ISO, and other styles

35

Ellis, RM, JD Quilligan, NH Williams, and JK Yandell. "Cobalt, Iron and Ruthenium Complexes of Picolinic and Dipicolinic Acids: Syntheses, Solution Properties and Kinetics of Electron Transfer Reactions With Cytochrome C(II) and Some Inorganic Reductants." Australian Journal of Chemistry 42, no. 1 (1989): 1. http://dx.doi.org/10.1071/ch9890001.

Full text

Abstract:

Tris picolinate complexes of CO111 and RU111 have been synthesized, and their standard potentials measured (432 �10, 403 �2 mV) at 25�C and ionic strength 0.1 mol dm-3. The self-exchange rate constant of Ru ( pic )3O/- was found to be (1 .4 �0.9)×108 dm3 mol-1 s-l, from reaction with cytochrome C(II), Co( bpy )32+ and ~Co( phen )32+. For the reaction between Fe( dipic )2- and cytochrome ~(II), at 2S260C, pH 5.5 and I 0.1 mol dm-3 (KNO3), the second-order rate constant was (3.2 �0.l)×105 dm3 mol-1 s-1,with ΔH+ 19.9 �0.9 kJ mol-1 and ΔS+ -72.8 �.7 J K-1 mol-l. The self-exchange rate constant of Fe( dipic )2-/2- was reevaluated as (5.8 �0.2)×106 dm3 mol-l s-1.

APA, Harvard, Vancouver, ISO, and other styles

36

Castrejon, I., J. Molina Collada, C. Perez-Garcia, P. Vela-Casasempere, C. Diaz-Torne, C. Bohórquez, J. M. Blanco, and F. Sánchez-Alonso. "POS1439 CANCER IN PATIENTS WITH RHEUMATIC DISEASES EXPOSED TO DIFFERENT BIOLOGIC AND TARGETED SYNTHETIC DMARDS IN REAL-WORLD CLINICAL PRACTICE: DATA FROM A MULTICENTER REGISTER." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 1063. http://dx.doi.org/10.1136/annrheumdis-2022-eular.3834.

Full text

Abstract:

BackgroundExtensive evidence has confirmed no increased risk of cancer associated to either conventional synthetic DMARDs or anti-TNF in patients with rheumatic diseases. The risk of cancer in biologic (bDMARDs) different to anti-TNF and targeted synthetic (tsDMARDs) is considerably less investigated. As new therapies are emerging, more data in real-world registries are needed to confirm safety in other treatment groups.ObjectivesTo compare the risk of cancer of tsDMARDs and other bDMARDs versus anti-TNF in patients with rheumatic diseases.MethodsData of patients enrolled in BIOBADASER 3.0 up to October 2021 with the start of any bDMARD or tsDMARD were analyzed. For each group, demographic and clinical variables were estimated. Changes to therapy and occurrence of serious adverse events collected annually. Incident cancer was defined as any cancer during the exposure classified according to Meddra dictionary leading to therapy discontinuation. Incidence rate ratios of cancer per 1000 patients-year (PYs) and 95% confidence interval were estimated. Incidence rate ratio was calculated for each group versus anti-TNF.ResultsWe identified 271 cancers in BIOBADASER 3.0, corresponding to a cancer incident rate of 7.4 (6.5-8.3) per 1000 PY of exposure. Patients exposed to anti-TNF and anti-IL17 were younger, with lower disease duration and comorbidity versus other groups. Proportionally more malignancies were identified in the anti-CTLA-4 group (3.4%) versus the anti-TNF group (2.9%). The rates of incident cancer ranged between 2.6 events/1000 PY in the anti-IL17 group and 15.3 events/1000 PY in the anti-CTLA-4 group. The rate of cancer did not differ significantly in patients exposed to JAKi [0.8 (95% CI 0.4-1.5)], anti CD20 [1.1 (95% CI 0.6-1.8)], or anti-IL6 [1.3 (95% CI 0.9-1.9)] versus anti-TNF; it was significantly lower in patients exposed to anti-Il17 [0.4 (95% CI 0.2-0.9)], and significantly higher in patients exposed to anti-CTLA-4 [2.2 (95% CI 1.4-3.2)]. The most frequent malignancy was non-melanoma skin cancer, followed by solid cancer (mainly breast cancer with 24 events and lung cancer with 14 events) and melanoma (13 events).Table 1.New Cancer Diagnosis Among Patients with anti-TNF versus other therapiesAnti-TNF (N=6356)JAKi (N=1079)Anti-CD20 (N=667)Anti-IL6 (N=1178)Anti-CTLA-4 (N=783)Anti-IL17 (N=1051)Female, n (%)3738 (58.8)868 (80.4)523 (78.4)947 (80.4)598 (76.4)492 (46.81)Mean age, (SD)54.8 (14.7)58.5 (12.4)60.9 (13.6)59.8 (15.1)64.0 (12.8)52.2 (11.6)Mean start age, (SD)49.1 (14.0)56.6 (12.3)57.9 (13.5)55.7 (15.2)59.7 (13.0)49.8 (22.2)Disease duration, median (IQR)6.2[2.2-13.0]10.4[4.7 -17.2]11.0[5.1-18.5]8.3[3.2-15.1]10.3[5.2-17.0]3.1[0.3-10.7]Charlton Index1.9 (1.3)2.4 (1.6)2.4 (1.7)2.4 (1.7)2.8 (1.9)1.8 (1.3)First line biologic, n (%)99 (53.2)2 (22.2)1 (7.1)6 (20.0)5 (18.5)2 (66.7)New cancer diagnosis, n (%)186 (2.9%)9 (0.8%)14 (2.1%)30 (2.5%)27 (3.4%)5 (0.5%)Median years of follow-up months4.2 [2.3-7.3]2.4 [1.4-3.2]1.0 [1.0-1.0]2.6 [1.3-6.6]4.4 [1.5-5.7]1.8 [1-5-2.2]Time of exposure, yrs26233.51652.71871.53196.71762.11921Cancer Incidence Rate (per 1000 PY) ancer Incide7.1 (6.1-8.2)5.4 (2.8-10.5)7.5 (4.4-12.6)9.4 (6.6-13.4)15.3 (10.5-22.3)2.6 (1.1-6.3) .6 (1.1-6.3).5.2 (4.4-6.1)6.3 (1.6-8.1)5.9 (3.3-10.6)7.5 (5-11.2)10.8 (6.9-16.9)1.6 (0.5-4.8) .6 (0.5-40.3 (0.2-0.6)0 (0-0)1.1 (0.3-4.3)0.3 (0-2.2)0.6 (0.1-4)0 (0-0) (0-0)1-4)3)9)) Rate (per1.6 (1.2-2.2)1.8 (0.6-5.6)0.5 (0.1-3.8)1.6 (0.7-3.8)4 (1.9-8.3)1 (0.3-4.2)Rate ratio (vs anti-TNF)NA0.8 (0.4-1.5)1.1 (0.6-1.8)1.3 (0.9-1.9)2.2 (1.4-3.2)0.4 (0.2-0.9)ConclusionIn this register-based study, rates of incident cancer did not differ between patients treated with anti-TNF and other bDMARDs or tsDMARDs, with the possible exception of a potential increased risk in patients treated with anti-CTLA-4.AcknowledgementsThank you to all patients, rheumatologists, and to the research personnel from the Spanish Foundation of Rheumatology who made this study possible.Disclosure of InterestsIsabel Castrejon: None declared, Juan Molina Collada: None declared, Carolina Perez-Garcia: None declared, Paloma Vela-Casasempere Speakers bureau: ROCHE, UCB, GSK, LILLY, Consultant of: PFIZER, BMS, LILLY, UCB, GSK, Abbvie, Fresenius Kabi, Grant/research support from: ROCHE, ABBVIE, PFIZER, BMS, LILLY, SANDOZ, AMGEN, Cesar Diaz-Torne: None declared, Cristina Bohórquez: None declared, J M Blanco: None declared, Fernando Sánchez-Alonso: None declared

APA, Harvard, Vancouver, ISO, and other styles

37

Ashari, Asma, and Alizae M. Mohamed. "Relationship of the Dental Aesthetic Index to the oral health-related quality of life." Angle Orthodontist 86, no. 2 (May 27, 2015): 337–42. http://dx.doi.org/10.2319/121014-896.1.

Full text

Abstract:

ABSTRACT Objective: To assess the impact of malocclusion on the quality of life. Materials and Methods: This cross-sectional study involved 150 subjects attending the Primary Care Unit with no history of orthodontic treatment. The Dental Aesthetic Index (DAI) with 10 occlusal characteristics were measured on study models. Oral health-related quality of life (OHRQoL) was assessed with the Malaysian version of the Oral Health Impact Profile questionnaire (OHIP-14). The Spearman rank-order correlation coefficient was used to evaluate the relationship between the malocclusion and quality of life. Results: Significantly weak correlations (r = .176) were found between the DAI and the OHRQoL. Females and the younger age group (12–19 years) tended to score higher on the OHIP-14 than their counterparts. For males, domain 3 (psychological discomfort; r = .462), domain 4 (physical disability; r = .312), domain 7 (handicap; r = .309), and overall score (r = .289) were weak correlates but significant to the DAI compared with females. The older age group showed a significant weak correlation in domain 3 (psychological discomfort; r = .268) and domain 7 (handicap; r = .238), whereas the younger age group showed no correlation with any domain. Conclusions: The DAI score does not predict the effect of malocclusion on the OHRQoL.

APA, Harvard, Vancouver, ISO, and other styles

38

Ленькова, Екатерина Николаевна, and Игорь Александрович Бондарь. "К ВОПРОСУ О ВЛИЯНИИ КОЧЕВЫХ ПЛЕМЁН СТЕПИ НА ПРОИСХОЖДЕНИЕ РЯДА СИМВОЛОВ РАННЕСРЕДНЕВЕКОВОГО ПОКЛОННОГО КАМНЯ БЛИЗ СЕЛА РУДЬ." Археология Евразийских степей, no. 5 (October 29, 2021): 343–57. http://dx.doi.org/10.24852/2587-6112.2021.5.343.357.

Full text

Abstract:

Настоящая статья посвящена открытию и изучению результатов исследования нового славянского культового памятника периода распространения христианства в Днестровско-Прутском междуречье. Поклонный камень расположен близ села Рудь в Молдавии. Новый памятник является центральной доминантой раннесредневекового археологического комплекса IX–X вв, и может быть охарактеризован как пирамидальная стела с ярко выраженным антропоморфным обликом лицевой стороны. Поклонный камень предназначался для нужд культового и календарного характера и ориентирован на астрономически важные события. Некоторые знаки стелы прошли через процесс регионального и локального синкретизма. Главные символы и знаки лицевой стороны поклонного камня группируются в три сакральных сюжета. Уникальный объект не имеет прямых известных аналогов и содержит в себе признаки влияния древнерусского государства, Византии и викингов. На сакральном объекте представлены солярные и лунарные знаки, антропоморфные фигуры, крестообразные тамги, ранее неизвестный тип двузубца. Главной целью исследования авторов является обнаружение и идентификация влияния кочевых племён и полукочевников в происхождении некоторых символов, изображённых на поклонном камне «Рудь». Настоящее исследование призвано выявить следы раннего взаимодействия между славянскими племенами летописных тиверцев и уличей с кочевыми племенами Евразийской степи. Библиографические ссылки Амелькин А. О. «Знаки Рюриковичей» на стенах гробницы Царского кургана под Керчью// Древнейшие государства Восточной Европы 1999 год / Отв. ред. Г.В. Глазырина. М.: Восточная литература, 2001. C. 239–254. Археология Украинской ССР. Т. 3. Раннеславянский и древнерусский периоды / Отв. ред. В.Д. Баран. Киев: Наукова думка, 1986. 575 с. Атанасов Г. За един старобългарски скален манастир от X–XI век в Централна Молдова // Българите в Северното Причерноморие. Изследования и материали. Том втори. Велико Търново : Аста, 1993. С. 61–73. Бондарь И. Интерпретация лапидарных символов на раннесредневековом поклонном камне близ села Рудь. // Conferinţa ştiinţifică internaţională. Chişinău 2020, 131 p. Бондарь И. Интерпретация сакральных символов и сюжетов на раннесредневековом поклонном камне близ села Рудь. // Tyragetia. 2021. Vol. XV. Nr. 1 С. 361–385. Бондарь И.А. Новый скандинавский амулет в зверином стиле и рунической надписью в контексте древнегерманской мифологической системы мира // Скандинавская филология. Т. 19. Вып. 1, 2021. С. 190–213. Веймарн Е. В., Чореф М. Я. Пещерный ансамбль Чильтер в Крыму// Пещеры Грузии / Отв. ред. К.Ш. РаквиашвилиТбилиси: Мецниереба, 1978. С. 139–153. Гайдукевич В.Ф. Боспорские города. Уступчатые склепы. Эллинистическая усадьба. Илурат. Л.: Наука, 1981. 136 с. Голубева Л.А. Весь и славяне на Белом озере. X–XIII вв. М.: Наука, 1973. 216 с. Гросу В.Г., Василаки К.Г. Лапидарные знаки бутученских пещер // Известия Академии Наук Молдавской ССР. Серия общественных наук. 1984. №3. С. 63–69. Добровольский И.Г., Дубов И.В., Кузьменко Ю.К. Рунические граффити на восточных монетах // Мельникова Е.А. Скандинавские рунические надписи. М.: Наука, 1977. C. 142–152. Добровольский И.Г., Дубов И.В., Кузьменко Ю.К. Граффити на восточных монетах: Древняя Русь и сопредельные страны. Л.: Изд-во Л. ун-та, 1991. 192 с. Дончева-Петкова Л. Знаци върху археологически паметници от средновековна България IV-X век. София: Изд-во на Българската ак-ия на науките, 1980. 184 с. Драчук В.С. Системы знаков Северного Причерноморья (Тамгообразные знаки северопонтийской периферии античного мира первых веков нашей эры). Киев: Наукова думка, 1975. 173 с. Инкова М. За християнската символика на знака «ипсилон» в старобъгарската култура// Проблеми на изкуството. 2014. №3. С. 3–10. Кляшторный С.Г. Древнетюркские рунические памятники как источник по истории Средней Азии. М.: Наука. 1964. 215 с. Коваленко С., Грамма А., Левинский А. Культовый пещерный комплекс Холеркань-Мэркауць// Revista Archeologică. 2008. Vol. IV. Nr.2 . С. 186–207. Коршун В. Привески 11-13 веков из коллекции сайта «Домонгол»// Домонгол. Альманах древней культуры и искусства / Отв. ред. А.Н. Трошин. Рыбинск: Искатели, 2010. С. 62–69. Малов С.Е. Памятники древнетюркской письменности Монголии и Киргизии. М., Л.: Изд-во АН СССР, 1959. 111 с. Михеев С.М. Княжеские печати с тамгами и атрибуция знаков Рюриковичей XI–XII в. // Древняя Русь. Вопросы медиевистики. 2017. №4 (70). С. 17–41. Могаричев Ю.М. Пещерные церкви Таврики. Симферополь: Таврия. 1997. 384 с. Музыченко Б.Я., Слободянюк С.В., Стафеев С.К., Томилин М.Г. История оптики: Часть 1. Визирные системы древности. СПб.: СПбГУ ИТМО, 2009. 104 с. Остапенко А.А. Христианские древности Рязанской земли XI-XVI вв. Дисс. … канд. ист. наук. М.: ИА РАН, 2015. 508 с. Покровская Л.В., Степанов А.М., Сингх В.К. Нательные кресты, крестовидные и крестовключенные привески XI – начала XII в. // В камне и в бронзе / Сост. А.Е. Мусин, О.Д. Щеглова / Труды ИИМК РАН. Т. XLVIII. СПб.: ИИМК РАН, 2017. С. 467–474. Рабинович Р.А., Ткачук М.Е. Исследования на поселении древнерусской культуры у с. Рудь в Молдове // Археологические вести. 1995. № 4. С. 165–170. Рабинович Р.А. Пруто-Днестровское междуречье в контексте культурно-исторических связей окружающих регионов в середине V – середине XI вв. // Древности. Исследования. Проблемы. Сборник статей в честь 70-летия Н.П.Тельнова / Отв. ред. В.С.Синика, Р.А. Рабинович. Кишинёв-Тирасполь: ПГУ им. Т.Г.Шевченко; НИЛ «Археология»; ВАШ, 2018. С. 465–483. Рашев Р. Още за християнския смисъл на някои „прабългарски знаци”. // Историкии. Юбилеен сборник в чест на доц. д-р Ст. Витлянов по случай неговата 60-годишнина. Т. 3/ Отв. ред. И. Карайотов. Шумен, 2008. С. 25–31. Рогова И.Г. «М-образные» тамги-петроглифы Среднего Енисея: опыт типологии и хронологической атрибуции знаков// Теория и практика археологических исследований. 2020. №3 (31). С. 53–64. Рыбаков Б.А. Знаки собственности в княжеском хозяйстве Киевской Руси X-XII вв. // СА. 1940. Вып. VI. С. 227–257. Рыбаков Б.А. Русские датированные надписи XI–XIV веков / САИ. Вып. Е1-44. М.: Наука, 1964. 48 с. Рязанцев А. Новый археологический комплекс в левобережье р. Прони // Домонгол. Альманах древней культуры и искусства / Отв. ред. А.Н. Трошин. Рыбинск: Искатели, 2010. С. 122–125. Соломоник Э.И. Сарматские знаки Северного Причерноморья. Киев: АН УССР, 1959. 175 с. Хамайко Н.В. Древнерусская бронзовая ювелирная форма из раскопок на Киевском Подоле // Славяно-русское ювелирное дело и его истоки. Материалы Международной научной конференции, посвященной 100-летию со дня рождения Гали Фёдоровны Корзухиной (Санкт-Петербург, 10–16 апреля 2006 г.) / Ред. А.А. Пескова, О.А. Щеглова, А.Е. Мусин. СПб.: Нестор-история, 2010. С. 420–429. Хейердал Т. Искусство острова Пасхи. М.: Искусство, 1982. 165 с. Якубовський В. I. Давньоруський скарб з с. Городище Хмельницькоï областi // Археологiя. 1975. № 16, С. 87–104. Ямаева Е.Я. Алтайские тамги (некоторые проблемы этнокультурных контактов народов Алтая и Центральной Азии). Горно-Алтайск, 2004. 56 с. Яценко С.А. Знаки-тамги ираноязычных народов древности и раннего средневековья. М.: Восточная литература, 2001. 190 с. Agrigoroaei V. „Vikingi sau ruși. Noi cercetări asupra complexului de la Basarabi-Murfatlar” // Apulum.2006. XLIII/2, P. 25–49. Androshchuk F. When and How Were Byzantine Miliaresia Brought to Scandinavia? Constantinople and the dissemination of silver coinage outside the empire. Constantinople as Center and Crossroad. // Transactions of the Swedish Research Institute in Istanbul, vol. 23, 2019. P. 55–88. Bârnea I. Les monuments rupestres des Basarabi en Dobroudja // Cahiers archéologiques. Fin de l'antiquité et Moyen Âge, vol. 13, 1963. P. 207–208. Bâzgu E., Şinhani T. Şinhani, Un schit rupestru necunoscut – Holercani-Marcăuţi // Sud-Est Cultural, Nr. 4, 1997. P. 86-89. Hammarberg I., Rispling G. Graffiter pa vikingatida mynt. (Festskrift om mønter til Brita Malmer) // Hikuin N. 11, 1985. P. 63–78. Jolivet-Lévy C. Les églises byzantines de Cappadoce. Le programme iconographique de l’abside et de ses abords. Paris: Presses du CNRS, 1991. 391 p. Jungner H. Högstena-galdern: en västgötsk runbesvärjelse mot gengångare // Fornvännen. Journal of Swedish antiquarian research. Bd. 33, 1936. Р. 277-304. Svärdstгöin E. Högstenableckets rungalder // Fornvännen. Journal of Swedish antiquarian research. Bd. 62, 1967. Р. 12–21. Waddell L. A. Phœnician Origin of Britons, Scots, and Anglo-Saxon. London: Williams and Norgate, LTD. 1924. 450 p. Warren R., Elliott V. Runes: An Introduction. Manchester: Manchester University Press, 1980. 124 р.

APA, Harvard, Vancouver, ISO, and other styles

39

Smolen, J. S., T. Korotaeva, M. Nurmohamed, S. Siebert, P. Bergmans, K. De Vlam, E. Gremese, et al. "AB0530 EFFECT OF SKIN SYMPTOMS ON DISEASE IMPACT IN PATIENTS WITH PSORIATIC ARTHRITIS RECEIVING THE IL-12/23 INHIBITOR USTEKINUMAB OR TNF INHIBITORS IN THE REAL-WORLD PSABIO STUDY." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 1295–96. http://dx.doi.org/10.1136/annrheumdis-2021-eular.767.

Full text

Abstract:

Background:Psoriatic arthritis (PsA) is characterised by musculoskeletal symptoms, and patients (pts) with PsA usually experience psoriasis concurrently. Real-world data reflecting impact of skin symptoms on PsA disease burden are limited.Objectives:Analyse effectiveness of ustekinumab (UST) and tumour necrosis factor inhibitor (TNFi) therapy on extent of skin involvement, and the impact this has on PsA disease burden and drug persistence.Methods:PsABio (NCT02627768) is a prospective, observational study of 1st/2nd/3rd-line UST or TNFi treatment in PsA in 8 European countries. Extent of skin involvement was categorised as body surface area (BSA): clear/almost clear; <3% but not clear/almost clear; 3–10%; or >10%. Pt-reported disease impact was evaluated by PsAID-12, including assessment of two skin-related domains (D): D3 (skin problems, including itching) and D10 (embarrassment and/or shame because of appearance). Estimated persistence at 1 year was assessed across baseline (BL) BSA categories.Results:At BL, significantly more pts receiving UST than TNFi had BSA >10% (Figure 1). BL disease impact (PsAID-12) was worse in pts with BSA >10% than <3% in D3, D10 and total (non-overlapping 95% CIs suggest significance) (Table 1). BSA improved from BL to 1 year with both treatments. At 1 year, 64% of pts in both groups had clear/almost clear skin and only 3% had BSA >10% (Figure 1). At 1 year, both treatments significantly reduced disease impact (PsAID-12 total), and D3 and D10 scores, irrespective of BL BSA category, but most markedly in pts with higher BL BSA (Table 1). Worse BL psoriasis was generally associated with longer persistence for both treatments; however, at 1 year, pts with BSA >10% had significantly shorter persistence with TNFi (mean [95% CI]: 361 [336; 387] days) than with UST (410 [394; 426] days).Conclusion:In PsA, interleukin-12/23 inhibition (UST) and TNFi therapy in routine care rapidly and substantially reduced extent of skin involvement and related disease impact. Pts with highest BL skin involvement had significantly longer drug persistence with UST than with TNFi. Together, PsABio data suggest that successful treatment of skin involvement in PsA with biologics reduces disease burden and may improve persistence, especially in pts with worse BL psoriasis.Figure 1Table 1.PsAID-12 scores at BL and change from BL scores at 6 months and 1 year, by BL BSA categoryMean (95% CI)Domain 3(skin problems, including itching)Domain 10(embarrassment and/orshame because of appearance)Total PsAID-12USTTNFiUSTTNFiUSTTNFiPsAID-12 score at BL by BL BSA <3%4.2 (3.7; 4.8)3.1 (2.7; 3.6)3.9 (3.3; 4.4)3.1(2.6; 3.6)5.7(5.3; 6.0)5.0 (4.6; 5.3) 3–10%6.4 (5.9; 6.8)5.8 (5.3; 6.3)4.1 (3.5; 4.7)4.5 (3.9; 5.1)5.4 (5.1; 5.8)5.8 (5.4; 6.1) >10%7.9 (7.5; 8.3)6.7 (6.0; 7.5)6.1 (5.4; 6.8)5.8 (4.8; 6.8)6.2 (5.7; 6.6)6.1 (5.6; 6.7)Change from BL in PsAID-12 score at 6 months by BL BSA <3%-1.5 (-2.1; -0.9)-0.8 (-1.3; -0.3)-1.5 (-2.0; -0.9)-1.2 (-1.6; -0.7)-1.6 (-2.0; -1.2)-1.9 (-2.2; -1.5) 3–10%-3.2 (-3.8; -2.7)-2.4 (-3.0; -1.9)-1.9 (-2.5; -1.3)-2.0 (-2.5; -1.5)-2.0 (-2.4; -1.6)-2.4 (-2.8; -2.0) >10%-4.2 (-4.9; -3.6)-2.5 (-3.2; -1.9)-2.9 (-3.5; -2.2)-1.6 (-2.4; -0.8)-2.4 (-2.8; -2.0)-2.2 (-2.7; -1.7)Change from BL in PsAID-12 score at 1 year (LOCF) by BL BSA <3%-1.5 (-2.1; -0.9)-0.8 (-1.3; -0.3)-1.6 (-2.2; -1.1)-1.2 (-1.7; -0.7)-1.6 (-2.0; -1.2)-1.9 (-2.3; -1.5) 3–10%-3.5 (-4.0; -2.9)-3.2(-3.7; -2.7)-2.0 (-2.6; -1.4)-2.5 (-3.0; -2.0)-2.2 (-2.6; -1.7)-3.0 (-3.4; -2.6) >10%-4.9 (-5.5; -4.3)-3.1 (-4.0; -2.3)-3.5 (-4.2; -2.8)-2.7 (-3.7; -1.8)-2.9 (-3.4; -2.4)-2.9 (-3.5; -2.2)PsAID-12 total score ≤4 is considered a patient-acceptable symptom state.BL, baseline; BSA, body surface area; CI, confidence interval; LOCF, last observation carried forward; PsAID-12, 12-item Psoriatic Arthritis Impact of Disease questionnaire; TNFi, tumour necrosis factor inhibitor; UST, ustekinumabAcknowledgements:This study was funded by Janssen.Disclosure of Interests:Josef S. Smolen Speakers bureau: AbbVie, Amgen, AstraZeneca, Astro, Bristol-Myers Squibb, Celgene, Celltrion, Chugai, Gilead, ILTOO, Janssen, Lilly, MSD, Novartis- Sandoz, Pfizer, Roche, Samsung, Sanofi, UCB, Grant/research support from: AbbVie, AstraZeneca, Lilly, Novartis, Roche, Tatiana Korotaeva Speakers bureau: AbbVie, Amgen, Biocad, Janssen, Lilly, MSD, Novartis, Novartis-Sandoz, Pfizer, UCB, Consultant of: AbbVie, Amgen, Biocad, Janssen, Lilly, MSD, Novartis, Novartis-Sandoz, Pfizer, UCB, Grant/research support from: Pfizer, Michael Nurmohamed Speakers bureau: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Menarini, MSD, Mundipharma, Pfizer, Roche, Sanofi, UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Janssen, Menarini, MSD, Mundipharma, Pfizer, Roche, Sanofi, UCB, Grant/research support from: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Menarini, MSD, Mundipharma, Pfizer, Roche, Sanofi, UCB, Stefan Siebert Speakers bureau: AbbVie, Amgen (previously Celgene), Biogen, Janssen, Novartis, UCB, Consultant of: AbbVie, Janssen, UCB, Grant/research support from: Amgen (previously Celgene), Boehringer Ingelheim, Bristol-Myers Squibb, GSK, Janssen, Novartis, Pfizer, UCB, Paul Bergmans Shareholder of: Johnson & Johnson, Employee of: Janssen, Kurt de Vlam Speakers bureau: AbbVie, Amgen, Eli Lilly, Novartis, UCB, Paid instructor for: Amgen, Galapagos, UCB, Consultant of: Eli Lilly, Galapagos, Johnson & Johnson, Novartis, UCB, Grant/research support from: Celgene, Elisa Gremese: None declared., Beatriz Joven-Ibáñez Speakers bureau: AbbVie, Celgene, Janssen, Novartis, MSD, Pfizer, Wim Noel Employee of: Janssen, Petros Sfikakis Consultant of: AbbVie, Actelion, Boehringer Ingelheim, Enorasis, Farmaserv-Lilly, Genesis, Gilead, MSD, Novartis, Pfizer, UCB, Grant/research support from: AbbVie, Amgen, Boehringer Ingelheim, Faran, Janssen, Pfizer, Roche, Elke Theander Employee of: Janssen, Laure Gossec Consultant of: AbbVie, Amgen, Bioepis, Biogen, Bristol-Myers Squibb, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Sanofi-Aventis, UCB, Grant/research support from: Amgen, Galapagos, Janssen, Lilly, Pfizer, Sandoz, Sanofi.

APA, Harvard, Vancouver, ISO, and other styles

40

Gorodnik, Alexander, and Amos Nevo. "Lifting, restricting and sifting integral points on affine homogeneous varieties." Compositio Mathematica 148, no. 6 (October 11, 2012): 1695–716. http://dx.doi.org/10.1112/s0010437x12000516.

Full text

Abstract:

AbstractIn [Gorodnik and Nevo,Counting lattice points, J. Reine Angew. Math.663(2012), 127–176] an effective solution of the lattice point counting problem in general domains in semisimpleS-algebraic groups and affine symmetric varieties was established. The method relies on the mean ergodic theorem for the action ofGonG/Γ, and implies uniformity in counting over families of lattice subgroups admitting a uniform spectral gap. In the present paper we extend some methods developed in [Nevo and Sarnak,Prime and almost prime integral points on principal homogeneous spaces, Acta Math.205(2010), 361–402] and use them to establish several useful consequences of this property, including:(1)effective upper bounds on lifting for solutions of congruences in affine homogeneous varieties;(2)effective upper bounds on the number of integral points on general subvarieties of semisimple group varieties;(3)effective lower bounds on the number of almost prime points on symmetric varieties;(4)effective upper bounds on almost prime solutions of congruences in homogeneous varieties.

APA, Harvard, Vancouver, ISO, and other styles

41

Michalski, Jeff, Paul Northcott, Yimei Li, Catherine Billups, Kyle Smith, Peter Burger, Thomas Merchant, et al. "MBCL-15. IMPACT OF MOLECULAR SUBGROUPS ON OUTCOMES FOLLOWING RADIATION TREATMENT RANDOMIZATIONS FOR AVERAGE RISK MEDULLOBLASTOMA: A PLANNED ANALYSIS OF CHILDREN’S ONCOLOGY GROUP (COG) ACNS0331." Neuro-Oncology 22, Supplement_3 (December 1, 2020): iii391. http://dx.doi.org/10.1093/neuonc/noaa222.491.

Full text

Abstract:

Abstract The COG conducted a randomized trial for average-risk medulloblastoma (AR-MB). Patients age 3–21 years were randomized to a radiation boost to the whole posterior fossa (PFRT) or an involved field volume (IFRT) after receiving CSI. Patients age 3–7 years were also randomized to standard dose CSI (23.4Gy, SDCSI) or low dose CSI (18Gy, LDCSI). 464 evaluable patients were available to compare PFRT vs. IFRT and 226 for SDCSI vs. LDCSI. 380 cases had sufficient tissue for DNA methylation-based molecular classification: 362 confirmed medulloblastoma; 6 non-medulloblastoma; 12 inconclusive. Molecular subgrouping confirmed the following representation amongst the evaluable cohort: 156 Group 4 (43.1%), 76 Group 3 (21.0%), 66 SHH (18.2%), 64 WNT (17.7%). Five-year event-free survival (EFS) estimates were 82.5±2.7% and 80.5±2.7% for IFRT and PFRT, respectively (p=0.44). Five-year EFS estimates were 71.4±4.4% and 82.9±3.7% for LDCSI and SDCSI, respectively (p=0.028). EFS distributions differed significantly by subgroup (p<0.0001). Group 3 had the worst outcome, while WNT had the best outcome. There was a significant difference in EFS by RT group among SHH patients; SHH patients receiving IFRT arm had better EFS compared to PFRT (p=0.018). There was a significant difference in EFS distributions by CSI group in Group 4 patients; young Group 4 patients treated with SDCSI had better EFS compared to LDCSI (p=0.047). As previously reported, IFRT is noninferior to PFRT in all patients with AR-MB but LDCSI is worse than SDCSI in younger children. Significant differences in outcome by study randomization and molecular subgroup are observed.

APA, Harvard, Vancouver, ISO, and other styles

42

Bylicki, Olivier, Celine Ferlay, Christos Chouaid, Armelle Lavolle, Fabrice Barlesi, Radj Gervais, Virginie Westeel, et al. "Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 7574. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.7574.

Full text

Abstract:

7574 Background: Continuous exposure of tumor cells to maintenance therapy in advanced NSCLC might lead to resistance to subsequent treatments. IFCT–GFPC 0502 study showed a progression-free survival (PFS) benefit with gemcitabine (G) or erlotinib (E) maintenance compared to observation (O) after cisplatin-G induction chemotherapy. The trial included a pre-defined second-line therapy with pemetrexed (P), allowing post-hoc assessment of its efficacy according to previous maintenance treatment or treatment-free interval. Methods: Stage IIIB/IV NSCLC patients (pts) with a PS of 0-1 were randomized after 4 cycles of cisplatin-G chemotherapy to O or to receive maintenance therapy with G or E until disease progression. P was given as second-line treatment on disease progression in all arms. PFS and OS were assessed from the beginning of P therapy according to randomization arm. Tumor response to P and tolerance were also analyzed. Results: Of the 464 pts randomized to either O (155), G (154) or E (155), 360 pts (78 %) received P as second-line therapy, i.e. 130 (84%), 114 (74%) and 116 (75%) in O, G and E arm, respectively. Baseline characteristics remained well balanced between arms (overall median age of 58 years, 28% female, 91% stage IV, 41% PS 0, 65/19/16%, adenocarcinoma/squamous/other, 10% non-smokers and 56% responders to induction CT). Median number of delivered P cycles was 3 (1-40) in all arms. Response rate was 19%, 7% and 15% for non-squamous pts in O, G and E, respectively. Median PFS did not significantly differ between G and O (4.2 vs 3.9 months, HR [95% CI] 0.81 [0.62-1.06]) or E and O (4.2 vs 3.9 months, HR 0.83 [0.64-1.09]). OS data showed a non-significant improvement with G vs O (HR 0.81 [0.61-1.07]) or E vs O (HR 0.80 [0.61-1.05]), with a median of 7.5, 8.3 and 9.1 months for O, G and E, respectively. Results were similar when analysis was restricted to non-squamous pts. Grade 3-4 treatment-related AEs were similar in O (33.1%), G (31.6%) and E (25%). Conclusions: Maintenance therapy with continuation of G or switch to E does not impair the efficacy of second-line P by comparison with administration after a treatment-free interval.

APA, Harvard, Vancouver, ISO, and other styles

43

Ошанов, Орынбай. "АС БЕРУ ЖӘНЕ ТАС МҮСІН (жік түскен дәстүрлер)." Kazakhstan Archeology, no. 1 (11) (March 25, 2021): 101–19. http://dx.doi.org/10.52967/akz2021.1.11.101.119.

Full text

Abstract:

Мақалада қазақтың ас беру дәстүрі мен тас мүсіннің ерте замандарда бір ғұрыптық шара болғандығы қарастырылып жан-жақты дәлелденеді. Тас мүсін тұрған жерлердің қазақтың ас берген «ошақ» орындарымен қатар келуі екі ғұрыптың бастауы бір екендігін көрсетеді. Далалық зерттеу барысында Қарағанды облысының Ақтоғай ауданы жерінде анықталған «Орманбет ошағы», «Ербекей ошағы», «Шегетай ошағы» орындары және осы алқапта орналасқан тас мүсіндер дәлелге келтіріледі. Мақалада экспедициялық жұмыстардың нәтижесі және ас беру барысында орын алатын салт-дәстүрлер және көне ғұрыптар сөз болады.Тас мүсіннің бойындағы «ыдыс», «аяқ-табақ» секілді дүниелер осы көне ас беру ғұрпымен байланысты туындағаны және т.б. жайттар қарастырылады. Ас беру ғұрпының қоғамдық ролі, тарихи-саяси маңызы анықталады. Мақалада қазақпен қатар қырғыз халқындағы ас беру дәстүрі қоса сипатталады. Библиографические ссылки 1. Ақжолтай Ағыбай батыр. Жезқазған: Облтипография, 1992. 180 б. 2. Аманбаев Зияда. Әулет аралық естелік. Естелік-шежіре. 1-бөлім. Балқаш: Қалалық баспахана, 2001. 160-бет. 3. Әбішев Х. Аспан сыры. Алматы: Қазақ мем-тік саяси әдебиет баспасы, 1962. 251 б. 4. Броневский С.Б. Записки генерал-майора Броневского о киргиз-кайсаках Средней орды // Отечественные записки. 1830. Ч. 43. № 124. С. 119–356. 5. Валиханов Ч.Ч. Следы шаманства у киргизов // Собрание сочинений в пяти томах. Т. 4. Алма-Ата: Гл. Ред. Каз. Сов. Энцикл., 1985. 463 с. 6. Венюков М.И. Путешествие по окраинам русской Азии и записки о них. СПб: Типография Императорской Академии наук, 1868. 528 с. 7. Грач А.Д. Древнетюркские изваяния Тувы. М.: Изд-во вост. лит., 1961. 96 с. 8. Дневные записки путешествия капитана Н. Рычкова в Киргис-кайсацкой степи 1771 году. СПб.: Типография Императорской Академии наук, 1772. 105 с. 9. Досымбаева А. Западный Тюркский каганат. Культурное наследие казахских степей. Алматы: Типография Комплекс, 2006. 168 с. 10. Ермоленко Л.Н. Средневековые каменные изваяния Казахстанских степей (типология, семантика в аспекте военной идеологии и традиционного мировоззрения). Новосибирск: Изд-во ИАЭт СО РАН, 2004. 132 с. 11. Зеланд Л.Н. Киргизы (этнологический очерк) // Записки Западно-сибирского отдела РГО. 1885. Кн. 7, вып. 2. С. 1–78. 12. Кастанье И.А. Древности Киргизской степи и Оренбургского края // Труды ОУАК. 1910. Вып. 22. 332 с. 13. Кастанье И.А. Надгробная сооружения киргизских степей // Труды ОУАК. 1911. Вып. 26. 102 с. 14. Киргиз-кайсаки Большой, Средней и Малой орды по записям Андреева, с дополнениями П.К. Фролова и издателя // Сибирский вестник. 1820. Ч. IX–XI. 183 с. 15. Конур-Аулие // Витебская Губернская Ведомости. 1892. № 63. 16. Кызласов Л.Р. О назначении древнетюркских каменных изваяний, изображающих людей // СА. 1964. № 2. С. 27–39. 17. Құрманқұлов Ж., Ермоленко Л. Ежелгі Сарыарқа тас мүсіндер (каз., орыс, ағыл. тілд.). Қарағанды: «Credos Ltd C», 2014. 168 б. 18. Левшин А.И. Описание киргиз-казачьих, или киргиз-кайсацких орд и степей. Ч. 3: Этнографические известия. СПб.: Типография Карла Края, 1832. 304 с. 19. Манас: Великий поход. Кыргызский эпос / Пер. С. Липкина и др. Бишкек: Шам, 2004. 404 с. 20. Марғұлан Ә.Х. Ежелгі жыр, аңыздар: Ғылыми-зерттеу мақалалар. Алматы: «Жазушы», 1985. 368 б. 21. Марғұлан Ә. Ұлытау төңірегіндегі тас мүсіндер // Ә.Х. Марғұлан шығармалары. Алматы: «Алатау», 2007. IV т. 221–274-бб. 22. Народы России. Киргизы: [этнографические очерки]. СПб.: «Досуг и дело», 1880. 58 с. 23. Радлов В.В. Из Сибири (страницы дневника) / Пер. с нем. К.Д. Цивиной и В.Е. Чистовой. Прим. и послесл. С.И. Вайнштейна. М.: Наука, 1989. 749 с. 24. Руденко С.И. Культура населения Горного Алтая в скифское время. М.-Л: Изд-во АН СССР, 1953. 402 с. 25. Смағұлов Е.М. Қазақтың ас беру дәстүрі: қоғамдық-әлеуметтік қызметі (XVIII–XIX ғғ. деректер бойынша): тарих ғыл. канд. ... дис. автореф. Алматы, 2005. 33 б. 26. Тұрсын Жұртбай. Құнанбай (Жәбір сұлтаны) // Абай әлемі (ұлы ойшылдың өмірі мен шығармашылығына арналған онлайн-эниклопедия). URL: https: // abaialemi.kz /post/ view?id=910 27. Халид Құрбанғали. Қазақта мәйіт шығару // Тауарих хамса: (Бес тарих). ауд. Б. Төтенаев, А. Жолдасов. Алматы: «Қазақстан», 1992. 304 б. 28. Чорманов М. Казахские народные обычаи. Караганда: «Арко», 2000. 104 с. 29. Шарипов С. Бағаналы елінің жайы // Шығармалар жинағы. ІІ т. Алматы: «Жазушы», 1982. 508 б. 30. Шер Я.А. Каменные изваяния Семиречья. М.–Л.: Наука, 1966. 141 с. 31. Шомбал-Кукашев Р. О символике старинного казахского поминального ритуала «түйе шешу» // Қазақтың әдет-ғұрыптары мен салт-дәстүрлері: өткендегісі және бүгіні. Алматы: Ғылым, 2001. С. 351–373.

APA, Harvard, Vancouver, ISO, and other styles

44

Carstensen, E., and John S. Yudkin. "Platelet Catecholamine Concentrations after Short-Term Stress in Normal Subjects." Clinical Science 86, no. 1 (January 1, 1994): 35–41. http://dx.doi.org/10.1042/cs0860035.

Full text

Abstract:

1. Four studies were designed to test the hypothesis that platelet catecholamine levels may provide a stable index of circulating plasma catecholamine concentrations, and that these are unaffected by acute elevations of plasma levels with physical and psychological stress. 2. To assess the biological variability within individuals, ten subjects were sampled on five occasions over 8–30 h. The intra-individual coefficients of variation for plasma and platelet noradrenaline levels were 193 +10% and 9.5 +4.2%, respectively, and for plasma and platelet adrenaline levels 48.3 +22% and 25.3 +8.4%, respectively. 3. Three other studies investigating the response to physical and psychological stress were performed. In the first study, plasma and platelet catecholamine levels were studied in 12 healthy subjects before and after bicycle ergometry. Plasma catecholamine concentrations increased [noradrenaline by +346 + 323% (P = 0.002) and adrenaline by +314 + 352% (P -0.003)], whereas platelet concentrations showed little change [noradrenaline +4+18% (P = 0.94) and adrenaline +38+ 116% (P = 0.67)]. 4. In the study, catecholamine concentrations were measured in eight subjects after hand immersion in iced water. Plasma noradrenaline concentrations increased significantly (+58 +19%, P = 0.001), but no significant change was found in plasma adrenaline concentrations (+8+44%, P = 0.48). Platelet catecholamine concentrations showed no significant change (noradrenaline +15 +15%, P = 0.052, and adrenaline 19 +82%, P = 0.84). 5. In the third study, catecholamine concentrations were measured in 22 medical students before and after their end-of-year examination. There was no significant change in plasma noradrenaline or adrenaline concentrations (+20 +39%, P = 0.08, and −2 +33%, P = 0.36, respectively) nor in platelet concentrations (noradrenaline +6+19%, P = 0.15, and adrenaline +34 +72, P = 0.65). 6. In 53 subjects sampled between 08.00 and 12.00 hours, plasma and platelet noradrenaline concentrations were significantly correlated (r, = 0.47, P <0.001), but the relationship between plasma and platelet adrenaline concentrations in these subjects did not achieve significance (rs = 0.17, P <0.23). 7. In conclusion, platelet catecholamine concentrations seem to be unaffected by acute short-term stress and may provide a reliable indicator of chronic sympatho-adrenomedullary arousal.

APA, Harvard, Vancouver, ISO, and other styles

45

Jia, Zhihui, Xiaotong Wen, Xiaohui Lin, Yixiang Lin, Xuyang Li, Guoqing Li, and Zhaokang Yuan. "Working Hours, Job Burnout, and Subjective Well-Being of Hospital Administrators: An Empirical Study Based on China’s Tertiary Public Hospitals." International Journal of Environmental Research and Public Health 18, no. 9 (April 25, 2021): 4539. http://dx.doi.org/10.3390/ijerph18094539.

Full text

Abstract:

(1) Purpose: To analyze the role of job burnout in connection with working hours and subjective well-being (SWB) among hospital administrators in China’s tertiary public hospitals. (2) Methods: A multi-stage, stratified, cluster random sampling method was used to select 443 hospital administrators in six tertiary public hospitals for study. The data were collected and analyzed using the working hours measuring scale, Maslach burnout, and the subjective well-being schedule. Pearson correlation, structural equation model, and bootstrap tests were conducted to examine the association between job burnout, working hours, and SWB. (3) Results: Among the 443 respondents, 330 worked more than 8 h per day on average (76.2%), 81 had the longest continuous working time more than 16 h (18.7%), and 362 worked overtime on weekends (82.2%). The prevalence of job burnout in hospital administrators was 62.8%, among which, 59.8% have mild burnout and 3.00% have severe burnout. In the dimension of emotional exhaustion, depersonalization, and reduced personal achievement, the proportion of people in high burnout was 21.0% (91/433), 15.0% (65/433), and 45.3% (196/433), respectively. Job burnout has a mediating effect between working hours and SWB, which accounted for 95.5% of the total effect. (4) Conclusion: Plagued by long working hours and severe job burnout, the hospital administrators in China’s tertiary public hospitals may have low SWB. Working hours have a negative direct impact on job burnout and SWB, and an indirect impact on SWB through job burnout as a mediator. Targeted strategies should be taken to adjust working hours to promote the physical and mental health of hospital administrators.

APA, Harvard, Vancouver, ISO, and other styles

46

Abuabdou, Ahmed Y., Eric R. Rosenbaum, Saad Usmani, Bart Barlogie, and Michele Cottler-Fox. "A Better Mobilization Regimen for Newly Diagnosed Multiple Myeloma Patients,." Blood 118, no. 21 (November 18, 2011): 4051. http://dx.doi.org/10.1182/blood.v118.21.4051.4051.

Full text

Abstract:

Abstract Abstract 4051 Introduction: What constitutes an acceptable mobilization regimen for collecting CD34+ cells depends on whether the goal of collection is to obtain a minimum number versus optimal number of cells. When treating patients with high-risk myeloma it may be important to obtain an optimal number. Here we compare retrospectively our earlier mobilization regimen, VTD-PACE, with MVTD-PACE in newly diagnosed, previously untreated multiple myeloma patients. Materials and Methods : We reviewed data for all patients who collected hematopoietic progenitor cells on Total Therapy protocols TT3a/TT3b with VTD-PACE (n=394) from February 2004 to September 2008 (138 females and 256 males, median age 59y; range 31–75), and on TT4/TT5 with MVTD-PACE (n=188) from August 2008 to May 2011 (78 females and 110 males, median age 61y, range 30–76). Based on their predicted first day collection with a large volume leukapheresis (30L processed), using our center's predictive formula (Blood 2010; 116(21):1182a), patients were stratified into 4 mobilizer types: poor (<2×106 CD34+ cells/kg), intermediate (≥2 to 10×106), good (>10 to 20×106) and excellent (>20×106). Variables examined included number of CD34+ cells/μl blood on day 1 and day 2 of collection (we have a minimum 2 day collection requirement), number of collection days to reach our minimum goal of 20×106 CD34+ cells/kg, and total CD34+ cells/kg collected for both chemotherapy groups. Variables for both groups stratified by mobilizer type were compared using two-tailed student's t-tests, except for the poor mobilizer group, where population size was too small for formal statistical analyses (VTD-PACE n=7, MVTD-PACE n=4), although averages were calculated. Results : There was no significant difference between VTD-PACE and MVTD-PACE for CD34+ cells/μl blood on day 1 of collection among the excellent [mean 368.9 (n=184) vs. 434.6 x106 (n=92); p-value 0.07], good [mean 138.6 (n=102) vs. 128.6 x106 (n=40); p-value 0.19], and intermediate [mean 60.1 (n=100) vs. 55.9 x106 (n=52); p-value 0.39] groups. A statistically significant difference between VTD-PACE and MVTD-PACE was found for CD34+ cells/μl blood on day 2 of collection for excellent mobilizers [mean 333.8 (n=184) vs. 460 ×106 (n=92); p-value <0.001], but not for the good [mean 165.7 (n=102) vs. 189.5×106 (n=40); p-value 0.21] and intermediate [mean 80.1 (n=101) vs. 102.3 ×106 (n=52); p-value 0.07] groups. When CD34+ cell/kg collection totals with VTD-PACE and MVTD-PACE were compared, a significant difference was seen for the intermediate mobilizer group only [mean 23.6 (n=101) vs. 26.3 ×106 (n=52); p-value 0.03]. For the poor mobilizer group, VTD-PACE had an average CD34+ cells/μl blood of 13.5×106 for day 1 of collection and 17.0 ×106 for day 2, with a total of 14.5×106 CD34+cells/kg collected; while MVTD-PACE had an average of 13.2×106 CD34+ cells/μl blood for day 1 of collection, 24.9×106 for day 2, with a total of 24.2×106CD34+ cells/kg collected. The number of collection days was similar between VTD-PACE and MVTD-PACE in the excellent mobilization group (2 days), but was slightly more for VTD-PACE compared to MVTD-PACE for the good (2.1 vs. 2 days), intermediate (3.2 vs. 2.9 days), and poor (6.1 vs. 5.8 days) groups. Conclusion : Both regimens allow more than minimum collections, but MVTD-PACE provides a higher peak number of CD34+ cells/μl blood, resulting in a slightly lower mean number of days of collection than VTD-PACE to reach an optimal collection. Disclosures: No relevant conflicts of interest to declare.

APA, Harvard, Vancouver, ISO, and other styles

47

Broom, Reuben James, Vicky Hinder, Katrina Sharples, Janie Proctor, Steven Duffey, Stephanie Pollard, Peter C. C. Fong, et al. "RAD001 and zoledronic acid in patients with renal cell carcinoma with bone metastases (RAZOR): A randomized phase II trial." Journal of Clinical Oncology 31, no. 6_suppl (February 20, 2013): 402. http://dx.doi.org/10.1200/jco.2013.31.6_suppl.402.

Full text

Abstract:

402 Background: Bone metastases (BM) from renal cell carcinoma (RCC) are common, cause morbidity, and have been identified as an adverse prognostic feature. Previous trials have not assessed the effects of modern therapies on BM from RCC. Randomized data has demonstrated that zoledronic acid (Z) reduces skeletal-related-events (SREs) in RCC patients (pts). Bone turnover markers can identify pts at risk of SREs among those receiving Z. We sought to evaluate the effect on BM of RAD001 (R) (everolimus) alone compared to R+Z in the first-line setting. Methods: 30 treatment naïve pts with RCC and ≥ 1 BM were randomized 1:1 to R 10mg daily vs. R+Z 4mg IV 4-weekly (dose adjusted for creatinine clearance [CrCl]). Key eligibility criteria were ECOG PS ≤ 2, no bisphosphonates, or radiotherapy within 4 wks and CrCl >35ml/min. Bone-specific assessments were performed at baseline, wks-1, 4, 8, and 12. Treatment was continued on allocated arm until progression (RECIST 1.1). The primary objective was to assess the difference in bone turnover markers over the first 12 wks. The primary endpoint was urine N-telopeptide (uNTX) level with secondary endpoints being plasma C-telopeptide (CTX), quality of life (FACT-BP, BPI), progression free survival (PFS), SREs, and safety. Results: Heng prognostic group poor, intermediate, and good risk was 20.0%, 46.7%, 33.3% in R+Z and 40.0%, 46.7%, 13.3% in R. Over first 12 wks, the reduction in mean: uNTX on R+Z relative to R was 68.4% (95% CI (60.1%, 74.9%); p<0.0001); CTX on R+Z relative to R was 77% (95% CI (68%, 83%); p<0.0001). For FACT-BP there was no evidence of a difference (p = 0.5) but addition of Z was favourable for BPI Severity -1.1 (-2.2, 0.23; p = 0.05) and BPI Interference -1.3 (-2.5, 0.03; p = 0.06). Median PFS was 7.5 mo (95% CI 3.4, 14.7) on R+Z and 4.6 mo (95% CI 3.2, 6.3) on R (p = 0.03). Median time to 1st SRE was 9.6 mo (95% CI 4.3, 15.5) on R+Z and 5.2 mo (95% CI 1.6-8.2) on R (p = 0.03). Conclusions: Addition of Z to R significantly reduced bone resorption markers in this RCC population of pts with the adverse prognostic feature of BM. Pts receiving R+Z had prolonged time to 1st SRE and PFS; larger studies are required to further evaluate the addition of bone-specific to targeted therapies in this disease. Clinical trial information: ACTRN12609000980235.

APA, Harvard, Vancouver, ISO, and other styles

48

Christiansen, S. N., L. Midtbøll Ørnbjerg, S. H. Rasmussen, A. G. Loft, J. K. Wallman, F. Iannone, B. Michelsen, et al. "OP0220 SECULAR TRENDS IN BASELINE CHARACTERISTICS, TREATMENT RETENTION AND RESPONSE RATES IN 17453 BIONAÏVE PSORIATIC ARTHRITIS PATIENTS INITIATING TNFI – RESULTS FROM THE EUROSPA COLLABORATION." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 131.2–132. http://dx.doi.org/10.1136/annrheumdis-2021-eular.422.

Full text

Abstract:

Background:Knowledge of changes over time in baseline characteristics and tumor necrosis factor inhibitor (TNFi) response in bionaïve psoriatic arthritis (PsA) patients treated in routine care is limited.Objectives:To investigate secular trends in baseline characteristics and retention, remission and response rates in PsA patients initiating a first TNFi.Methods:Prospectively collected data on bionaïve PsA patients starting TNFi in routine care from 15 European countries were pooled. According to year of TNFi initiation, three groups were defined a priori based on bDMARD availability: Group A (1999–2008), Group B (2009–2014) and Group C (2015–2018).Retention rates (Kaplan-Meier), crude and LUNDEX adjusted1 remission (Disease Activity Score (DAS28) <2.6, 28-joint Disease Activity index for PsA (DAPSA28) ≤4, Clinical Disease Activity Index (CDAI) ≤2.8) and ACR50 response rates were assessed at 6, 12 and 24 months. No statistical comparisons were made.Results:A total of 17453 PsA patients were included (4069, 7551 and 5833 in groups A, B and C).Patients in group A were older and had longer disease duration compared to B and C. Retention rates at 6, 12 and 24 months were highest in group A (88%/77%/64%) but differed little between B (83%/69%/55%) and C (84%/70%/56%).Baseline disease activity was higher in group A than in B and C (DAS28: 4.6/4.3/4.0, DAPSA28: 29.9/25.7/24.0, CDAI: 21.8/20.0/18.6), and this persisted at 6 and 12 months. Crude and LUNDEX adjusted remission rates at 6 and 12 months tended to be lowest in group A, although crude/LUNDEX adjusted ACR50 response rates at all time points were highest in group A. At 24 months, disease activity and remission rates were similar in the three groups (Table).Table 1.Secular trends in baseline characteristics, treatment retention, remission and response rates in European PsA patients initiating a 1st TNFiBaseline characteristicsGroup A(1999–2008)Group B(2009–2014)Group C(2015–2018)Age, median (IQR)62 (54–72)58 (49–67)54 (45–62)Male, %514847Years since diagnosis, median (IQR)5 (2–10)3 (1–9)3 (1–8)Smokers, %161717DAS28, median (IQR)4.6 (3.7–5.3)4.3 (3.4–5.1)4.0 (3.2–4.8)DAPSA28, median (IQR)29.9 (19.3–41.8)25.7 (17.2–38.1)24.0 (16.1–35.5)CDAI, median (IQR)21.8 (14.0–31.1)20.0 (13.0–29.0)18.6 (12.7–26.1)TNFi drug, % (Adalimumab / Etanercept / Infliximab / Certolizumab / Golimumab)27 / 43 / 30 / 0 / 036 / 31 / 14 / 5 / 1421 / 40 / 21 / 8 / 10Follow up6 months12 months24 monthsGr AGr BGr CGr AGr BGr CGr AGr BGr CRetention rates, % (95% CI)88 (87–89)83 (82–84)84 (83–85)79 (78–80)72 (71–73)72 (71–73)68 (67–69)60 (59–61)60 (59–62)DAS28, median (IQR)2.7 (1.9–3.6)2.4 (1.7–3.4)2.3 (1.7–3.2)2.5 (1.8–3.4)2.2 (1.6–3.1)2.1 (1.6–2.9)2.1 (1.6–3.1)2.0 (1.6–2.9)1.9 (1.5–2.6)DAPSA28, median (IQR)10.6 (4.8–20.0)9.5 (3.9–18.3)8.7 (3.6–15.9)9.1 (4.1–17.8)7.7 (3.1–15.4)7.6 (2.9–14.4)6.7 (2.7–13.7)6.6 (2.7–13.5)5.9 (2.4–11.8)CDAI, median (IQR)7.8 (3.0–15.2)8.0 (3.0–15.0)6.4 (2.6–12.2)6.4 (2.5–13.0)6.2 (2.5–12.1)5.8 (2.2–11.4)5.0 (2.0–11.0)5.5 (2.0–11.2)5.0 (2.0–9.0)DAS28 remission, %, c/L47 / 4255 / 4661 / 5153 / 4362 / 4566 / 4864 / 4268 / 3775 / 41DAPSA28 remission, %, c/L22 / 1926 / 2228 / 2325 / 2031 / 2232 / 2336 / 2334 / 1938 / 21CDAI remission, %, c/L23 / 2123 / 1926 / 2227 / 2127 / 2029 / 2134 / 2231 / 1735 / 19ACR50 response, %, c/L26 / 2322 / 1824 / 2027 / 2223 / 1721 / 1523 / 1518 / 1014 / 8Gr, Group; c/L, crude/LUNDEX.Conclusion:Over the past 20 years, patient age, disease duration and disease activity level at the start of the first TNFi in PsA patients have decreased. Furthermore, TNFi retention rates have decreased while remission rates have increased, especially remission rates within the first year of treatment. These findings may reflect a greater awareness of early diagnosis in PsA patients, a lowered threshold for initiating TNFi and the possibility for earlier switching in patients with inadequate treatment response.References:[1]Arthritis Rheum 2006; 54: 600-6.Acknowledgements:Novartis Pharma AG and IQVIA for supporting the EuroSpA Research Collaboration Network.Disclosure of Interests:Sara Nysom Christiansen Speakers bureau: BMS and GE, Grant/research support from: Novartis, Lykke Midtbøll Ørnbjerg Grant/research support from: Novartis, Simon Horskjær Rasmussen: None declared, Anne Gitte Loft Speakers bureau: AbbVie, Janssen, Lilly, MSD, Novartis, Pfizer, UCB, Consultant of: AbbVie, Janssen, Lilly, MSD, Novartis, Pfizer, UCB, Grant/research support from: Novartis, Johan K Wallman Consultant of: Celgene, Eli Lilly, Novartis, Florenzo Iannone Speakers bureau: Abbvie, MSD, Novartis, Pfizer and BMS, Brigitte Michelsen Consultant of: Novartis, Grant/research support from: Novartis, Michael J. Nissen Speakers bureau: Novartis, Eli Lilly, Celgene, and Pfizer, Consultant of: Novartis, Eli Lilly, Celgene, and Pfizer, Jakub Zavada: None declared, Maria Jose Santos Speakers bureau: AbbVie, Novartis, Pfizer, Manuel Pombo-Suarez: None declared, Kari Eklund: None declared, Matija Tomsic Speakers bureau: Abbvie, Amgen, Biogen, Medis, MSD, Novartis, Pfizer, Consultant of: Abbvie, Amgen, Biogen, Medis, MSD, Novartis, Pfizer, Björn Gudbjornsson Speakers bureau: Amgen and Novartis, İsmail Sari: None declared, Catalin Codreanu Speakers bureau: AbbVie, Amgen, Egis, Novartis, Pfizer, UCB, Grant/research support from: AbbVie, Amgen, Egis, Novartis, Pfizer, UCB, Daniela Di Giuseppe: None declared, Bente Glintborg Grant/research support from: Pfizer, Biogen, AbbVie, Marco Sebastiani: None declared, Karen Minde Fagerli: None declared, Burkhard Moeller: None declared, Karel Pavelka Speakers bureau: AbbVie, Roche, MSD, UCB, Pfizer, Novartis, Egis, Gilead, Eli Lilly, Consultant of: AbbVie, Roche, MSD, UCB, Pfizer, Novartis, Egis, Gilead, Eli Lilly, Anabela Barcelos: None declared, Carlos Sánchez-Piedra: None declared, Heikki Relas: None declared, Ziga Rotar Speakers bureau: Abbvie, Amgen, Biogen, Medis, MSD, Novartis, Pfizer, Consultant of: Abbvie, Amgen, Biogen, Medis, MSD, Novartis, Pfizer, Thorvardur Love: None declared, Servet Akar: None declared, Ruxandra Ionescu Speakers bureau: Abbvie, Amgen, Boehringer-Ingelheim Eli-Lilly,Novartis, Pfizer, Sandoz, UCB, Gary Macfarlane Grant/research support from: GlaxoSmithKline, Marleen G.H. van de Sande: None declared, Merete L. Hetland Speakers bureau: Abbvie, Biogen, BMS, Celltrion, Eli Lilly, Janssen Biologics B.V, Lundbeck Fonden, MSD, Pfizer, Roche, Samsung Biopies, Sandoz, Novartis., Mikkel Østergaard Speakers bureau: AbbVie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Centocor, GSK, Hospira, Janssen, Merck, Mundipharma, Novartis, Novo, Orion, Pfizer, Regeneron, Schering-Plough, Roche, Takeda, UCB and Wyeth, Consultant of: AbbVie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Centocor, GSK, Hospira, Janssen, Merck, Mundipharma, Novartis, Novo, Orion, Pfizer, Regeneron, Schering-Plough, Roche, Takeda, UCB and Wyeth

APA, Harvard, Vancouver, ISO, and other styles

49

Prieto-Peña, D., F. Genre, S. Remuzgo Martinez, V. Pulito-Cueto, B. Atienza-Mateo, B. Sevilla, J. Llorca, et al. "AB0146 BAFF, APRIL y BAFFR: DIFFERENTIAL BIOMARKERS BETWEEN IgA VASCULITIS AND IgA NEPHROPATHY?" Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 1203–4. http://dx.doi.org/10.1136/annrheumdis-2022-eular.425.

Full text

Abstract:

BackgroundIgA vasculitis (IgAV) and IgA nephropathy (IgAN) are inflammatory conditions [1, 2], that share pathogenic mechanisms [1], in which B-lymphocytes are described as key cells implicated in these processes. BAFF, APRIL and BAFF-R are cytokines implicated in the development of B-lymphocytes [3, 4] and in autoimmune processes [5, 6]. In this regard, an influence of BAFF, APRIL and BAFFR polymorphisms was observed on several immune-mediated conditions, being BAFF GCTGT>A a shared insertion-deletion variant for inflammatory conditions [7, 8].ObjectivesTo determine whether BAFF, APRIL and BAFFR could be used as differential biomarkers between IgAV and IgAN.MethodsBAFF rs374039502 (which colocalizes with BAFF GCTGT>A), two tag variants within APRIL (rs11552708 and rs6608) and two tag variants within BAFFR (rs7290134 and rs77874543) were genotyped in 394 Caucasian IgAV patients, 95 patients with IgAN and 832 matched healthy controls.ResultsSimilar genotype and allele frequencies were observed in the whole cohort of patients with IgAV when compared to those with IgAN when BAFF, APRIL and BAFFR variants were analyzed independently (Table 1). In accordance with that, no BAFF, APRIL and BAFFR genotype or allele differences were detected between IgAV patients who developed nephritis and patients with IgAN (Table 1). Additionally, no statistically significant differences were observed between the whole cohort of patients with IgAV and healthy controls as well as between patients with IgAN and healthy controls when each when BAFF, APRIL and BAFFR genetic variant was also analyzed independently (Table 1). Similar results were disclosed when haplotype frequencies of APRIL and BAFFR were compared between the different comparative groups above mentioned (data not shown).Table 1.Genotype and allele frequencies of BAFF, APRIL and BAFFR in the whole cohort of patients with IgAV, patients with IgAV who developed nephritis, patients with IgAN and healthy controls.PolymorphismChangeData setGenotypes, % (n)Alleles, % (n)1/21/11/22/212BAFF rs374039502T/AIgAV92.1 (363)7.9 (31)0.096.1 (757)3.9 (31)IgAV with nephritis90.1 (128)9.9 (14)0.095.1 (270)4.9 (14)IgAN91.6 (87)8.4 (8)0.095.8 (182)4.2 (8)Controls91.8 (764)7.8 (65)0.4 (3)95.7 (1593)4.3 (71)APRIL rs11552708G/AIgAV78.7 (310)20.1 (79)1.3 (5)88.7 (699)11.3 (89)IgAV with nephritis81.1 (116)18.9 (27)0.090.6 (259)9.4 (27)IgAN75.8 (72)23.2 (22)1.1 (1)87.4 (166)12.6 (24)Controls78.7 (655)19.7 (164)1.6 (13)88.6 (1474)11.4 (190)APRIL rs6608C/TIgAV72.6 (286)25.4 (100)2.0 (8)85.3 (672)14.7 (116)IgAV with nephritis75.5 (108)23.1 (33)1.4 (2)87.1 (249)12.9 (37)IgAN65.3 (62)30.5 (29)4.2 (4)80.5 (153)19.5 (37)Controls71.0 (591)26.6 (221)2.4 (20)84.3 (1403)15.7 (261)BAFFR rs7290134A/GIgAV58.9 (232)35.5 (140)5.6 (22)76.6 (604)23.4 (184)IgAV with nephritis60.1 (86)32.2 (46)7.7 (11)76.2 (218)23.8 (68)IgAN57.9 (55)38.9 (37)3.2 (3)77.4 (147)22.6 (43)Controls58.7 (488)35.1 (292)6.3 (52)76.2 (1268)23.8 (396)BAFFR rs77874543G/CIgAV83.2 (328)15.5 (61)1.3 (5)91.0 (717)9.0 (71)IgAV with nephritis83.1 (118)16.9 (24)0.091.5 (260)8.5 (24)IgAN86.3 (82)13.7 (13)0.093.2 (167)6.8 (13)Controls83.7 (696)16.0 (133)0.4 (3)91.6 (1525)8.4 (139)IgAV: IgA vasculitis; IgAN: IgA nephropathy.ConclusionOur results reveal a similar BAFF, APRIL and BAFFR genetic distribution in IgAV and IgAN, suggesting that these genes could not be used as differential biomarkers between these pathologies.References[1]N Engl J Med 2013;368:2402-14;[2]Am J Kidney Dis 1988;12:373-7;[3]J Exp Med 1999;189:1747-56;[4]Nat Genet 2005;37:793-4;[5]Arthritis Res Ther 2018;20:158;[6]Arthritis Res Ther 2020;22:157;[7]Engl J Med 2017;376:1615-26;[8]Sci Rep 2018;8:8195.AcknowledgementsThis study was supported by the European Regional Development Fund (ERDF) and “Fondo de Investigaciones Sanitarias” (grant PI18/00042 and PI21/00042) from ‘Instituto de Salud Carlos III’ (ISCIII, Health Ministry, Spain). DP-P is a recipient of a Río Hortega programme fellowship from the ISCIII, co-funded by the European Social Fund (ESF, `Investing in your future´) [grant number CM20/00006]; SR-M is supported by funds of the RETICS Program co-funded by ERDF [grant number RD16/0012/0009]; VP-C is supported by a pre-doctoral grant from IDIVAL [grant number PREVAL 18/01]; RL-M is a recipient of a Miguel Servet type II programme fellowship from the ISCIII, co-funded by ESF `Investing in your future´ [grant number CPII21/00004].Disclosure of InterestsDiana Prieto-Peña: None declared, Fernanda Genre: None declared, Sara Remuzgo Martinez: None declared, Verónica Pulito-Cueto: None declared, Belén Atienza-Mateo: None declared, Belén Sevilla: None declared, Javier Llorca: None declared, Norberto Ortego: None declared, Maite Leonardo: None declared, Ana Peñalba: None declared, Luis Martín-Penagos: None declared, Jose Alberto Miranda Fillloy: None declared, J. Narváez: None declared, LUIS CAMINAL MONTERO: None declared, PAZ COLLADO: None declared, Antonio Fernandez-Nebro: None declared, Gisela Díaz-Cordoves: None declared, Secundino Cigarrán: None declared, Jesús Calviño: None declared, Carmen Cobelo: None declared, Diego de Argila: None declared, Esther F. Vicente-Rabaneda: None declared, Esteban Rubio-Romero: None declared, MANUEL LEON LUQUE: None declared, Juan María Blanco-Madrigal: None declared, E. Galíndez-Agirregoikoa: None declared, Oreste Gualillo: None declared, Javier Martin Ibanez: None declared, Santos Castañeda: None declared, Ricardo Blanco Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Consultant of: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Grant/research support from: Abbvie, MSD and Roche, Miguel A González-Gay Speakers bureau: Abbvie, MSD, Jansen, and Roche, Grant/research support from: Abbvie, Pfizer, Roche, Sanofi, Lilly, Celgene, MSD and GSK, Raquel López-Mejías: None declared

APA, Harvard, Vancouver, ISO, and other styles

50

Sagar, G. R. "Uses and Usefulness of Paraquat." Human Toxicology 6, no. 1 (January 1987): 7–11. http://dx.doi.org/10.1177/096032718700600102.

Full text

Abstract:

1 Paraquat was discovered in 1955 and introduced to the market place in 1962. During the 23 years between introduction and the present day numerous successful practical uses of the herbicide have been developed. In addition the characteristics of the chemical have allowed significant changes to be made in the ways that some crops are grown. 2 Paraquat is a relatively non-selective foliage-applied contact herbicide. It is inactivated on contact with almost all naturally occurring soils and it was this property, perhaps above all others, that provided the greatest breakthrough in chemical weed control at the time of its discovery. 3 Inactivation on contact with soil means that no biologically active residues remain in the soil, thus allowing planting or sowing to be carried out almost immediately after spraying. Although the non-systemic (contact) property of paraquat makes it less than ideal for the long-term control of perennial weeds, the same property is of real advantage when parts of crop plants are sprayed accidentally, for usually only the part receiving the spray is affected. 4 Total annual usage of all herbicides in agriculture and horticulture in England and Wales, UK, over the period of 1980-1983 has been estimated at 26 360 tonnes used on 12 402 x 103 ha (1 hectare = 1 x 104 m2). For paraquat (not including its mixtures with diquat and monolinuron) 270 tonnes were sprayed over 392 218 ha/year. It is estimated from sales records that in Europe 5 x 106 ha are sprayed annually with paraquat. 5 The paper reviews the need for the use of herbicides and the properties that are important for particular crop-weed situations, but concentrates on the properties of paraquat that make it an essential agent of weed control in many areas of agriculture, horticulture and forestry.

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic '362.196 462 4'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles